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i 
ABSTRACT 
 
Chronic Kidney Disease (CKD) is common and often has a major impact on the 
health of those affected. In this thesis I have focused on areas of uncertainty that may 
have major implications for patient care. 
 
Firstly, I assessed the determinants of increased mortality in a multi-ethnic primary 
care population. Secondly, I investigated the differential progression of CKD between 
ethnicities. Thirdly, I assessed if tryptase, as a marker of mast cell activation, could be 
used to stratify risk in CKD. Finally, I investigated the impact of CKD on health 
related quality of life (HRQL) and the association between HRQL and clinical end-
points. 
 
I found that: (i) comorbidity has a profound impact at a population level on survival in 
CKD; (ii) albuminuria is the principle modifiable risk factor for progression to end-
stage renal disease (ESRD) in people of South Asian ethnicity; (iii) serum tryptase is 
an independent prognostic factor for ESRD in patients with CKD receiving treatment 
with an ACEi or ARB; and (iv) Low HRQL is common in CKD and reduced HRQL 
is associated with a higher risk for death. 
 
The findings from this thesis contribute to the understanding of CKD in ethnically 
diverse, high-risk populations and form the basis for further studies. 
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1 INTRODUCTION 
 
Chronic kidney disease (CKD) is a major public health problem. It affects up to one 
in seven adults (1-5), and the prevalence of CKD varies with age, gender and ethnic 
mix of the population studied (6-13). It is increasingly seen as a global health problem 
due to its high prevalence and association with adverse outcomes irrespective of the 
country reporting CKD prevalence and outcomes (4, 14-16). 
 
The accepted definition for CKD was initially proposed by National Kidney 
Foundation – Kidney Disease Initiative (NKF-KDOQI) in 2002 (17) and is shown in 
Figure 1-1. 
 
Figure 1-1. Definition of chronic kidney disease (17) 
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate 
Kidney damage for ≥ 3 months, as defined by structural or functional 
abnormalities of the kidney, with or without decreased glomerular filtration 
rate (GFR), manifest by either 
 Pathophysiological abnormalities 
 Markers of kidney damage, including abnormalities in the 
composition of the blood or urine, or abnormalities in imaging 
tests. 
 GFR <60 mL/min/1.73m2 for ≥ 3 months, with or without kidney 
damage. 
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A diagnosis of CKD requires knowledge of kidney function as measured by 
glomerular filtration rate (GFR) or estimated (e)GFR and urinalysis for quantification 
of albuminuria or proteinuria. Individuals with a normal eGFR and no proteinuria 
may still have CKD as diagnosed by other urinary abnormalities or structural 
problems of kidneys, demonstrated on imaging. 
 
In this introduction I discuss aspects of CKD of particular relevance to the hypotheses 
addressed and results reported in this thesis. 
 
1.1 Assessments of renal function 
1.1.1 Creatinine 
Serum creatinine is an end-product of muscle catabolism. It is not protein bound and 
is freely filtered across the glomerulus. Due to its ease of measurement and 
widespread availability of the assay, it is the most commonly used marker of 
glomerular filtration (18).  The generation of creatinine is proportional to muscle 
mass, and therefore may vary by age, gender, ethnicity and body size. Whilst its 
utility as an index of renal function has been superseded by more accurate estimates 
of renal function, it remains a key component of the majority of eGFR equations 
discussed in Section 1.1.4. 
 
Given the importance of creatinine in nephrology practice and beyond, the ability to 
accurately assess creatinine is vital. Previously, different assays showed significant 
variation, some by as much as 30% (19). In order to reduce intra-laboratory variation, 
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manufacturers of creatinine assays calibrate their assay to an isotope dilution mass 
spectrometry (IDMS) traceable value. Whist this has improved the situation, a recent 
study has demonstrated some variability remains (20). 
 
1.1.2 Cystatin C 
Cystatin C is a protein produced at an apparently constant rate by all nucleated human 
cells. Its low molecular mass allows it to be freely filtered by the glomerulus before 
being resorbed and catabolised by tubular epithielial cells; consequentially, only a 
small amount is excreted in the urine (18). Cystatin C can be used as an alternative to 
creatinine to estimate GFR (21). Its utility has been increased with more affordable 
assays, a standardisation of measurement and an increased recognition that it may be 
a better marker of adverse prognosis in CKD patients than creatinine (22, 23). As 
discussed in Section 1.1.4.2, it has been incorporated into the latest Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equations (24). 
 
1.1.3 Measured GFR 
Historically, the gold-standard technique to measure GFR has been inulin clearance. 
However, this test is invasive and time-consuming, ideally requiring a continuous 
infusion of inulin to achieve a steady state and multiple timed urine collections (18). 
More recently, radiolabelled plasma clearance methods, which are closely related to 
inulin clearance, have been used, including in the development a number of the eGFR 
equations discussed below in Section 1.1.4. GFR is calculated from plasma clearance 
after a bolus intravenous injection of an exogenous filtration marker (25). Several of 
these substances involve the use of radioactive agents (e.g. 
99m
Tc-DTPA and 
52
Cr-
4 
EDTA). Iohexol is a nonradioactive contrast agent which performs well against inulin 
clearance (25). However, even these direct measurements of GFR exhibit variability 
(26).  
 
1.1.4 Estimated Glomerular Filtration Rate Equations 
Different equations can be used to calculate the eGFR. Historically, the Cockcroft-
Gault formula (27), developed against creatinine clearance and introduced in 1976, 
was used. The formula, illustrated in Figure 1-2, requires an anthropometric 
measurement (i.e. weight), a value not routinely available from a laboratory 
perspective, thereby limiting its clinical utility. Whilst the Cockroft-Gault formula has 
been superseded by other equations, it had a key role in defining dose adjustments for 
medications with significant renal clearance. 
 
Figure 1-2. Cockcroft-Gault formula (27) 
 
 
 
 
1.1.4.1 MDRD Equation 
The Modification of Diet in Renal Disease (MDRD) group developed a formula to 
predict GFR from serum creatinine concentration and other factors (28). They 
evaluated numerous equations (Figure 1-3), which included serum and urine 
variables.  
[(140-Age) x Weight (kg)]            x 0.85 if Female 
[72 x 88.4 x Serum Creatinine (μmol/L) 
5 
 
Figure 1-3. Equations evaluated in the MDRD study (28) 
 
Abbreviations: Alb, serum albumin; CCr, creatinine clearance (mL/min/1.73m2); 
Curea, urea clearance (mL/min/1.73m2); PCr, plasma creatinine concentration 
(mg/dL); SUN, serum urea nitrogen concentration (mg/dL); UUN, urine urea 
nitrogen concentration (g/d) 
 
The equation with routinely available clinical data (Figure 1-3, equation 5) was 
subsequently refined further with removal of serum urea to form the 4-variable 
MDRD formula (Figure 1-4); this equation had the greatest utility for clinical practice 
with eGFR derived from serum creatinine, age, gender and ethnicity. This equation 
performed well in comparison with plasma clearance methods (29) and was 
subsequently incorporated into national and international guidelines. It is the equation 
provided by most UK laboratory reports and has been validated for IDMS traceable 
creatinine (30).  
 
Equation 1: GFR = 0.69 x [100/PCr] 
Equation 2: GFR = 0.81 x [Cockcroft-Gault formula] 
Equation 3: GFR = 0.81 x [CCr] 
Equation 4: GFR = 1.11 x [(CCr + Curea)/2] 
Equation 5: GFR = 1.04 x [CCr]
+0.751 
x [Curea]
+0.226 
x [1.109 if patient 
black] 
Equation 6: GFR = 198 x [PCr]
-0.858
 x [age]
-0.167 
x [0.822 if patient is 
female] x [1.178 if patient is black] x [SUN]
-0.293 
x [UUN]
+0.249 
 
Equation 7: GFR = 170 x [PCr]
-0.999 
x [age]
-0.176 
x [0.762 if patient is 
female] x [1.180 if patient is black] x [SUN]
-0.170 
x [Alb]
+0.318
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Figure 1-4. 4-variable MDRD Equation (29) 
 
 
 
 
Abbreviations: GFR, glomerular filtration rate; PCr, plasma creatinine concentration 
(μmol/L) 
 
The MDRD equation was developed and validated in people with CKD. It has been 
shown to lose precision and underestimate measured GFR at higher levels of GFR; 
this is most notable for GFRs greater than 60/ml/min/1.73m
2  
(31, 32). UK guidelines 
recommend that eGFR values above 60/ml/min/1.73m
2  
be interpreted with caution, 
‘bearing in mind that estimates of GFR become less accurate as true GFR increases’ 
(33). 
 
1.1.4.2 CKD-EPI Equations 
To improve the utility of kidney function estimation in clinical practice, the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) developed new estimating 
equations for GFR, which involved a two slope-linear spline (essentially different 
equations depending on level of renal function). One equation, which has been 
introduced into clinical practice, uses serum creatinine (28) whilst others utilise 
cystatin C with or without serum creatinine (21). The CKD-EPI creatinine equation is 
currently being rolled out in UK clinical chemistry laboratories and is recommended 
in the current version of the NICE CKD guideline (33). The equations are shown in 
Table 1-1.   
GFR (ml/min/1.73m
2
) =186 x [PCr x 88.4]
-1.154 
x [age]
-0.203 
x [0.742 
if patient is female] x [1.210 if patient is black]
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Table 1-1. Final equations evaluated in the CKD-EPI study. Adapted from (21) to incorporate UK creatinine units 
Equation and Gender Serum 
Creatinine 
Serum 
Cystatin C 
Equation for Estimating GFR 
    μmol/L mg/l   
CKD-EPI creatinine 
   
 
Female ≤61.9 
 
144 × ((Scr x 88.4)/0.7)
−0.329 
× 0.993
Age
 [× 1.159 if black]  
 
Female >61.9 
 
144 × ((Scr x 88.4)/0.7)
−1.209 
× 0.993
Age
 [× 1.159 if black]  
 
Male ≤79.6 
 
141 × ((Scr x 88.4)/0.9)
−0.411 
× 0.993
Age
 [× 1.159 if black]  
 
Male >79.6 
 
141 × ((Scr x 88.4)/0.9)
−1.209 
× 0.993
Age
 [× 1.159 if black]  
CKD-EPI cystatin C equation 
   
 
Female or Male 
 
≤0.8 133 × (Scys/0.8)−0.499 × 0.996Age [× 0.932 if female]  
 
Female or Male 
 
>0.8 133 × (Scys/0.8)
−1.328 
× 0.996
Age
 [× 0.932 if female]  
CKD-EPI creatinine-cystatin C equation 
  
 
Female ≤61.9 ≤0.8 130 × ((Scr x 88.4)/0.7)−0.248 × (Scys/0.8)−0.375 × 0.995Age [× 1.08 if black]  
   
>0.8 130 × ((Scr x 88.4)/0.7)
−0.248 
× (Scys/0.8)
−0.711 
× 0.995
Age
 [× 1.08 if black]  
 
Female >61.9 ≤0.8 130 × ((Scr x 88.4)/0.7)−0.601 × (Scys/0.8)−0.375 × 0.995Age [× 1.08 if black]  
   
>0.8 130 × ((Scr x 88.4)/0.7)
−0.601 
× (Scys/0.8)
−0.711
 × 0.995
Age
 [× 1.08 if black]  
 
Male ≤79.6 ≤0.8 135 × ((Scr x 88.4)/0.9)−0.207 × (Scys/0.8)−0.375 × 0.995Age [× 1.08 if black]  
   
>0.8 135 × ((Scr x 88.4)/0.9)
−0.207 
× (Scys/0.8)
−0.711
 × 0.995
Age
 [× 1.08 if black]  
 
Male >79.6 ≤0.8 135 × ((Scr x 88.4)/0.9)−0.601 × (Scys/0.8)−0.375 × 0.995Age [× 1.08 if black]  
   
>0.8 135 × ((Scr x 88.4)/0.9)
−0.601 
× (Scys/0.8)
−0.711 
× 0.995
Age 
[× 1.08 if black]  
 
Abbreviations: Scr, serum creatinine (μmol/L); Scys, serum cystatin (mg/l) 
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1.1.4.3 Comparative performance of eGFR equations 
When evaluating the accuracy of eGFR equations, a frequently used technique is to 
assess the percentage of eGFR that differs by more than 30% from the actual GFR 
(P30). In development and validation cohorts the CKD-EPI creatinine equation has a 
lower P30 for overall eGFR, eGFR below 60ml/min/1.73m
2
 and eGFR equal to or 
above 60ml/min/1.73m
2
 compared to the MDRD eGFR (32). Additionally the CKD-
EPI creatinine-cystatin C equation performed better than the CKD-EPI equations with 
creatinine or cystatin C alone (21). Whilst this is likely to influence assessments of 
prevalence of CKD on a population level, it is unclear if the use of a different 
equation has any impact on the clinical care of an individual patient (34). 
 
1.1.5 Ethnicity 
The application of a correction factor for ethnicity is required in both the MDRD and 
CKD-EPI equations. Many large databases [Section 1.9.2.1] either provide no or very 
limited ethnicity data, making the true prevalence of CKD difficult to estimate as their 
eGFR records cannot be corrected for ethnicity (1). 
 
Previous studies have validated the eGFR equations in the North American African-
Caribbean population (29) and some Asian populations (35-37). However, there are 
limited data amongst certain Asian populations, including people from Bangladesh, 
India and Pakistan (38); indeed, these groups form an integral part of the West 
Midlands population and, as discussed later in Section 1.5.1, appear to have a faster 
rate of progression to end stage renal disease (ESRD) (2, 6, 39).  
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1.1.6 Assessment of proteinuria 
The significance of proteinuria, and in particular albuminuria, in the natural history of 
diabetic kidney disease (DKD) has been recognised for many years (40, 41). The 
cumulative impact of the eGFR and albuminuria in CKD secondary to other 
aetiologies was discussed at the Kidney Disease: Improving Global Outcomes 
(KDIGO) controversies conference (42) before being comprehensively studied by the 
Chronic Kidney Disease Prognosis Consortium (43-46). These landmark studies were 
a key component of the drive to incorporate the quantification of albuminuria into a 
CKD staging system (Section 1.2.2). 
 
Guidelines suggest the use of urine albumin creatinine ratio (ACR) as the standard of 
care for quantification of albuminuria in routine clinic practice, although some units 
continue to measure protein creatinine ratio (PCR). Table 1-2 indicates the conversion 
between urine protein concentration, ACR and PCR. 
 
Table 1-2. Comparisons between different tests to quantify proteinuria 
 
Albumin Creatinine 
Ratio 
Protein Creatinine 
Ratio 
Urine Protein 
concentration 
(mg/mmol) (mg/mmol) (g/L) 
30 50 0.5 
70 100 1 
 
1.2 Diagnosing CKD 
Estimated glomerular filtration rate (eGFR) is more sensitive for diagnosing CKD 
than serum creatinine alone (47) because, as discussed in Section 1.1.1, the generation 
of creatinine varies by age, gender, ethnicity and body size. Therefore the GFR for an 
 10 
80 year old white lady with a creatinine of 150 μmol/L with be different to the GFR 
for a 30 year old black man with an identical serum creatinine.  
 
1.2.1 2002 Staging system 
The first internationally accepted staging system was proposed in February 2002 by 
the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney 
Foundation (NKF). This divided CKD into 5 stages based on eGFR (48, 49). A higher 
stage (from 1-5) indicates worse kidney function and patients are categorised into 
groups which are broadly associated with an increased risk of progression to end-
stage renal failure and mortality the higher the stage of CKD (50). This staging 
system is illustrated below (Table 1-3). 
 
Table 1-3. CKD stages as defined by K/DOQI guidelines (49) 
Stage GFR 
(ml/min/1.73m
2
) 
Description 
1 ≥90 Normal or increased GFR, with other 
evidence of kidney disease 
2 60-89 Slight decrease in GFR, with other 
evidence of kidney damage 
3 30-59 Moderate decrease in GFR, with or without 
other evidence of kidney damage 
4 15-29 Severe decrease in GFR, with or without 
evidence of kidney damage 
5 <15 Established renal failure 
 
Abbreviations: GFR, glomerular filtration rate 
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1.2.2 2012 Update to the Staging System 
As discussed previously in Section 1.1.6, the risk conveyed by CKD is associated 
with both the level of secretory renal function (i.e. creatinine or eGFR) and 
albuminuria, usually quantified in clinical practice as an urinary ACR (42, 44-46, 51, 
52). Large epidemiological studies suggest that an elevated ACR, regardless of eGFR 
(53), is associated with a high risk of progression. Recent studies show that levels 
previously seen as normal convey a higher risk of death (42).  
 
In recognition of the importance of albuminuria, KDIGO introduced an amendment to 
the CKD classification (42) and subsequently developed and published clinical 
practice guidelines for CKD in 2012 (54) (Table 1-4).  This updated staging system 
has been adopted internationally including by the UK, where it forms part of the 2014 
update of the National Institute of Health and Care Excellence (NICE) CKD 
guidelines (33). 
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Table 1-4. Updated CKD staging system from 2012 KDIGO clinical practice 
guidelines (54). Figure adapted from UK guidelines (33) 
Darker shades and arrows indicate increased risks of adverse outcomes 
GFR and ACR categories and risks 
of adverse outcomes 
ACR Categories (mg/mmol) and 
range 
<3 3-30 >30 
A1 A2 A3 
GFR categories 
(ml/min/1.73m
2
) 
and range 
≥90 G1 No CKD in 
absence of 
markers of 
kidney 
damage 
    
60-89 G2     
45-59 G3a       
30-44 G3b       
15-29 G4       
<15 G5       
Abbreviations: ACR, albumin creatinine ratio; GFR, glomerular filtration rate 
 
1.2.3 Number of eGFR readings required for diagnosis 
The diagnosis of CKD requires the abnormal eGFR or ACR to persist for at least 
three months. Guidelines indicate that, to confirm a diagnosis of CKD, at least two 
eGFR readings, separated by not less than a period of 90 days are required (33). 
Similarly, an initial ACR between 3mg/mmol and 70mg/mmol should be confirmed 
with a subsequent sample (33). 
 
Many previous studies investigating the prevalence of CKD have relied on a single 
eGFR, which is likely to overestimate the prevalence. In the UK, studies which have 
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relied on single measurements have estimated a higher prevalence than those relying 
on multiple readings (1, 55, 56). 
 
1.3 Adverse outcomes associated with CKD 
Chronic kidney disease is often asymptomatic until advanced stages. Consequently, it 
is often under-recognised, despite frequently coexisting with conditions such as 
cardiovascular disease or diabetes (57). It is estimated that 30% of individuals with 
advanced CKD are referred late to nephrology services from primary and secondary 
care (58). This has implications for risk factor assessment and modification and 
timely provision of information and resources, such as preparation for ESRD; early 
identification facilitates more time for discussion regarding dialysis modality and 
access or plans for kidney transplantation which are linked to an improvement in 
quality of life and increased survival (59, 60). 
 
Advanced CKD does not just result in kidney specific complications. It is associated 
with a profound increase in morbidity and mortality; risk of death, cardiovascular 
events and hospitalisations all rise with CKD stage (50). Mortality is associated with 
both cardiovascular (50, 61) and non-cardiovascular causes (62). Even less advanced 
CKD represents a significant risk factor for cardiovascular disease and increased 
morbidity and mortality.  
 
The Chronic Kidney Disease Prognosis Consortium have performed numerous meta-
analyses assessing the impact of eGFR and albuminuria on outcomes in general and 
high risk population cohorts (63). They have confirmed lower eGFR and higher 
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albuminuria as risk factors for ESRD, acute kidney injury, progressive CKD and 
mortality (43, 44, 46).  This has enabled the production of heat maps to provide a 
visual representation of relative risks (Figure 1-5) (42). 
 
In the UK, there have been major initiatives to improve the early identification of 
people with CKD. These initiatives include the incentivised testing of kidney function 
in people with comorbidities associated with CKD, and the inclusion of patients with 
known CKD on a register held by the general practice. Most of these initiatives have 
been introduced through the UK quality and outcomes framework (QoF) (64) and 
have been complemented by the NICE CKD guideline which defines thresholds for 
referral of patients to secondary care nephrology services (33). 
 
Figure 1-5. Visual Representations of relative risks for adverse events in general 
population cohorts with albumin creatinine ratio available. Adapted from (42)  
Abbreviations: ACR, albumin creatinine ratio (mg/g*); eGFR, estimated glomerular 
filtration rate (ml/min/1.73m
2
). * Approximate conversion of ACR to UK units: 
mg/mmol = [mg/g] /10 
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1.3.1 Endpoints associated with CKD 
Endpoints can relate to clinical or surrogate events (65). Definitions of these 
endpoints can be found in Figure 1-6. As surrogate endpoints are typically a 
biological marker (biomarker), the definition for this is also provided. 
 
Figure 1-6. Definitions of clinical and surrogate endpoints (65) 
 
 
 
 
 
 
 
 
 
 
 
 
The endpoints used in this thesis are clinical; the two key outcomes of interest are 
death or progression to ESRD (defined as the initiation of renal replacement therapy 
(RRT) i.e. chronic dialysis or renal transplantation). 
 
Whilst clinical endpoints may be suitable for high risk populations, there is often a 
significant time period from the point of first detection in CKD to a clinical endpoint. 
Clinical endpoint – A characteristic or variable that reflects how a 
patient feels, functions or survives.  
Surrogate endpoint – A biomarker that is intended to substitute for 
a clinical endpoint. A surrogate endpoint is expected to predict 
clinical benefit (or harm or lack or benefit or harm) based on 
epidemiological, therapeutic, pathophysiologic, or other scientific 
evidence. 
Biological Marker (biomarker) – A characteristic that is objectively 
measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention. 
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Guidelines suggest that early intervention (Section 1.7) in patients with CKD will 
have a greater effect on slowing the progression of CKD and delaying the time to 
ESRD. However, in order to prove such strategies to delay progression work, 
appropriate endpoints need to be selected; this is where surrogate endpoints may be 
helpful as they should allow a distal endpoint to be replaced with a more proximal one 
(66).  Previous studies have used an increase in albuminuria (67, 68) or the doubling 
of creatinine (69) as a surrogate for progression of renal disease.  
 
A doubling of serum creatinine corresponds to a 57% reduction in eGFR which may 
still require long follow up periods (70). Attention has therefore focused on whether 
declines in eGFR smaller than the equivalent of a doubling of serum creatinine could 
be used whilst still being associated with the risk of ESRD. This has been investigated 
by the CKD Prognosis Consortium investigators, and they proposed a 30% reduction 
in eGFR over two years as a surrogate marker (70). A scientific workshop sponsored 
by the NKF and the United States Food and Drug Administration proposed a more 
conservative 40% decline over two-three years given the potential for acute (i.e. 
treatment of concomitant illness) effects on eGFR (71). 
 
A further endpoint of interest in studies of CKD include the incidence of 
cardiovascular events. Tracking these events accurately in routine clinical care is 
challenging and ideally requires an informatics solution to access national data 
regarding hospital admissions and diagnosis, such as Hospital Episodes Statistics 
(HES) data. This dataset has been utilised for recent studies investigation the 
outcomes of patients with CKD (72). The use of HES data requires a specific clause 
in the ethical permission; this was not initially obtained during the design of the Renal 
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Impairment in Secondary Care (RIISC) study that forms a significant part of this 
thesis (73). 
 
1.3.2 Health-Related Quality of life 
Early symptoms of CKD tend to be non-specific, such as fatigue, before symptoms 
more easily attributable to kidney disease develop (74). This burden of symptoms 
may impact negatively on health-related quality of life (HRQL). 
 
There is increasing evidence of an association between pre-dialysis CKD and 
impaired HRQL as assessed by a variety of patient reported outcome measures 
(PROMs) (75-78).  However, information on the relationship between HRQL, CKD 
and other adverse outcomes is limited; this is an area I explore further in Chapter 6. 
Additionally, information on the measures of HRQL utilised in this thesis can be 
found in Chapter 2 (Section 2.4.2).  
 
1.3.3 Burden on Society 
Kerr and colleagues performed economic modelling to estimate the annual cost of 
CKD (stage G3-G5) to the NHS in England (79). The direct cost to the English 
National Health Service (NHS) in 2009-10 was estimated as £1.44-1.45 billion or 
approximately 1.3% of all NHS spending during that year. More than half of this was 
spent on RRT with significant additional costs due to the excess strokes and 
myocardial infarctions sustained in patients with CKD. 
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In the developing world, for example in South Asian countries, CKD is a major public 
contributor to the overall burden of non-communicable disease (80). Many countries 
in the developing world do not have comprehensive health care systems with 
universal access, and RRT will be unaffordable to many (81). 
 
1.4 Risk Prediction for Patients with CKD 
Section 1.3 described major outcomes associated with CKD. Previous work focusing 
on modelling risk of adverse events in CKD are discussed below. 
 
1.4.1 ESRD 
1.4.1.1 Risk equations 
Providing patients with clinically relevant information regarding the probability of 
specific clinical events and outcomes (endpoints), requires an ability to utilise large 
quantities of data in a way that can practically inform the decision making progress. 
The incorporation of risk scores into nephrology practice, something used widely by 
other specialties (82), is facilitating this (83). 
 
Whilst earlier scoring systems had been developed (84), it was the publication of a 
validated scoring system by Tangri and colleagues in 2011 (85) which resulted in the 
increased use of risk scoring systems in CKD. This has subsequently undergone 
extensive validation in international cohorts, including the addition of both four-
variable (age, gender, eGFR, ACR) and eight-variable (age, gender, eGFR, ACR, 
calcium, phosphate, bicarbonate, albumin) variants and the addition of an adjustment 
factor for populations outside North America (86). The variables used in the Tangri 
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equations and original Hazard Ratios [HRs] and 95% confidence intervals are shown 
in Table 1-5.  
 
Table 1-5. Hazard Ratios (and 95% confidence intervals) in the original 4- and 8- 
variable equations. Adapted from (86) 
  4-variable 8-variable 
  HR (95% CI) HR (95% CI) 
Age (per 10 year increase) 0.80 (0.75-0.86) 0.82 (0.77-0.88) 
Male Gender 1.28 (1.04-1.58) 1.17 (0.95-1.46) 
eGFR (per 5 ml/min/1.73m
2
 
increase) 
0.57 (0.54-0.61) 0.61 (0.58-0.65) 
ACR (mg/g, per log increase) 1.57 (1.44-1.71) 1.40 (1.28-1.53) 
Calcium (per 1mg/dl)  0.80 (0.68-0.95) 
Phosphate (per 1mg/dl)  1.30 (1.18-1.43) 
Bicarbonate (per 1 mEq/l)  0.93 (0.90-0.96) 
Albumin (per 1 g/dl)   0.71 (0.56-0.90) 
 
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval; eGFR, 
estimated glomerular filtration rate; HR, hazard ratio 
 
An alternative risk equation in an American cohort has recently been proposed 
incorporating age, gender, eGFR, proteinuria/ albuminuria, haemoglobin 
concentration, systolic blood pressure, antihypertensive medication use, and a 
modified Diabetes Complications Severity Index (87).  Interestingly, given the 
recognition of albuminuria as such a prominent continuous risk factor for progression, 
it only incorporates ACR as a dichotomous variable (with 30mg/g [3.39mg/mmol] as 
the cut point). 
 
Reviewing the conception and validation cohorts for the prediction models, the 
absence of large South Asian populations in these studies is noticeable (63). This is an 
important omission, and raises the question of validity of such equations in ethnically 
diverse populations.   
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In the manuscripts describing the prediction models by both Tangri and Schroeder, it 
is the use of four variables (age, gender, eGFR and ACR) that convey the strongest 
risk; whilst additional variables do improve the discrimination and calibration of 
models, their impact is modest. This may suggest that attempting to add additional 
biochemical or standard demographic factors to population based models is likely to 
have limited effect, and perhaps emphasis should be placed on a more personalised 
approach focusing on sub-groups of patients (stratified medicine; Section 1.8). 
 
1.4.1.2 Aetiology of renal disease as a risk factor for renal progression 
Whilst there is significant variation in eGFR decline between individuals with the 
same aetiology of renal disease, patients affected by some specific kidney diseases 
progress more rapidly, these include autosomal dominant polycystic kidney disease 
(ADPKD) and diabetic kidney disease (DKD) (88-90). 
 
1.4.2 Death 
An ability to predict death, especially death prior to the progression for ESRD, is 
valuable as it influences the need to provide information and interventions (for 
example arteriovenous fistula formation) (91). However, this can be challenging as  
multiple non-renal and renal confounders, including both lower eGFR and higher 
albuminuria, have been shown to be associated with death (43). Non-renal 
determinants associated with an increasing mortality risk include increasing age, male 
gender, comorbidity, and lifestyle factors (e.g. smoking) (92, 93). 
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Bansal and colleagues developed a prediction equation to estimate the five-year risk 
of mortality among individuals aged 65 years or older with CKD in the 
Cardiovascular Health Study (94). They identified nine clinical variables (age, gender, 
ethnicity [white/ black], eGFR, ACR, diabetes, smoking, prevalent heart failure, 
prevalent stroke) influencing risk of death; these and their associated weighting scores 
are shown in Table 1-6. Estimate of risk for five year mortality depended on the total 
points and ranged from 3.87% for zero points to 93.7% for ten or more points. 
 
Table 1-6. Points associated with each risk factor associated with mortality in 
Cardiovascular Health Study. Adapted from (94) 
 
Risk Factor Categories Points Risk Factor Categories Points 
Age (years) 
 
  ACR >3.39 mg/mmol 
 
 
70-74 0 
 
No 0 
 
75-79 1 
 
Yes 1 
 
80-84 2 Diabetes 
  
 
≥85 4 
 
No 0 
Gender 
 
  
 
Yes 1 
 
Female 0 Smoking 
  
 
Male 1 
 
Never 0 
Ethnicity 
 
  
 
Former 1 
 
Black 0 
 
Current 2 
 
White 1 Prevalent Heart Failure 
 eGFR (ml/min/1.73m
2
)   
 
No 0 
 
50-59 0 
 
Yes 2 
 
40-49 1 
Prevalent 
Stroke 
  
 
30-39 2 
 
No 0 
  <30 4   Yes 1 
 
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration 
rate 
 
Consistent with the lack of information on risk factors for progression to ESRD, there 
are also limited data for the determinants of mortality risk in South Asian patients 
with CKD, despite previous studies indicating survival differences between ethnic 
groups (11, 95-99).  
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1.5 Additional Demographic Variables 
The ability to predict the risk of adverse events for patients with CKD is an aspect of 
clinical research which impacts directly on nephrology practice. Whilst prediction 
equations make use of demographic factors such as age and gender, two components 
that are notably absent in the majority of equations are ethnicity and socio-economic 
status (SES). These are both important considerations in an area as diverse as the 
West Midlands (see Section 2.1). Whilst these variables are increasingly the subject of 
discussion, data from UK populations are relatively sparse. The next sections in this 
introduction provide a concise review of the association between ethnicity and SES on 
outcomes. 
 
1.5.1 Influence of Ethnicity on Adverse Outcomes 
Section 1.1.5 described how knowledge of ethnicity is needed for correction factors 
for the most commonly used eGFR equations, and that certain ethnicities appear to 
have a faster rate of progression to ESRD. This section provides a concise review of 
the relevant literature assessing the influence of ethnicity on mortality, CKD and 
cardiovascular disease. Due to the population mix in the West Midlands, it mainly 
focuses on three main ethnicities; white (Caucasian), South Asian (including 
individuals of Bangladeshi, Indian and Pakistani descent) and black (individuals from 
or who have ancestors from Africa or the Caribbean). 
 
An important consideration in the relationships between ethnicity and the adverse 
outcomes discussed below is whether ethnicity is a risk factor per se, or whether any 
association may be due to other differences between ethnicities which are themselves 
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associated with adverse outcomes; for example, the prevalence of diabetes is higher in 
certain ethnic groups and other differences may exist in SES (see Section 1.5.2), the 
proportion of individuals who undertake high risk behaviours (such as smoking) or 
the age distribution of the population studied (100-102).  
 
1.5.1.1 Ethnicity and Chronic Kidney Disease 
The majority of work investigating global differences in CKD has focused on people 
with end stage renal disease. Jha and colleagues investigated CKD from a global 
perspective and acknowledged precise calculations of the prevalence of early stage 
CKD are difficult, with individual studies confounded by heterogeneity of the 
population screened and that, within countries, some subgroups (including different 
ethnic groups) may be at increased risk of developing CKD, CKD disease 
progression, or both (4). It is therefore important to investigate observed differences 
within ethnicities in the population to be studied; interestingly, systematic reviews 
estimating ethnic differences have frequently not included data from the United 
Kingdom (12).  
 
A study investigating CKD prevalence in a nationally representative sample of Health 
Survey for England data did not identify any statistically significant difference in 
CKD prevalence by ethnicity, although the authors acknowledged there were very few 
cases from the key minority ethnic groups; therefore it is questionable if this study 
produced robust data on ethnic differences (2). Another UK study, this time 
investigating the prevalence of CKD in people with diabetes, found lower rates of all 
CKD (stage G3 and above), but an increased odds ratio for more severe CKD (G4/5 
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or proteinuria) in people of South Asian and black ethnicities (6). This higher 
proportion of more severe CKD is consistent with other UK data suggesting an 
increased update of renal replacement therapy by South Asian and black populations 
(39), and a lower median age of starting renal replacement therapy (103). Despite this 
increased requirement for RRT, people of asian and black ethnicities have a reduced 
likelihood of receiving a living donor kidney transplantation (104). 
 
1.5.1.2 Ethnicity and Mortality 
Ethnicity information is not captured on death certificates in England and Wales. 
Consequently, there are limited published data on any population differences in 
mortality between ethnicities in the UK.  Studies have modelled the relationship 
between mortality, age, deprivation and ethnic proportion and suggest broadly similar 
life expectancies for white and Asian populations but lower life expectancy for black 
men and women (105).  
 
Information investigating mortality and ethnicity in CKD populations not on dialysis 
is also limited, but a study investigating mortality in a Canadian CKD cohort of three 
different ethnicities (Caucasian, Oriental Asian and South Asian) found all cause 
mortality rates were higher in Caucasian than the other two ethnicities (11). The 
Kidney Early Evaluation Programme, based in the United States of America, also 
identified mortality differences by ethnicity; with white ethnicity as the reference 
population, Hispanics and Asians (predominantly Oriental Asians) had a lower risk of 
death, African Americans had a similar risk, and American-Indians and Alaska 
Natives had a higher risk of death (106).  
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It is not possible to conclude from these data whether differences in mortality 
identified in studies investigating populations with CKD were due the presence of 
kidney disease or linked to differences in the population studied. This again highlights 
the need to analyse populations of direct relevance to clinical practice within the UK, 
and will be a focus of this thesis. 
 
1.5.1.3 Ethnicity and Cardiovascular Disease 
United Kingdom standardised mortality ratios (SMR) for ischaemic heart disease vary 
by ethnicity (107). When compared to the white population, South Asians have a 
higher SMR and the black population have a lower SMR. There is also evidence that 
the decline in cardiovascular disease observed in the white UK population has not 
been mirrored in these ethnic minority populations (107).  
 
Several studies have investigated why this observed disparity in cardiovascular 
disease exists. Rana and colleagues conducted a systematic review and meta-analysis 
investigating any difference between cardiovascular risk factors and disease 
management practices in white and South Asian residents of Canada (108), a country 
with universal health coverage. Including 50 articles with over 5.8 million individuals, 
they did not demonstrate any differences in access to cardiovascular investigations or 
outcomes but did show a higher prevalence and incidence of cardiovascular disease 
and increased risk factors including diabetes, hypertension, higher body fat and a 
more sedentary lifestyle. This emphasises the significance of the clinical and 
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demographic differences between ethnicities, and the need to ensure these potential 
are recognised in any analyses conducted. 
 
Studies have also investigated whether there are difference in outcomes following 
myocardial infarctions or interventional cardiology procedures. Jones and colleagues 
utilised the British Cardiovascular Intervention Society national database to perform a 
retrospective analysis of 279,256 patients undergoing primary coronary intervention 
between 2004 and 2011 (100). In similarity to the meta-analysis described above, they 
identified differences in demographics and risk factors at presentation; South Asians 
were younger and had more extensive disease and a greater prevalence of risk factors 
including diabetes. However, after correcting for these differences, in-hospital and 
medium-term mortality of South Asians was no worse than that of Caucasians. Other 
studies yield conflicting results, with Gijsberts and colleagues finding Indian and 
Malay patients had a higher risk for all-cause mortality following ST-elevation 
myocardial infarctions than Caucasians, albeit in a study that looked at different 
ethnic groups in different health care settings (Netherlands and Singapore) (109). 
 
1.5.2 Influence of Socioeconomic Status on Adverse Outcomes 
Socio-economic inequalities in health have been described in many North American 
and European studies, with associations found between SES and outcomes including 
all-cause mortality, cardiovascular disease and prevalence and progression of CKD. 
Many of these studies describe populations and access to healthcare that is markedly 
different to the population of the United Kingdom (UK), thereby making it unclear 
how applicable these findings are to our local population. Section 2.1.4 provides 
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specific SES information for the West Midlands, and I have summarised the recent 
and most pertinent published literature below. 
 
1.5.2.1 Socio-economic Status and Chronic Kidney Disease 
Whilst there are limited published data on the association between SES and CKD in 
the United Kingdom, the majority suggest an inverse relationship between SES and 
CKD. 
 
Bello and colleagues investigated the association between deprivation and CKD stage 
at presentation referred to the nephrology unit in Sheffield, UK (110). Deprivation 
was divided into quintiles using the Index of Multiple Deprivation score (see Section 
2.2.7) and the study found that people who lived in areas with low SES were at 
greatest risk for more advanced CKD at presentation. However, in a multivariable 
analysis, the observed difference was attenuated in all but the most deprived quintile; 
the significant factors that remained were the most deprived SES quintile, 
hypertension and diabetes. A higher prevalence of CKD G3-G5 and higher 
albuminuria, both risk factors for progression of CKD (Section 1.2.2), were found in 
individuals with a lower SES in an combined analysis of data from the Health Survey 
for England 2009 and 2010 (111). Taken together, these studies suggest that those 
from the most deprived areas potentially have more severe CKD at presentation and 
increased risk factors for progression to ESRD. UK studies also identify that people 
from more deprived areas have higher incident and prevalent rates of renal 
replacement therapy (112) but less access to living donor transplantation (104, 113), a 
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treatment associated with better life expectancy and quality of life when compared to 
other modalities (114, 115). 
 
1.5.2.2 Socio-economic Status and Mortality 
Stringini and colleagues recently published a multicohort study and meta-analysis, 
synthesising data from 48 independent prospective cohort studies from high income 
countries, including the UK (116). Socioeconomic status was indexed by occupation, 
coded into the European Socio-Economic Classification, and the study demonstrated 
that participants with lower SES had a higher mortality risk and reduced life 
expectancy both in models adjusted for age, marital status and ethnicity and for a 
more comprehensive multivariable model. Their analyses suggests low SES was 
associated with 2.1 years of life lost between 40 and 85 years of age, compared to 0.7 
years lost for obesity, 3.9 years lost for diabetes an 4.8 years lost for current smoking. 
In their discussion, and in similarity to ethnicity, the authors describe how SES is 
often intertwined with other risk factors for health or disease (such as smoking status 
or levels of health education). Additionally, they recognise other measures of SES 
which assess more than a single component may be helpful when measuring on a 
population basis. Indeed, the measure of SES utilised elsewhere in this thesis, the 
Index of Multiple Deprivation (see Section 2.2.7) utilises seven domains to assess 
SES. Although there were low levels of heterogeneity (i.e. variation) across the 
cohorts, one potential criticism of the meta-analysis is the lack of inclusion of any 
analysis investigating the impact of universal health care provision on outcomes.  
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1.5.2.3 Socio-economic Status and Cardiovascular Disease 
The Scottish Intercollegiate Group Network published their guideline entitled ‘Risk 
Estimation and the Prevention of Cardiovascular Disease’ in 2017 (117) and included 
the statement that ‘for given levels of other factors, populations which are more 
deprived have higher cardiovascular disease risk’. A UK based study validating the 
QRISK2 cardiovascular disease algorithm in patients from different ethnicities and 
SES was conducted by Hippisley-Cox and colleagues (118). Socioeconomic status 
was assessed by the Townsend deprivation score (119) and divided into quintiles. 
Cardiovascular disease incidence rates increased with each deprivation quintile, and 
remained after adjustment for other risk factors. In similarity to mortality and SES, 
the reasons for the association between cardiovascular risk factors and SES are 
considered multifactorial; studies have shown that individuals who have most to gain 
from assessment and risk factor modification are the least likely to attend screening 
programmes (120) and strategies, including within Birmingham (121), aim to reduce 
this disparity. 
 
1.6 Novel Biomarkers in Chronic Kidney Disease 
Previous sections have described the variables associated with progression to ESRD 
(Section 1.4.1) and death (Section 1.4.2) in individuals with CKD, including 
descriptions of the most commonly used risk prediction equations and a recognition of 
the potential significance of ethnicity and socioeconomic status (Section 1.5). In 
addition to the widely used and readily available assays, there has been significant 
research into novel biomarkers which may improve risk stratification in the CKD 
population (122, 123). Many such biomarkers have been studied in basic science and 
clinical settings.  
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Whilst several biomarkers have been identified as being associated with renal 
progression and/ or death, their use on a population level only leads to a modest 
improvement, at best, when combined with established clinical characteristics and 
laboratory variables.  
 
This thesis does not aim to comprehensively describe or assess the utility of a range of 
biomarkers in the populations studied. However, certain biomarkers were assessed as 
a component of the study carried out in the high-risk CKD population ((73); see 
Section 2.3 for details of study). Here I discuss these biomarkers which have been 
comprehensively investigated (high sensitivity c-reactive protein, serum 
immunoglobulin free light chains) or, in the case of serum tryptase (Chapter 5), 
studied for the first time in a clinical context.  
 
1.6.1 High Sensitivity C-Reactive protein 
C-reactive protein (CRP) is a protein produced by hepatocytes and is widely used in 
the monitoring of acute inflammatory conditions. The development of high sensitivity 
CRP (hsCRP) assays have allowed accurate measurement of CRP concentrations into 
the normal range. High sensitivity CRP has been demonstrated to provide information 
regarding future risk of cardiovascular events and mortality (124, 125), including in 
the dialysis population (126). 
 
Studies investigating the relationship between elevated CRP concentrations and 
progression to ESRD have yielded conflicting results. Sarnak and colleagues found no 
independent association between CRP and GFR decline in the MDRD study (127) 
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whereas an association of CRP with progression to ESRD, and the composite of death 
and ESRD, was found in a post hoc analysis of the Trial to Reduce Cardiovascular 
Events with Aranesp Therapy (TREAT) study (128). 
 
1.6.2 Polyclonal Serum Free Light Chains 
Polyclonal serum free light chains (sFLCs) are produced during immunoglobulin 
synthesis and their circulating concentrations are a balance between production 
(potentially representing activity of the adaptive immune system (129)) and clearance. 
Whilst there is some reticulo-endothelial clearance, the majority of sFLCs are cleared 
by the kidney; consequently concentrations of sFLCs are elevated in individuals with 
renal impairment (130). Two types of sFLCs are produced, kappa and lambda, which 
can be analysed together (combined FLC; cFLC), as separate isotypes, or as a ratio 
(kappa-lambda ratio). 
 
Hutchison and colleagues investigated FLC concentrations in patients with type II 
diabetes before the onset of overt renal disease and demonstrated evidence of elevated 
serum FLC before other evidence of renal dysfunction (131). Analysis of the 
relationship between sFLCs and adverse outcomes in CKD have been studied by 
several research groups (including our Birmingham group), with conflicting results. 
Of five prospective studies to date in CKD, four studied UK populations (132-135) 
and one investigated sFLC in a French cohort (136). Three of these studies (Assi; 
n=1695, Hutchison; n=848 and Ritchie; n=872) reported an independent relationship 
between sFLC concentrations and death. Haynes and colleagues (n=364) found the 
association between sFLCs and ESRD was explained by baseline eGFR. Desjardins 
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and colleagues (n=133) analysed Kappa and Lambda FLC separately and found 
Kappa FLC was associated with mortality in univariable but not multivariable 
analyses; no association was demonstrated with Lambda FLC in either univariable or 
multivariable analyses. 
 
Two studies analysed the association between sFLC and progression to ESRD (132, 
134). Haynes and colleagues reported an increased risk of ESRD, but significance was 
lost when eGFR was included in the multivariable analyses. However, Ritchie and 
colleagues, analysing sFLC concentrations within the chronic renal insufficiency 
standards implementation study (CRISIS; see Section 1.10.3.2) identified an increased 
risk of ESRD in the highest two quartiles of sFLC.  
 
The studies discussed above suggest, but are certainly not conclusive of, an 
independent relationship between sFLCs and death, and possibly progression to 
ESRD. These data, and our group’s interests and expertise in FLCs, justify their 
inclusion and further analyses. 
 
1.6.3 Mast Cell activation and serum tryptase 
Agents which block the renin angiotensin aldosterone system (RAAS) pathway, such 
as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor 
blockers (ARBs) have an ability to reduce proteinuria above their blood pressure 
lowering effects (discussed in Section 1.7). However, not all activation of angiotensin 
(AT) relies on the pathway blocked by ACEi/ARBs; indeed the concept of RAAS 
 33 
breakthough refers to the ability of AT to be activated by pathways which bypass the 
protective effects of ACEi/ARB (137).  
 
Mast cells are predominantly known for their roles in allergic disease and host 
defence against parasites (138). However these cells have a diverse functional 
capability beyond these roles; mast cell degranulation releases preformed mediators 
and compounds, including growth factors, proteases, leukotrienes, cytokines and 
chemokines; these are responsible for a range of physiological effects (139). Whilst 
mast cells are found infrequently in normal kidney tissue, an increased number of 
mast cells has been demonstrated to be associated with the severity of interstitial 
fibrosis in patients with progressive CKD due to a variety of aetiologies (140-149). 
 
The association between mast cells and renal dysfunction may be explained in part by 
the biological effect of mast cell proteases. Tryptase is an inflammatory and 
profibrotic protease that is released from mast cells (150, 151) and serum tryptase 
concentrations have been shown to increase with worsening renal impairment (152). 
Chymase, the other major protease released from mast cells, can convert ATI to ATII 
and activate transforming growth factor beta (TGF (153, 154). There are no 
previously published studies investigating the relationship between protease 
concentration and clinical outcomes in individuals with CKD, and I have investigated 
this as a component of this thesis. I focused on serum tryptase due to the previous 
published literature on association with renal impairment and the commercial 
availability of a sandwich immunoassay against tryptase (Phadia AB, Uppsala, 
Sweden; Section 2.4.5.3). 
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1.7 Current Treatment Strategies 
Unless caused by a specific immune medicated process (e.g. a primary or secondary 
glomerulonephritis that may be responsive to treatment with immunosuppression) 
individuals with CKD have limited effective treatment options.  
 
Accurate management of hypertension, particularly in proteinuric kidney disease is 
the cornerstone of treatment for the large majority of patients. Angiotensin converting 
enzyme inhibitors (ACEi)/angiotensin II blockers (ARB) further reduce CKD 
progression in patients with proteinuric CKD compared to other anti-hypertensive 
agents (155). Cholesterol lowering therapy (statins and ezetimibe) reduce 
atherosclerotic events (156) but do not slow the rate of progression of CKD.  
 
Certain therapies have been demonstrated to be beneficial in specific aetiologies. 
Tolvaptan has been demonstrated to slow the increase in total kidney volume and the 
decline in kidney function in patients with ADPKD (157) and has been licensed for 
use, in select circumstances, by NICE (158). Several potential agents may reduce 
renal progression in diabetes; empagliflozin and canagliflozin, examples of sodium-
glucose cotransporter 2 inhibitors, have recently been shown to decrease albuminuria 
and CKD progression in a study of type 2 diabetics with an eGFR >55ml/min/1.73m
2 
(159, 160) and there have been encouraging results in recent phase 2 studies 
suggesting selective inhibition of C-C chemokine receptor type 2 may slow renal 
progression in DKD (161). However, caution is needed given phase 3 studies of 
intervention in CKD have usually not confirmed positive results from phase 2 studies 
(162-164). 
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Given this limited arsenal of proven therapies, identification of people at greatest risk 
remains paramount, both to provide an opportunity to counsel and modify risk factors 
as appropriate, but also to identify those who may benefit most from targeted 
intervention in a clinical or clinical trial setting. 
 
1.8 Stratified medicine 
Risk prediction equations, such as the one proposed by Tangri and colleagues 
(Section 1.4) (85), provide tools to stratify risk based on common biochemical and 
demographic markers. Attempts to improve population based models through the 
addition of standard demographic factors or standard or novel biomarkers to date has 
only led to modest improvement in the performance of these models. 
 
Alternative approaches are therefore needed. These include: an urgent need to focus 
on patients who are at high risk of progression, including as a consequence of 
ethnicity, a better understanding of impact of HRQL on patients with CKD, and a 
focus on identifying which patients respond to (and would therefore benefit from) 
specific treatments and then to identify why this is.  
 
This movement towards a more personalised approach to healthcare delivery, 
whereby detailed risk stratification may enable care to be directed to those at greatest 
risk is referred to as stratified medicine. This was defined by the PROGRESS group 
as ‘the targeting of treatments (including pharmacological and non-pharmacological 
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interventions) according to the biological or risk characteristics shared by subgroups 
of patients’ (165). 
 
1.9 Research Questions Addressed in this Thesis  
Given the need to stratify risk as reliably as possible on a population and individual 
basis, and given the relative paucity of data regarding outcomes for patients of South 
Asian ethnicity, this thesis describes my research investigating the following  
 Do certain ethnic groups have a higher risk of adverse outcomes, including 
progression to ESRD or death?  
 Could novel biological markers help predict who may, or may not, respond to 
certain therapies? I assessed the association between serum tryptase, a product 
of mast cell activation, and progression to ESRD or death in patients with 
advanced CKD. Patients were stratified by the use of ACEi/ARBs. 
 What is the relationship between HRQL and CKD stage, and the impact of 
HRQL on progression to ESRD or risk of death?  
 
1.10 Data Sources 
To achieve answers to these research questions, appropriate data sources need to be 
available in order to be interrogated. Whilst the specifics of these are examined in the 
methods section, the key features indicating high quality data are discussed below. 
 
1.10.1 High Quality Data 
There does not seem to be a specific definition or set criteria to what constitutes high 
quality data. However, key features can be found in Figure 1-7. 
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Figure 1-7. Features of high quality data 
 
 
 
As I wished to perform analyses relevant to the UK, and in particular the ethnically 
and socio-economically diverse population in the West Midlands, the source data 
needed to be relevant and transferable to the local population. Potential sources of 
these data are discussed below. 
 
1.10.2 Primary Care Data 
Medical records held by primary care practices in the UK are extensive, including 
details regarding diagnoses and prescribed drugs, and whether an individual is on a 
disease-specific risk register. Additionally these records are often linked to laboratory 
and blood pressure data. Each practice has an information governance policy and may 
store the data in different ways, depending on the information technology (IT) system 
used. As there is likely to be variation between practices, both from a clinical and data 
collection point of view, an ideal dataset would cover a number of practices thereby 
being as representative as possible to the population studied. These datasets may be 
national or local and, for it to be useful in examining the relationship between CKD 
and outcomes, would require a measurement of renal function. 
 
Accuracy and reliability – Have the variables been entered 
correctly? 
Validity – Are they representative of the population being studied? 
Timeliness – Are the data recent? 
Relevance – Does it contain the information required for the 
appropriate analyses to be performed? 
Completeness – Are there missing data and, if so, can it be 
quantified? 
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1.10.2.1 National Primary Care Data 
The Health Improvement Network  (THIN) dataset is a large, UK database of patients 
registered in over 400 primary care practices covering more than 3.7 million active 
patients. It has been utilised for multiple epidemiological research studies (166). It 
provides information on comorbidities including CKD, and contains eGFR and ACR 
data; indeed it has been used locally to investigate the accuracy of primary care 
coding of CKD (1). This work by Jain and colleagues identified inaccuracies in the 
coding of patients onto CKD risk registers. A further limitation of this dataset is the 
lack of patient level ethnicity data; eGFR may therefore not have been adjusted for 
ethnicity and comparisons between ethnicities would not be possible, making it 
unsuitable for use in this thesis. 
 
1.10.2.2 Local Primary Care Data 
In recognition that people living in inner-city Birmingham have a lower life 
expectancy than the national average, with unmet healthcare needs, resources and 
technology were allocated with an aim to improve the quality of healthcare. This 
included a targeted data collection across the majority of primary care practices in 
Heart of Birmingham (HoB) primary care trust (PCT), initially aimed at increasing 
the diagnosis of diabetes, cardiovascular and kidney disease among its deprived and 
ethnically diverse population (the ‘deadly trio’ programme) (167). This database is 
local, contains appropriate information on renal function comorbidities and has 
detailed demographic information, including self-reported ethnicity.  
 
 39 
1.10.3 Secondary Care data 
There are numerous secondary care datasets investigating CKD. Internationally, the 
largest of the studies have been included as part of the CKD prognosis consortium 
(63); these studies typically have at least 1,000 participants and information at 
baseline on eGFR and albuminuria. The studies included in the CKD prognosis 
consortium can be broadly divided into three types; general population, high risk 
cohorts selecting people at high cardiovascular risk and cohorts specifically selecting 
subjects with CKD. Additionally, whilst the populations covered are diverse, the 
consortium recognise that some ethnicities are under-represented; black populations 
are mainly from within the USA and asian populations are predominantly Eastern 
Asian (63). Even if it were possible to obtain permission for the use of these data, the 
applicability of these data to the local West Midlands’ population is limited.  
 
A further global network of CKD cohorts, the international network of CKD disease 
cohort studies (iNET-CKD), includes twelve prospective cohort studies and two 
registries covering 21 countries (168). The goals of iNET-CKD are the ability to 
provide mutual assistance and shared expertise through sharing research tools and 
technologies, to provide opportunities for collaborative research and to enhance 
training of both young investigators and seasoned researchers. 
 
In addition to the studies identified in the CKD prognosis consortium or iNET-CKD, 
several international studies have recruited, or continue to recruit, adult patients with 
CKD across wide geographical areas in order to explore the determinants associated 
with CKD progression. These studies, and their objectives, are listed in Table 1-7.  
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Table 1-7. Key international studies investigating progression in adult CKD 
 
Cohort Population Aims Year 
recruitment 
commenced 
Number 
recruited 
Canadian study of prediction of 
death, dialysis and interim 
cardiovascular events 
(CanPREDDICT) (169) 
eGFR 15-45 ml/min/1.73m
2
 from 
outpatient nephrology clinics across 
Canada 
1. To examine the role of both 
traditional risk factors and a select 
panel of newer, non-traditional 
serum and urine biomarkers, in the 
progression of kidney disease and 
CVD in patients with CKD, alone 
and separately. 2. To develop robust 
predictive models to discriminate 
between high and low risk patients. 
2008 2546 
Chronic Kidney Disease Japan 
Cohort (CKD JAC) (170) 
Japanese (or Asian patients living 
in Japan) adults with eGFR 10-
59m/min/1.73m
2
  
1. To identify risk factors for 
progression of CKD in Japanese 
subjects. 2. To identify the impact of 
CKD on HRQL. 3. To assess the 
frequency of hospitalisation and 
economic impact of CKD 
2007 2977 
Chronic Renal Insufficiency 
Cohort (CRIC) (171) 
Secondary care, all CKD stages To identify risk factors for the 
progression of CKD and the 
development of CVD. 2. To develop 
predictive models to identify high-
risk subgroups, informing future 
treatment trials and increasing 
application of available therapies. 
2003 3612 
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Table 1-7 continued… 
 
Cohort Population Aims Year 
recruitment 
commenced 
Number 
recruited 
French CKD-renal epidemiology 
and information network cohort 
(CKD-REIN) (172) 
eGFR 15-59 ml/min/1.73m
2
 from 
nephrology clinics 
1. To assess the interaction between 
psychosocial, environmental, 
biological and genetic factors with 
outcomes. 2. To assess new 
biomarkers to predict outcomes. 3. 
To evaluate provider practices and 
their relation with outcomes 
including PROMs. 4. To identify 
and quantify costs, and cost 
effectiveness, of different treatment 
practices. 
 
2014 3600* 
German CKD study (GCKD) 
(173)  
Secondary care, eGFR 30- 
60ml/min/1.73m
2
 or significant 
proteinuria (albuminuria 
>300mg/day or proteinuria > 500 
mg/day) with a 
eGFR>60ml/min/1.73m
2
  
1. To identify and validate risk 
factors for progression of CKD, the 
development of CVD, and the 
relationship between CKD and 
CVD. 2. To determine gender based 
differences in risk. 3. To assess 
impact of CKD on HRQL. 
2010 4914 
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR: estimated glomerular filtration rate; HRQL, health related 
quality of life; PROMs, patient reported outcome measures. * Signifies recruitment in progress.
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Given the limitations, and potential lack of applicability, of the datasets described 
above, the use of UK based CKD studies may be better suited to answering my 
research questions. Currently there is no national secondary care CKD cohort. A 
summary of selected, prospective, observational UK studies of CKD, selected as they 
had at least a two year follow up period and greater than 250 participants, are 
discussed below.  
 
1.10.3.1 Chronic Renal Impairment in Birmingham (CRIB) (174, 175) 
This study was designed before the K/DOQI CKD staging system was introduced in 
2002. CRIB recruited 369 individuals with CKD (serum creatinine greater than 130 
μmol/L) from a single centre in Birmingham alongside control groups to investigate 
the relationship between kidney function and cardiovascular risk factors patients with 
CKD not requiring renal replacement therapy. Patient follow up was a mean of six 
years; no further clinical assessment took place during that period, the outcomes 
reported were ESRD and all cause mortality. 
 
1.10.3.2 Chronic Renal Insufficiency Implementation Study (CRISIS) (176-178) 
A single centre study from Manchester, CRISIS aimed to recruit patients 18 years and 
older who were referred for management of CKD and had an eGFR below 60 
ml/min/1.73m
2
 but had no immediate requirement to start dialysis. Recruitment 
started in 2002 and, by 2015, over 3000 patients were enrolled. Patients were 
managed in accordance with standard clinical practice guidelines and followed until 
death or initiation of RRT (dialysis or transplantation). 
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1.10.3.3 Renal Risk in Derby (R2ID) (179)  
R
2
ID study commenced recruitment in 2008 and is a collaboration between primary 
and secondary care researchers. It is a primary care cohort of patients with stage G3 
CKD (30-59 ml/min/1.73m
2
) who were recruited directly from 32 participating 
primary care practices. It was created to examine the renal and cardiovascular risks 
associated with less advanced CKD, and included measurements of vascular health 
including PWV (Section 2.4.4.2) and advanced glycation end products (Section 
2.4.4.3). 
 
1.10.3.4 Renal Impairment in Secondary Care Study (RIISC) (73, 180) 
The UK based secondary care studies discussed above all had relatively broad 
inclusion criteria, whether the study was based in primary or secondary care. In order 
to focus on the individuals at the greatest risk of progression of renal disease, our 
group designed the RIISC study. This focuses on advanced and/or progressive CKD 
and includes detailed bioclinical phenotyping collected using standard operating 
procedures (SOPs) within an ethnically diverse population. The RIISC study is 
discussed in detail in the methods section. 
 
1.11 Introductory Conclusions 
In this introduction I have described CKD and the burden it places on individuals and 
society. The previously identified risk factors for ESRD and death have been 
discussed, including the potential challenges of adding additional demographic factors 
or biological markers to the established risk factors on a population level. Of the 
factors utilized in widely accepted risk scores, it is age, gender, eGFR and ACR that 
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are most strongly associated with adverse outcomes. Additionally I have highlighted 
the paucity of data regarding in the impact of ethnicity, in particular South Asian 
ethnicity, and socioeconomic status, on adverse outcomes in CKD. 
 
Through a review of the literature and, in recognition of the ethnically diverse 
population we cover, I have identified research questions and discussed the potential 
data sources that could be used to address these questions.  
 
 
In this thesis I present data on a series of studies that focus on patients with CKD. I 
have utilised both primary care and secondary care cohorts. One cohort is 
representative of patients who are undergoing routine clinical care on a population 
basis (primary care; the ‘deadly trio programme’) and the other a specific group 
recruited through secondary care clinics (The RIISC study). 
 
Chapter 2 describes the cohorts and statistical techniques utilised in the thesis. 
 
Chapter 3 reports the impact of ethnicity, comorbidity and renal function on death in 
an ethnically diverse, primary care population. 
 
Chapter 4 focuses on the impact of ethnicity on adverse outcomes, most notably 
progression to ESRD, within the secondary care nephrology setting. 
 
Chapter 5 investigates the relationship of serum tryptase, a product of mast cell 
activation which may be involved in non-classical activation of the RAAS pathway, 
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to progression of ESRD within the secondary care RIISC study. I explore whether this 
relationship is influenced by participants use of angiotensin converting enzyme 
inhibitors or angiotensin II blockers (i.e. medication which influence the RAAS 
pathway). 
 
Chapter 6 examines HRQL in the secondary care CKD population. I investigate the 
impact of CKD on HRQL and whether there is an association between HRQL on 
clinical end-points. 
 
The cohorts and statistical techniques used will now be described in Chapter 2. 
 
 
  
 
 
 
  
 46 
2 METHODS 
 
In order to address the research questions summarised at the end of Chapter 1, I 
collected, reviewed and analysed data from both primary care and secondary care 
cohorts. The methodologies utilised were adjusted for the research questions and the 
cohorts within which a given research question was addressed. 
 
2.1 Description of the population in the West Midlands 
In order to provide context to the cohorts utilised in this thesis, a brief narrative is 
provided below describing the population of the West Midlands, with a particular 
emphasis on inner city Birmingham, from which the primary care cohort is derived. 
 
The West Midlands has been described by the Office for National Statistics as a 
region of contrast and diversity (181). There is a mixture of large urban areas 
(Birmingham is the largest urban area outside London) and countryside, and areas 
with high deprivation but also areas of prosperity.  
 
The West Midlands is home to the largest non-white population outside London, with 
14% of the population classed as non-White (181). Data from the 2011 census 
indicate the ‘Asian or Asian British’ ethnic group are the biggest non-White ethnic 
group, followed by ‘Black or Black British’ (182). Table 2-1 compares the ethnicity 
data for England, the West Midlands and Birmingham. 
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Table 2-1. Ethnicity Data from 2011 Census; Birmingham compared to National 
and Regional Data. Adapted from (182). Data shown as percentages. 
 
  White Asian Black Mixed/ Other 
  
Total Total South 
Asian 
Other 
Asian 
Total Total Other Mixed 
England & Wales 86.0 7.5 5.3 2.2 3.3 3.2 1.0 2.2 
England 85.4 7.8 5.6 2.3 3.5 3.3 1.0 2.3 
West Midlands 
Region 82.7 10.8 8.9 1.9 3.3 3.2 0.9 2.4 
West Midlands 
County 70.1 18.8 15.9 2.9 6.0 5.1 1.5 3.5 
Birmingham 53.3 26.6 22.5 4.1 9.0 6.1 2.0 4.4 
 
2.1.1 Age Distribution and Educational Attainment 
The West Midlands has a higher proportion of young (under 16 years) and old (over 
65 years) inhabitants compared to the average for English regions (181). It therefore 
has a lower proportion of working age individuals (between 16 and 64 years). 
Additionally, 2009 data indicate the West Midlands has the highest proportion of 
working age people with no qualifications in England. 
 
2.1.2 The Economy and the Labour Market 
The West Midlands was the industrial and manufacturing heartland of England for 
many years, with the presence of core industries of coal, steel and metal working, and 
a concentration of motor vehicle manufacturers. This has changed dramatically in the 
past three decades, with major economic restructuring and a movement from 
manufacturing to service sector industries. The proportion of workforce employed in 
manufacturing industries has reduced from 22.4% in 1996 to 11.2% in 2010 and the 
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largest employment sectors are now ‘wholesale and retail trade; repair of vehicles’ 
(15.%) and ‘human health and social work activities’ (13.4%) (181). 
 
2.1.3 Socioeconomic Status 
The West Midlands is socioeconomically diverse, with some of the most and least 
deprived areas in England; the majority of the most deprived areas are concentrated in 
the regions towns and cities, although some rural areas also have high levels of 
deprivation. The Index of Multiple Deprivation (described in more detail in Section 
2.2.7) provides a summary measure of relative deprivation based on small areas 
(called Lower Layer Super Output Areas; LSOAs). Figure 2-1 provides a graphical 
representation of the levels of deprivation within the West Midlands. Notably, the 
primary care population described in Section 2.2 is primarily based in the 
Birmingham authority area in which 56% of LSOAs are in the most deprived quintile 
(181). 
Figure 2-1. Graphical representation of socioeconomic status of the West 
Midlands by Index of Multiple Deprivation quintiles (181) 
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The diversity described above provides an ideal population from which to explore the 
research questions posed in Section 1.9.  
 
The primary and secondary care cohorts interrogated in this thesis will now be 
described.  
 
2.2 Primary Care 
This cohort was interrogated for the analyses described in Chapter 3. 
 
2.2.1 Cohort Information 
The cohort was derived from Heart of Birmingham Primary Care Trust (HoB PCT) 
which had a registered population of 312,070 on September 2008. The majority of the 
population (62%) were non-white (183). Sixty nine percent of the population were 
below 40 years of age.  
 
Participating primary care practices gave permission for enhanced data to be collected 
centrally, utilising software able to identify comorbidities through their classification 
on chronic disease registers [Enhanced Healthcare Services, Essex, UK]. 
 
2.2.2 Ethics 
Data were fully anonymised and available as a component of an on-going clinical 
development programme. The responsible NHS Research and Development 
 50 
Consortium stated that this study did not require ethical submission to an NHS 
research ethics committee as it represented an evaluation of part of an on-going 
primary care trust (PCT) programme. For PCT data extraction the PCT professional 
executive committee and GP locality leads provided approval for the programme, 
including evaluation and publication. 
 
2.2.3 Inclusion and Exclusion Criteria  
The inclusion criteria comprised 
 Registration in a practice participating in the enhanced data collection 
initiative. 
 Individuals aged 40 years and over. 
 
Exclusion criteria 
 No kidney function checked within the last 12 months. 
 Isotope Dilution Mass Spectrometry (IDMS) conversion for creatinine not 
available. 
 Individuals who left a participating practice during the study period. 
 An estimated glomerular filtration rate (eGFR) less than 15ml/min/1.73m2. 
 
2.2.4 Assessment of estimate Glomerular Filtration Rate 
Estimated GFR reporting was not universally recorded on primary care systems in 
2008. Investigations from practices participating in the enhanced data collection were 
sent to one of four laboratories. Whilst a standardised IDMS (Section 1.1.1) MDRD 
eGFR (28) was routinely reported by one laboratory, if this was not available the 
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eGFR was calculated utilising laboratory provided correction factors for the creatinine 
to generate IDMS traceable MDRD eGFR.  
 
One general practice in the catchment area was excluded as IDMS traceable creatinine 
was not available from a fourth laboratory that provided blood tests specifically for 
that catchment area. 
 
2.2.5 Study Duration 
The follow up period was 23 months from May 2008 until February 2011. Individuals 
who had left the included practices during the follow up were excluded from the 
analyses (11.1%). 
 
2.2.6 Data Collection 
Data for the following variables were electronically collected from primary care 
records 
 Age 
 Gender 
 Ethnicity. This was self-reported, considered the ‘gold standard’ for 
classification (184). 
 Current smoking status 
 Socio-economic status (SES) (Section 2.2.7) 
 eGFR and/or creatinine 
 Urinary albumin creatinine ratio (ACR) 
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 Vascular comorbidity (atrial fibrillation, chronic kidney disease, diabetes 
mellitus, heart failure, hypertension, ischaemic heart disease and stroke) as 
defined by a relevant clinical (Read) code specified by the UK pay for 
performance (QOF) business rules (185).  
 
2.2.7 Assessment of Socioeconomic Status 
Socio-economic status (SES) was assessed using the Index of Multiple Deprivation 
(IMD 2007) (186); this utilises the postcode from an individual’s address to identify 
the Lower Layer Super Output Area (LSOA) where the individual resides. Each of the 
32,482 LSOAs in England are assigned a score and rank for the IMD 2007, with 
lower ranks corresponding to the most deprived areas. The Index of Multiple 
Deprivation has been validated as superior to traditional deprivation indexes such as 
the Townsend score (119), due to its use of multiple domains reflective of 
socioeconomic deprivation (187). The IMD 2007 score incorporates seven areas of 
deprivation:  income deprivation; employment deprivation; health deprivation and 
disability; education; skills and training deprivation; barriers to housing and services; 
living environment deprivation; and crime. For the analyses presented, deprivation 
was divided into quintiles, with the most deprived quintile as the reference population 
(i.e. how mortality in less deprived quintiles compared to the most deprived quintile). 
 
2.2.8 Mortality data 
Mortality data was obtained from the Primary Care Mortality Database (188),  a 
resource developed by The NHS Information Centre in partnership with the Office for 
National Statistics (ONS). Data obtained from ONS records are linked to the general 
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practice where the individual was registered. This allowed data to be extracted for 
specific general practices (i.e. those within HoB PCT).  
 
2.3 Secondary Care; The Renal Impairment in Secondary Care Study 
The Renal Impairment in Secondary Care (RIISC) study was evaluated for the 
analyses in Chapters 4, 5 and 6.  
 
2.3.1 Cohort Information 
The RIISC study is a multicentre, longitudinal observational study of advanced and/or 
progressive CKD which commenced recruitment in October 2010. A detailed protocol 
has previously been published (73). A summary of the study can be found below, 
focusing on the key components utilised in this thesis. 
 
All patients provided written consent and the study was conducted in accordance with 
the Declaration of Helsinki. 
 
2.3.2 Ethics 
The study protocol was approved by the South Birmingham Research Ethics 
Committee (number 10/H1207/6) and Research and Development department of 
University Hospitals Birmingham NHS Foundation Trust who were the study sponsor 
(RRK3917). The Trial is registered on clinicaltrials.gov, a registry and results 
database of publicly and privately supported clinical studies of human participants 
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conducted around the world (URL: https://clinicaltrials.gov/ct2/show/NCT01722383. 
Study identifier NCT01722383). 
 
2.3.3 Inclusion and Exclusion Criteria  
The following criteria were used to assess eligibility for study entry. 
 
Inclusion Criteria 
 An eGFR (using the four variable MDRD equation (28)) below 30 
ml/min/1.73m
2
. 
 An ACR above 70mg/mmol on at least three occasions. Where the recruiting 
site routinely assessed urinary Protein Creatinine Ratio (PCR), a cut off point 
greater than 100mg/mmol was used. 
And/or 
 A decline of 5ml/min/1.73m2/year or 10ml/min/1.73m2 over five years 
(Section 2.2.4). 
And 
 At least one year of secondary care renal follow up. 
 Six or more documented eGFR results over at least one year. 
  
These inclusion criteria were aligned to the 2008 National Institute for Health and 
Care Excellence (NICE) CKD guidelines for referral to secondary care nephrology 
services (58). 
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Exclusion Criteria 
 Current or previous immunosuppression for immune-mediated renal disease. 
 Established on renal replacement therapy (dialysis or kidney transplantation). 
 
Immune mediated renal disease may influence inflammatory and cardiovascular risk, 
either directly via immune processes or via the immunomodulatory medications used 
in their management. Similarly people established on RRT will have competing risks 
for adverse events. Individuals from these groups were therefore excluded from 
participation. 
 
2.3.4 Assessing progression in the screening process for the RIISC cohort 
A linear regression technique was used in the screening process to estimate CKD 
progression (73). This technique had been validated in previous research studies (189) 
and could be calculated relatively quickly from minimal data, something essential in a 
screening scenario. 
 
An individual’s eGFR values were used to estimate decline using a linear regression 
line calculated from the available data points. The slope of this line produced a value 
equivalent to eGFR change as ml/minute/1.73m
2
/day which was subsequently 
multiplied to give estimated ml/min/1.73m
2
/year and ml/min/1.73m
2
/5 year values. 
 
These analyses for renal progression were initially performed manually by the 
investigators before an informatics solution was sought, which calculated the slope of 
the line and the standard error. 
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2.3.5 Study Sites 
The RIISC study commenced recruitment in October 2010, initially recruiting from 
nephrology clinics associated with University Hospitals Birmingham NHS 
Foundation Trust (UHB). 
 
Recruitment was expanded to Heart of England NHS Foundation Trust (HEFT) in 
October 2012 following appropriate ethical approval and site initiation visits. 
 
2.3.6 Screening Process 
Figure 2-2 illustrates the pathway from initial screening to attendance at the baseline 
visit. Queries regarding an individual’s suitability for inclusion were discussed with 
the Chief Investigator or research fellow. 
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Figure 2-2. Screening process for eligibility for the RIISC study  
 
 
Abbreviation: ESRD, end stage renal disease 
 
If suitable, individuals were invited to participate in RIISC clinics. An appointment to 
a research clinic was generated and a Patient Information Sheet (PIS) sent to the 
patient [Appendix 1 and 2]. In order to reduce inconvenience and hospital visits, and 
encourage attendance, the study visit replaced a routine clinic attendance.  
 
2.3.7 Consent 
When an individual attended the research clinic, informed consent was taken by an 
appropriately trained and Good Clinical Practice certified investigator.  
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If they elected to enter the study, a consent form [Appendix 3] was signed and 
witnessed and the study investigations commenced.  
 
If an individual decided not to participate in the study, the reasons for this were 
obtained and categorised as follows 
 Informed refusal – this may have been over the telephone before a clinic 
attendance or during the research clinic 
 Unable to give informed consent 
 No longer meeting eligibility criteria including progression to ESRD prior to 
attendance at clinic 
 
This prospective evaluation of reasons for non-consent allowed PRISMA-style flow 
diagrams (190) to be accurately constructed and areas where adjustments to recruiting 
techniques identified. An example of this was an ethics amendment submitted to the 
South Birmingham Research Ethics Committee, asking permission to include a 
summary PIS [Appendix 4] to be included with the full length PIS to provide an 
succinct summary of what participating in the study would involve. 
 
If a patient elected not to enrol in the RIISC study, their normal clinic routine was 
followed including blood pressure check, phlebotomy, urine dipstick and protein 
quantification and clinical review. A routine medical review was carried out by a 
clinic doctor. The patients then returned to their regular clinic for follow up. 
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2.4 The Baseline RIISC Study Visit 
Individuals giving informed consent to take part in the trial underwent a multi-faceted 
bio-clinical assessment (see Figure 2-3).  
 
Figure 2-3. Overview of the RIISC Bio-clinical Assessment 
 
Abbreviations: HRQL, health related quality of life. 
 
The components of the assessment are described below. I have placed particular 
emphasis on those components used for the analyses in this thesis, but have included a 
brief description of other key components (e.g. different assessments of 
cardiovascular health) to enable an appreciation of the comprehensive bio-clinical 
assessment undertaken in RIISC. 
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2.4.1 Demographic and Socio-economic assessment 
Demographics including age, gender, ethnicity and country of birth were collected. As 
with the primary care cohort (Section 2.2), ethnicity was self-reported, considered the 
gold standard for classification (184), taking into account an individual’s cultural and 
self-identity. Ethnicity was categorised into five groups: white, black, South Asian, 
mixed ethnicity and other. 
 
Socio-economic status (SES), including ethnicity, educational background, 
occupational status and an assessment of deprivation were documented. The 
catchment areas of both recruiting centres cover a wide socioeconomic spectrum and 
have a high proportion of non-white ethnicity.  
 
In similarity to the technique used in the primary care cohort (Section 2.2.7), SES was 
assessed using the Index of Multiple Deprivation which utilises the postcode from an 
individual’s address to assign a score and rank; a lower rank corresponds to the most 
deprived areas. The RIISC study used data from IMD 2010, rather than IMD 2007 
used in the primary care work (191). 
 
2.4.2 Assessment of Health Related Quality of Life 
Health related quality of life (HRQL) can be assessed using disease specific or 
generic instruments. A systematic review of patient reported outcome measures 
(PROMs) used in CKD supported the use of preference-based utility measures, 
favouring the EuroQol, EQ-5D due to ease of use for patients and for the ability to 
derive utility values for health economic evaluation (192). 
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Data were collected from participants using the EQ-5D-3L (abbreviated to EQ-5D 
throughout this thesis).  This is a validated, generic preference-based measure of 
health status that comprises a 5-question multi-attribute questionnaire and a visual 
analogue self-rating scale (VAS) (193) [Appendix 5]. Respondents were asked to rate 
severity of their current problems (level 1=no problems, level 2=some/moderate 
problems, level 3=severe/extreme problems) for five dimensions of health: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression).  Health states 
were converted into an EQ-5Dindex score ranging from −0.594 to 1.0 (where 1 is full 
health and lower values indicate worse HRQL) using a set of weighted preferences 
produced from the UK population (194). The EQ VAS asks respondents to rate their 
own health state relative to full health (score=100) or worst imaginable health state 
(score=0). 
 
2.4.3 Anthropometrics 
Traditionally Body Mass Index (BMI; weight in kg / [height in metres]
2
) has been 
used for an assessment of obesity and therefore a marker of cardiovascular risk. It is 
recognised that BMI has limitations as it does not take into account body shape and 
may not be as useful in the assessment of individuals of non-white ethnicity (195). 
One reflection of this is that waist circumference, as a measure of abdominal obesity, 
rather than BMI is incorporated into the consensus criteria for diagnosis of the 
metabolic syndrome, a cluster of risk factors for cardiovascular disease and type 2 
diabetes (196).  
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We therefore collected the following measurements 
 Height 
 Weight 
 Waist Circumference 
 Hip Circumference 
 Thigh Circumference 
 
Readings were taken using appropriately calibrated equipment and research staff 
followed standard operating procedures (SOPs) to ensure consistency of results. 
 
2.4.4 Cardiovascular Profile 
2.4.4.1 Blood Pressure 
Brachial blood pressure (BP) was measured using the BpTRU fully automated 
sphygmomanometer (BpTRU Medical Devices, Coquitlam, BC, Canada), which 
obtained a series of six BP readings at one minute intervals following a five minute 
rest period. Mean BP was derived from the average of the second to sixth BP reading. 
This average reading have been reported to be comparable to mean daytime blood 
pressure from 24 hour ambulatory BP monitoring (197) and reduces the white coat 
response compared to manual office BP measurements (198). 
 
2.4.4.2 Central Blood Pressure and Arterial Stiffness 
Vascular calcification is common in CKD and is associated with increased mortality, 
especially due to cardiovascular disease events (199). Vascular calcification in CKD 
results from two distinct vascular pathologies, atherosclerosis and arteriosclerosis 
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(200). Atherosclerosis is an intimal disease characterised by fibroatheromatous 
plaques whereas arteriosclerosis is a disease of the arterial medial layer due to 
increased collagen content, calcification and proliferation of vascular smooth muscle 
cells (201). It is arteriosclerosis that dominates in more severe CKD. This results in 
increased arterial stiffness and pulse pressure and abnormal cardiac structure and 
function (202) with a subsequent increased risk of cardiovascular disease events and 
death. Studies in a variety of populations have demonstrated the independent 
association of cardiovascular outcomes and PWV (203) and the relationship between 
CKD, PWV and death (204).  
 
A variety of surrogate markers, using both invasive and non-invasive techniques, for 
arterial stiffness exist. The non-invasive Vicorder instrument [Smart Medical, 
Gloucestershire, UK] was utilised in the RIISC study. It measures peripheral and 
central blood pressure, and arterial stiffness by carotid-femoral pulse wave velocity 
(PWV) and calculation of augmentation index from pulse wave analysis (PWA). The 
Vicorder system has been shown to be operator independent and highly reproducible 
(205).  
 
The following data were collected 
 Peripheral systolic BP (SBP), diastolic BP (DBP), pulse pressure (PP), mean 
arterial pressure (MAP) 
 Central SBP, DBP, PP, MAP 
 Heart rate 
 Carotid-femoral pulse wave velocity 
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Central pressure waveforms were derived and analysed using pulse wave 
analysis to calculate central Augmentation index (AIx) (augmentation pressure 
divided by pulse pressure). Augmentation index varies according to heart rate 
(206). To enable comparisons, AIx was corrected to a HR of 75 beats per 
minute (AIx75). 
 
2.4.4.3 Advanced Glycation End products 
Advanced glycation end products (AGEs) are produced by the Malliard reaction, 
which results in irreversible covalent crosslinking of collagen and elastin with 
carbohydrates or carbonyl groups (207). AGEs have been implicated as a contributing 
factor to arteriosclerosis and cardiovascular disease (208). AGEs may accumulate in 
CKD due to an increased oxidative stress burden with advanced chronic kidney 
disease (208, 209). It has been proposed than AGEs serve as a measure of cumulative 
metabolic stress (210). Their levels have been shown to be independently associated 
with pulse wave velocity (211), mortality (212) and CKD progression (210). 
 
 
Advanced glycation end product accumulation in the skin was measured by skin auto-
fluorescence using a validated AGE Reader
TM
 (DiagnOptics BV, Groningen, The 
Netherlands). 
 
2.4.5 Biological Samples 
Routine clinical blood tests (full blood count, ferritin, urea and electrolytes, bone 
profile, bicarbonate, glucose, HbA1c, lipid profile) and analysis of urine (urine 
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dipstick and protein quantification for ACR) were performed in accordance with the 
current standard of care using local laboratories. 
 
Additional blood and urine samples were processed and stored according to 
established trial SOPs [Appendix 6]. The trial team planned to collect the following 
for all patients at all time-points 
 
 Serum –  5x500µl, 6x250µl and 1x100µl aliquots 
 Plasma – 4x500µl and 1x100µl aliquots. Note; plasma was not collected for 
the first 150 participants at the initial (UHB) recruitment site. 
 Urine – 5x1ml, 1x300µl and 1x100µl aliquots 
 Saliva – 2x500µl aliquots 
 
Samples were labelled with the site, study number, type of biological sample type and 
time-point and stored at minus 80°C in appropriately monitored freezers.  
 
The PAXgene tube system (Quiagen, Venlo, Netherlands) was used to collect DNA 
samples at a single time-point. This typically results in DNA yields of 150-500µg. 
DNA is extracted at a later date according to the manufacturers instructions. In 
accordance to manufacturer’s instructions, these samples were stored at minus 20°C 
for 1-7 days before being transferred to minus 80°C storage. 
 
With particular relevance to this thesis, the following additional assays were 
performed: 
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2.4.5.1 C-Reactive Protein 
C-reactive protein (CRP) was measured using the Full Range C-Reactive Protein Kit 
on a SPA
TM
 automated PLUS turbidimeter (The Binding Site Group Ltd, 
Birmingham, UK). The normal range for CRP is between 0.1 and 9 mg/L, with 90 
percent below 3 mg/L (213). 
 
2.4.5.2 Serum Free Light Chains 
Serum Kappa (κ) and Kambda (λ) free light chain (FLC) concentrations were 
measured by nephelometry on a Dade-Behring BNTMII Analyser (Siemens AG, 
Erlangen, Germany) using particle enhanced high-specificity homogenous 
immunoassays (Freelite
TM
; The Binding Site Group Ltd, Birmingham, UK). The 
normal reference ranges for serum FLC concentrations have been previously 
described as κ: 3.3–19.4 mg/L and λ: 5.7–26.3 mg/L, with the assay sensitivity being 
demonstrated as <1 mg/L. κ and λ FLC concentrations were combined to calculate the 
combined FLC (cFLC) concentrations. For the purpose of analysis, data are presented 
as cFLC and κ-λ FLC ratio.   
 
2.4.5.3 Serum Tryptase 
Serum tryptase concentration was measured by the ImmunoCAP Tryptase sandwich 
immunoassay (Phadia AB, Uppsala, Sweden).  Baseline tryptase levels in healthy 
individuals are reported by the manufacturer of the assay as 1-15 μg/L (214). This 
assay is utilised in Chapter 5. 
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2.4.6 Periodontal Assessment 
The periodontal component of the RIISC study, which included saliva sampling (215) 
and periodontal assessment, was designed in conjunction with clinicians from the 
Periodontal Research Group within the School of Dentistry at the University of 
Birmingham. The key aim of this component was to evaluate the association between 
chronic periodontitis and CKD progression. A description of the rationale, 
methodology and baseline results has previously published (180).  
 
2.4.7 Clinical review 
The final component of the RIISC bio-clinical assessment is a clinical review by a 
consultant nephrologist or clinical fellow (specialty trainee or equivalent), analogous 
to the routine review where best practice guidelines were used to assess and manage 
CKD and its complications and minimise cardiovascular risk. 
 
Data were recorded on the case report form (CRF) including: 
 
2.4.7.1 Renal diagnosis  
The known or presumed renal diagnosis was initially stated in free text and then 
classified as follows 
 Diabetes/ Diabetic kidney disease 
 Interstitial nephropathy 
 Ischaemic/ hypertensive 
 Adult polycystic kidney disease 
 Obstructive uropathy 
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 Reflux nephropathy 
 Primary glomerulonephritis 
 Hereditary 
 Other cystic renal disease 
 Secondary glomerulonephritis 
 Not known and other 
 Not stated 
 
The date of any renal biopsy was recorded. 
 
2.4.7.2 Comorbidities  
Medical history was listed. This enabled subjects with specific comorbidities (e.g. 
diabetes) to be analysed separately and for comorbidity scores to be calculated.  
 
The Charlson Comorbidity Index (CCI) is probably the most extensively studied 
index (216). The CCI and case definitions for each part is presented in Table 2-2. 
 
One constituent part of the CCI is moderate/ severe renal disease, defined as serum 
creatinine >3mg/dL (>265.2μmol/L). Therefore certain analyses involved including 
CCI without the renal disease points. 
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Table 2-2. Criteria and Scoring System for Charlson Comorbidity Index. Adapted from (216). 
Domain Definition Points 
Myocardial infarction One or more definite or probable myocardial infarcts. Patients should have been 
hospitalized for chest pain or an equivalent clinical event and have had 
electrocardiographic and/or enzyme changes. 
1 
Congestive Heart 
Failure 
Exertional or paroxysmal nocturnal dyspnoea and who have responded 
symptomatically (or on physical exertion) to digitalis, diuretics or afterload reducing 
agents. It does not include patients who are on one of those medications but who have 
had no response and no evidence of improvement of physical signs with treatment. 
1 
Peripheral Vascular 
Disease 
Intermittent claudication or those who have had a bypass for arterial insufficiency, 
those with gangrene or acute arterial insufficiency, and those with treated or untreated 
thoracic or abdominal aortic aneurysm (6cm or more) 
1 
Cerebrovascular 
Disease 
Patients with history of cerebrovascular accident with minor or no residua. 1 
Dementia Patients with moderate to severe chronic cognitive deficit resulting in impaired 
function from any cause. 
1 
Pulmonary disease Patients with asthma, chronic bronchitis, emphysema, and other chronic lung disease 
who have ongoing symptoms such as dyspneoa or cough, with mild or moderate 
activity 
1 
Connective Tissue 
Disease 
(Rheumatologic) 
Includes patients with systemic lupus erythematous, polymyositis, mixed connective 
tissue disease, rheumatoid arthritis, polymyositis, polymyalgia rheumatica, vasculitis, 
sarcoidosis, Sjogrens syndrome or any other systemic vasculitis.  
1 
Peptic ulcer disease Patients who have previously required treatment for ulcer disease, including those 
who have bled from ulcers. 
1 
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Table 2-2 continued… 
Domain Definition Points 
Liver disease Mild: Chronic Hepatitis or cirrhosis without portal hypertension 1 
 Moderate: Cirrhosis with portal hypertension, but without bleeding 3 
 
Severe: Patients with ascites, chronic jaundice, portal hypertension or a history of 
variceal bleeding or those who have had a liver transplant 
3 
Diabetes Moderate: Patients with diabetes and previous hospitalisations for ketoacidosis, 
hyperosmolar coma or control and those with juvenile onset or brittle diabetes 
1 
 Severe: Patients with retinopathy, neuropathy or nephropathy attributable to diabetes 2 
Hemiplegia (Paralysis) Includes patients with hemiplegia or paraplegia, whether it occurred as a result of a 
cerebrovascular accident or other condition 
2 
Renal Disease Moderate: Includes patients with a serum creatinine >3 mg/dl (>265 μmol/L)  2 
 Severe:  Includes patients on dialysis, those who have had a transplant, and those with 
uraemia 
2 
Tumour Patients with solid tumours without documented metastases but initially treated in the 
last 5 years, including breast, colon, lung and a variety of other tumours 
2 
Lymphoma Includes patients with Hodgkins, lymphosarcoma, Waldenstrom's 
macroglubulinaemia, myeloma and other lymphomas 
2 
Leukaemia Includes patients with acute and chronic myelogenous leukaemia, acute and chronic 
lymphocytic leukaemia, and polycythemia vera 
2 
Metastatic Cancer Patients with metastatic solid tumours including breast, lung, colon and other tumours 6 
AIDS Patients with diagnosed or probable Acquired Immunodeficiency Syndrome (AIDS), 
and those who are Human Immunodeficiency virus (HIV) positive and asymptomatic 
6 
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2.4.7.3 Medication  
Medication including doses were listed. These were then grouped according to their 
listing in the British National Formulary (217). 
 
2.4.7.4 Lifestyle factors 
Present and past use of tobacco and alcohol were recorded. 
 
2.4.8 Study Duration 
Patient recruitment commenced in October 2010. Patients consented for follow-up for 
ten years from recruitment. 
 
The censor date for each analyses presented is stated in the relevant results section. 
 
2.4.9 Follow-up RIISC Study Visit Schedule 
Given the typically long time course of CKD until clinical endpoints, the RIISC study 
was designed to follow people longitudinally. Visits were scheduled for 
 6 months 
 18 months 
 36 months (3 years) 
 60 months (5 years) 
 120 months (10 years) 
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These visits had the same investigations performed as the baseline visit, with the 
exception of the dental assessment which did not occur at 6 and 18 month time-points. 
Additionally clinical information was sought regarding clinical events, new diagnoses 
and medication changes. 
 
Participants were reviewed between these visits in their routine renal clinic at time-
points appropriate to their clinical situation. 
 
2.4.10 Study End-points 
Study end-points included progression to ESRD or death. Progression to ESRD was 
defined as the initiation of RRT (chronic dialysis or renal transplantation). Patient 
mortality was captured through linkage between electronic patient records and the 
ONS, which collects information on all registered deaths in the UK. 
 
2.4.11 Electronic Data Collection 
A screening spreadsheet was created by the study team to record participants, 
including their unique study number and dates of visits. Individuals who elected not to 
participate in the study were recorded, as described in Section 2.2.7, in order to 
document reasons for non-consent and to ensure these individuals were not re-invited 
to the RIISC study clinic. 
 
Initially, data were transcribed manually from paper copies of CRFs, including 
measurements taken from study visits and blood results, into a database (Microsoft 
Access, Washington, USA). Recognising this was time-consuming and had the 
 73 
potential to give rise to transcription errors (218), the informatics team at University 
Hospitals Birmingham were commissioned to work with us to create a bespoke 
informatics solution where data could be entered during the study visit (Figure 2-3). 
This resource was able to link to other IT systems within the hospital, including 
laboratory systems for blood results. Results from Heart of England NHS Foundation 
Trust were linked via comma separated value (CSV) files provided by the renal IT 
team. 
 
An illustration of the electronic database is shown in Figure 2-4. 
 
Figure 2-4. Screen image of bespoke RIISC electronic database. 
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2.5 Statistical Analyses 
This section describes the general statistic techniques used in this thesis. Specific 
techniques or explanations pertinent to a particular results section are presented within 
that section. 
 
Analyses for Chapter 3 were performed using PASW statistics 18 for Windows [IBM, 
Chicago, Il, USA]. Subsequent analyses (Chapters 4-6) were performed using Stata 
13.1 [Statacorp, College Station, Texas, USA]. The latter enabled competing risk 
analyses (Section 2.5.3.3 below) to be performed. 
 
2.5.1 Descriptive Statistics 
Data are presented as mean with standard deviation (SD) or median with interquartile 
range (IQR) depending on distribution. Continuous variables were compared using 
ANOVA (parametric distribution) or Kruskal-Wallis (non-parametric distribution). 
Categorical variables were compared using chi-squared tests. Statistical significance 
was defined as a two-tailed P-value <0.05. 
 
Correlation analyses were performed using Spearman’s Rank Correlation. Values (R) 
were defined as very weak (R=0-0.19), weak (R=0.2-0.39), moderate (R=0.4-0.59), 
strong (R=0.6-0.79) and very strong (R>0.8) (219).  
 
2.5.2 Regression Analyses 
Both logistic and linear regression analyses are utilised in Chapter 6. These 
techniques are described within that section. 
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2.5.3 Survival Analyses 
The focus of this thesis was to investigate the time from recruitment until an event of 
interest, for example death or progression to ESRD.  
 
At the end-of the follow-up period, some individuals will not have experienced the 
event of interest, and their true time to the event is unknown. This may arise in one of 
the following ways (220) 
 A patient has not (yet) experienced the relevant outcome. 
 A patient is lost to follow-up during the study period. 
 A patient experiences a different event that results in the individual no longer 
being followed up. A statistical approach to potentially deal with this is 
described in Section 2.5.3.3. 
 
Time-to-event (survival) analyses therefore need to include those who have 
experienced an event and whose true time to event is unknown. This can be achieved 
through the use of one, or several, survival analysis techniques. 
 
2.5.3.1 Kaplan-Meier plots 
The survival probability can be estimated non-parametrically from observed survival 
times using the Kaplan-Meier (KM) method (220). The KM survival plot is used to 
provide a graphical summary of the data and can graphically demonstrate whether 
there is a variation in the outcome over time. The log rank test is a non-parametric 
technique which can compare survival in two or more groups of patients. 
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2.5.3.2 Cox Regression Analyses 
If an adjustment for covariates or potential confounders is required, a different 
statistical approach is needed. The Cox proportional hazards model is the most 
commonly used approach for analysing multivariable survival time data in medical 
research (221). It provides probability (hazard ratio; HR) of an event at a given time 
(complete with 95% confidence intervals and P-value) with a specific pattern of 
covariates. Both univariable and multivariable regression analyses are presented.  
 
An assumption of the Cox model is that the probability of the outcome of interest is 
relatively constant throughout the follow up time. This proportionality hazard 
assumption can be assessed by examining KM plots and log-log plots.  
 
2.5.3.3 Competing Risk Analyses 
As described above, survival analyses, by their nature, use time-to-event data (222). 
Survival analyses including Cox proportional hazard analyses treat all censored events 
as ‘uninformative’; that is to say a patient being censored due to reaching the end of 
their follow up or due to another end-point (death in the case of ESRD or vice-versa) 
are treated equally. These alternative events are of clinical significance and of 
statistical importance; someone who has died will never reach ESRD (11). Therefore, 
in order to incorporate this into specific analyses, I performed competing risk analyses 
according to the method described by Fine and Gray (223) (Stata command stcrreg).  
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2.5.4 Missing data 
All analyses utilise a complete case approach. However, in similarity with many 
clinical studies, there are some missing data (224). Data completeness is described 
within each section. If a component has a significant amount of missing data, for 
example ACR results within Chapter 3, data were analysed for all individuals 
identified and then repeated for individuals who had an ACR recorded.  
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3 RESULTS 1. The impact of ethnicity, chronic kidney disease and 
cardiovascular comorbidity on mortality in a multiethnic 
primary care population. 
 
3.1 Preface 
In Chapter 1 I discussed the paucity of data regarding the impact of ethnicity on 
adverse outcomes in individuals with chronic kidney disease (CKD). In this chapter I 
report the results of an analysis of the impact of ethnicity, comorbidity and renal 
function (both eGFR and ACR) on death in an ethnically diverse primary care 
population. These analyses utilised the enhanced primary care data collected within 
Heart of Birmingham Primary Care Trust (HoB PCT) (Section 2.2). 
 
3.2 Abstract 
Background. Whilst studies have reported potential survival differences between 
ethnic groups, there has been limited reporting on the relative impact of comorbidities 
including kidney function on a population basis. This study assessed the impact of 
CKD and cardiovascular comorbidity on mortality in a multi-ethnic, primary care 
population. 
 
Methods. 31,254 Individuals aged 40 years and older, of South Asian, black or white 
ethnicity, registered with a general practice participating in an enhanced data 
collection project, and with their kidney function checked within the last 12 months, 
were included. The outcome measure assessed was all-cause mortality. 
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Results: Reduced estimated Glomerular Filtration Rate, higher albuminuria, older 
age, white ethnicity (versus South-Asian or black ethnicity) and increasing 
cardiovascular comorbidities were independent determinants of a higher mortality 
risk. In the multivariable model including comorbidities and kidney function, the 
hazard ratio for mortality for South Asians was 0.70 (95% confidence interval (CI) 
0.56 – 0.87, P=0.001) and for blacks was 0.53 (95% CI 0.40 – 0.70, P<0.001), 
compared to whites.  
 
Conclusions: The hazard ratio for death was lower for South Asian and black 
individuals compared to white individuals. This was, in part, independent of age, 
gender, socio-economic status (SES), kidney function and comorbidities. Risk of 
death was higher in individuals with CKD and in those with a higher cumulative 
cardiovascular comorbidity. 
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3.3 Introduction 
Chronic kidney disease (CKD) prevalence and the risk imparted by CKD may vary by 
ethnicity. As discussed earlier in Section 1.5.1, some studies indicate that CKD is 
more common in people of white ethnicity (5, 225) but non-white ethnic groups have 
a faster progression to end-stage kidney disease (11, 226). Paradoxically, when treated 
with chronic dialysis treatment, people of non-white ethnicity have a lower mortality 
risk than people of white ethnicity (9, 227).  An increased risk of death is also 
associated with other comorbidities, including hypertension, diabetes and 
cardiovascular disease (CVD) (228-233). 
 
Whilst previous studies have indicated survival differences between ethnic groups 
(11, 95-99), there has been limited reporting in these studies on the relative impact of 
comorbidities including kidney function on a population basis. This paucity of data 
reflects a shortfall in the availability of population based primary care databases 
linked to estimated Glomerular Filtration Rate (eGFR) and albuminuria reporting and 
traceable to mortality. Furthermore there are minimal comparative data on people of 
South Asian ethnicity; comparative studies usually report data on Chinese-Asians (5). 
 
In the United Kingdom, there has been a systematic improvement in chronic disease 
recognition through a primary care pay for performance system, the Quality and 
Outcomes Framework (QOF) (234, 235). This system utilises chronic disease 
registers for the identification, monitoring and management of patients with known 
comorbidities; a component of this monitoring involves measuring and documenting 
renal function. These disease registers can be combined with laboratory results and 
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linked with demographic and mortality data to better identify determinants of 
outcomes.  
 
I therefore utilised a primary care cohort incorporating chronic disease registers to 
perform a retrospective cohort study of the relationship between CKD, cardiovascular 
(CV) comorbidity and mortality within a deprived, inner-city multi-ethnic population. 
The study hypotheses were 
1. There are differences in mortality between different ethnic groups. 
2. These differences in mortality are explained by known risk factors including 
comorbidities, renal function, demographic and socioeconomic factors. 
 
This study incorporated all stages of kidney function, except stage G5 CKD (eGFR 
<15ml/min/1.73m
2
), in patients with known CV comorbidities and focused on three 
ethnic groups: South Asian (including individuals of Bangladeshi, Indian and 
Pakistani descent), black (individuals from or who have ancestors from Africa or the 
Caribbean) and white. 
 
3.4 Methods 
A description of the cohort, ethics permission, inclusion and exclusion criteria, study 
design, and statistical techniques are presented in the methods section of this thesis 
(Sections 2.2 and 2.5).  
 
3.4.1 Specific Statistical Analyses Related to this Chapter 
All analyses were performed using PASW statistics 18 for Windows [IBM, Chicago, 
Il, USA]. 
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Measurements for kidney function were divided into categories; eGFR into six 
categories (15-29, 30-44, 45-59, 60-89, 90-119 and ≥120 ml/min/1.73m2) with the 
eGFR range between 90 and 119 ml/min/1.73m
2
 as the reference population. 
Individuals with an eGFR <15 ml/min were excluded from the analysis. ACR was 
divided into five categories (<1.1 mg/mmol ‘optimal’, 1.1-2.99 ‘high normal’, 3-
29.99 ‘high’, 30-199.99 ‘very high’ and ≥200 ‘nephrotic’) in line with the KDIGO 
consensus conference (42). 
 
Age was divided into six categories (50 years and under, 51-60, 61-70, 71-80, 81-90, 
greater than 90 years) with the youngest group serving as comparator. 
 
The association between comorbidity, ethnicity and mortality was assessed by 
univariable analyses for all risk factors and then presented as three models.  Choice of 
model variables were determined by the availability in the dataset of demographic and 
clinical risk factors consistent with those utilised by other investigators in previous 
work in similar populations (236, 237), where the variable was available in this target 
population. Model 1 incorporates the number of identified vascular comorbidities 
(zero to seven), ethnicity, age, gender, smoking status and SES. Model 2 includes 
eGFR level with removal of CKD from the comorbidity score (possible scores 
therefore zero to six) in order to avoid the association between declining renal 
function and the likelihood of being on the CKD register. Model 3 added ACR to the 
variables in Model 2. 
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A complete case model was used in the analyses. All data were complete with the 
exception of ACR. Therefore data were analysed for all individuals identified 
(unadjusted, Model 1 and Model 2) and then repeated for individuals who had an 
ACR recorded (unadjusted and Models 1-3). An ‘enter’ technique was used for the 
regression analysis. 
 
3.5 Results 
3.5.1 Complete Cohort 
Figure 3-1 illustrates the section process for inclusion in the study.  
 
At inception (May 2008) 31,254 individuals fulfilled inclusion criteria for analysis. 
People of South Asian ethnicity formed the largest ethnic group (16,724, 53.4%), 
followed by people of white ethnicity (9146, 29.3%) and black ethnicity (5384, 
17.2%). Baseline characteristics of the study population are shown in Table 3-1. The 
age distribution differed between groups with South Asians significantly younger than 
the other two ethnic groups. There was no significant difference in gender mix 
between the three ethnic groups. Smoking was least common in the South Asian 
group.  The majority of all three ethnic groups resided in the most deprived quintile, 
with a higher proportion of people of South Asian and black ethnicity in this quintile 
than people of white ethnicity.  
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Figure 3-1. Flow Diagram indicating selection process for inclusion in the 
analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration 
rate; HoB, Heart of Birmingham Trust; IDMS, isotope dilution mass spectrometry.  
Excluded 
Population of practices who declined to participate in data collection 
project = 26,552 
Excluded 
eGFR <15 ml/min = 98 
Ethnicity missing = 6,813 
Ethnicity documented as mixed/ other / not stated = 1,630 
Excluded 
No renal function within the last 12 months = 38,561 
Left participating practice during study period = 9,907 
IDMS conversion for creatinine not available = 1,129  
Population for included practices = 285, 221 
Individuals ≥40 years with renal function available = 39,795 
Population for analyses 
Total 31,254 (ACR available in 11,205) 
 
White 9,146 (ACR available in 1,908) 
South Asian 16,724 (ACR available in 7,022) 
Black 5384 (ACR available in 2,275) 
Population Registered with GP in HoB = 311,773 
Individuals ≥ 40 years = 89,392 
Excluded 
Individuals < 40 years = 195,829  
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Table 3-1. Baseline characteristics by ethnicity. Complete Cohort. 
 
    All White South 
Asian 
Black P-value 
Number (%) 31254 (100) 9146 (29.3) 16724 
(53.4) 
5384 (17.2)   
Age      
 median (lower, 
upper quartile) 
59.0 
(50.0,71.0) 
65.0 (55.0, 
75.0) 
56.0 (49.0, 
68.0) 
61.0 (48.0, 
73.0) 
<0.001 
 50 and under 
(%) 
8421 (26.9) 1515 (16.6) 5124 (30.6) 1782 (33.1) <0.001 
 51-60 (%) 8017 (25.7) 1948 (21.3) 5170 (30.9) 899 (16.7)  
 61-70 (%) 6650 (21.3) 2459 (26.9) 3206 (19.2) 985 (18.3)  
 71-80 (%) 6006 (19.2) 2109 (23.1) 2568 (15.4) 1329 (24.7)  
 81-90 (%) 1974 (6.3) 1008 (11.0) 604 (3.6) 362 (6.7)  
 >90 (%) 186 (0.6) 107 (1.2) 52 (0.3) 27 (0.5)  
Gender      
 female (%) 15248 (48.8) 4384 (47.9) 8184 (48.9) 2680 (49.8) 0.085 
Smoking      
 n (%) 5150 (16.5) 2285 (25.0) 1812 (10.8) 1053 (19.6) <0.001 
IMD Rank      
 Quintile 1 (least 
deprived) (%) 
152 (0.5) 59 (0.6) 92 (0.6) 1 (0.0) <0.001 
 Quintile 2 (%) 316 (1.0) 132 (1.4) 173 (1.0) 11 (0.2)  
 Quintile 3(%) 3348 (10.7) 1860 (20.3) 1255 (7.5) 233 (4.3)  
 Quintile 4 (%) 5144 (16.5) 2243 (24.5) 2238 (13.4) 663 (12.3)  
 Quintile 5 (most 
deprived) (%) 
22294 (71.3) 4852 (53.1) 12966 
(77.5) 
4476 (83.1)  
AF       
 n (%) 807 (2.6) 515 (5.6) 212 (1.3) 80 (1.5) <0.001 
CKD      
 n (%) 3648 (11.7) 1318 (14.4) 1691 (10.1) 639 (11.9) <0.001 
Diabetes      
 n (%) 9931 (31.8) 1771 (19.4) 6415 (38.4) 1745 (32.4) <0.001 
Heart Failure      
 n (%) 822 (2.6) 308 (3.4) 385 (2.3) 129 (2.4) <0.001 
Hypertension      
 n (%) 16505 (52.8) 5181 (56.6) 8063 (48.2) 3261 (60.6) <0.001 
IHD      
 n (%) 4226 (13.5) 1417 (15.5) 2386 (14.3) 423 (7.9) <0.001 
Stroke      
  n (%) 1476 (4.7) 570 (6.2) 673 (4.0) 233 (4.4) <0.001 
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Table 3-1 continued… 
    All White South 
Asian 
Black P-value 
Comorbidities      
 median (lower, 
upper quartile) 
1.0 (0.0, 2.0) 1.0 (0.0, 
2.0) 
1.0 (0.0, 
2.0) 
1.0 (0.0, 
2.0) 
0.075 
 0 (%) 9879 (31.6) 2829 (30.9) 5459 (32.6) 1591 (29.6) <0.001 
 1 (%) 10707 (34.3) 3253 (35.6) 5524 (33) 1930 (35.8)  
 2 (%) 6845 (21.9) 1898 (20.8) 3694 (22.1) 1253 (23.3)  
 3 (%) 2667 (8.5) 785 (8.6) 1451 (8.7) 431 (8)  
 4 (%) 828 (2.6) 254 (2.8) 447 (2.7) 127 (2.4)  
 5 (%) 268 (0.9) 103 (1.1) 124 (0.7) 41 (0.8)  
 6 (%) 55 (0.2) 23 (0.3) 23 (0.1) 9 (0.2)  
 7 (%) 5 (<0.1) 1 (<0.1) 2 (<0.1) 2 (<0.1)  
Creatinine (µmol/L)      
 mean (SD) 87.0 (25.8) 88.2 (24.7) 84.6 (25.4) 92.3 (28) <0.001 
eGFR 
(ml/min/1.73m
2
) 
     
 median (lower, 
upper quartile) 
80.2 (66.7, 
94.3) 
74.9 (62.3, 
88.8) 
81.3 (68.1, 
95.3) 
85.5 (72.3, 
100.1) 
<0.001 
 >120 (%) 1473 (4.7) 264 (2.9) 802 (4.8) 407 (7.6) <0.001 
 90-120 (%) 8523 (27.3) 1842 (20.1) 4841 (28.9) 1840 (34.2)  
 60-89 (%) 16373 (52.4) 5077 (55.5) 8776 (52.5) 2520 (46.8)  
 45-59 (%) 3447 (11.0) 1389 (15.2) 1627 (9.7) 431 (8.0)  
 30-44 (%) 1134 (3.6) 466 (5.1) 517 (3.1) 151 (2.8)  
 15-29 (%) 304 (1.0) 108 (1.2) 161 (1.0) 35 (0.7)  
Died      
  n (%) 1435 (4.6) 681 (7.4) 541 (3.2) 213 (4.0) <0.001 
 
Abbreviations: AF, atrial fibrillation; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; IHD, ischaemic heart disease; IMD, index of multiple 
deprivation.  
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The number of vascular comorbidities was similar between groups, with 11-13% of 
each ethnic group having three or more comorbidities. Prevalence of different 
vascular comorbidities varied between groups: the white group had a lower reported 
prevalence of diabetes but a higher prevalence of CKD, atrial fibrillation, heart failure 
and stroke.  
 
Median eGFR (corrected for ethnicity as appropriate) was 80.2 ml/min/1.73m
2
 and 
was lowest in the white group (74.9 ml/min/1.73m
2
 compared to 81.3 ml/min/1.73m
2
 
for South Asian individuals and 85.5 ml/min/1.73m
2
 for those of black ethnicity; 
P<0.001). 21.5% of White, 13.8% of South Asian and 11.5% of Black individuals had 
an eGFR between 15 and 59 ml/min consistent with stage G3-G4 CKD. 
 
At the end of the study period a higher proportion of white individuals had died 
(7.4%) compared to the two other ethnic groups (South Asian 3.2%, Black 4.0%; 
P<0.001). 
 
3.5.2 Albumin Creatinine Ratio Cohort 
 
An ACR had been tested in 7022 (42.0%), 2275 (24.9%) and 1908 (20.9%) of South 
Asian, black and white individuals respectively. Table 3-2 lists the baseline 
characteristics for this subgroup. The median ACR was 1.1 mg/mmol and was highest 
in the South Asian group (1.2 mg/mmol compared to 1.0 mg/mmol for both white and 
black individuals; P<0.001). Age distribution, eGFR, smoking status, and deprivation 
demonstrated a similar pattern to the complete cohort described above.  
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Those with an ACR tested were more likely to have a greater vascular comorbid 
burden (18-20% having three or more comorbidities). A higher proportion of 
individuals of South Asian descent, male gender and with diabetes had their ACR 
tested. 
 
In concordance to the whole group analyses, deaths in the ACR cohort were highest 
amongst white individuals (7.8%) compared to the South Asian (3.6%) and black 
individuals (3.7%) (P<0.001). 
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Table 3-2. Baseline characteristics by ethnicity. ACR tested cohort. 
    All White South 
Asian 
Black P-value 
Number (%) 11205 (100) 1908 (17) 7022 (62.7) 2275 
(20.3) 
  
Age (years)      
 median (lower, 
upper quartile) 
59.0 (50.0, 
71.0) 
65.0 (55.0, 
75.0) 
57.0 (50.0, 
68.0) 
65.0 (49.0, 
74.0) 
<0.001 
 50 and under (%) 1900 (25.9) 304 (15.9) 1961 (27.9) 635 (27.9) <0.001 
 51-60 (%) 3024 (27.0) 413 (21.6) 2239 (31.9) 372 (16.4)  
 61-70 (%) 2370 (21.2) 496 (26.0) 1423 (20.3) 451 (19.8)  
 71-80 (%) 2251 (20.1) 456 (23.9) 1152 (16.2) 643 (28.3)  
 81-90 (%) 611 (5.5) 222 (11.6) 226 (3.2) 163 (7.2)  
 >90 (%) 49 (0.4) 17 (0.9) 21 (0.3) 11 (0.5)  
Gender      
 female (%) 4348 (38.8) 682 (35.7) 2754 (39.2) 912 (40.1) 0.008 
Smoking      
 n (%) 1869 (16.7) 518 (27.1) 872 (12.4) 479 (21.1) <0.001 
IMD Rank      
 Quintile 1 (least 
deprived) (%) 
30 (0.3) 4 (0.2) 25 (0.4) 1 (0.0) <0.001 
 Quintile 2 (%) 84 (0.7) 19 (1.0) 60 (0.9) 5 (0.2)  
 Quintile 3(%) 712 (6.4) 233 (12.2) 540 (5.7) 78 (3.4)  
 Quintile 4 (%) 1458 (13.0) 339 (17.8) 876 (12.5) 243 (10.7)  
 Quintile 5 (most 
deprived) (%) 
8921 (79.6) 1313 
(68.8) 
5660 (80.6) 1948 
(85.6) 
 
AF       
 n (%) 233 (2.1) 113 (5.9) 91 (1.3) 29 (1.3) <0.001 
CKD      
 n (%) 1637 (14.6) 356 (18.7) 921 (13.1) 360 (15.8) <0.001 
Diabetes      
 n (%) 6828 (60.9) 990 (51.9) 4505 (62.4) 1333 
(58.6) 
<0.001 
Heart Failure      
 n (%) 310 (2.8) 74 (3.9) 175 (2.5) 61 (2.7) 0.005 
Hypertension      
 n (%) 6189 (55.2) 1092 
(57.2) 
3679 (52.4) 1418 
(62.3) 
<0.001 
IHD      
 n (%) 1556 (13.9) 281 (14.7) 1071 (15.3) 201 (8.8) <0.001 
Stroke      
  n (%) 480 (4.3) 97 (5.1) 283 (4.0) 100 (4.4) 0.126 
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Table 3-2 continued… 
    All White South 
Asian 
Black P-value 
Comorbidities      
 median (lower, 
upper quartile) 
1.0 (1.0, 2.0) 2.0 
(1.0,2.0) 
1.0 (1.0, 2.0) 2.0 
(1.0,2.0) 
0.818 
 0 (%) 2510 (22.4) 472 (24.7) 1514 (21.6) 524 (23.0) <0.001 
 1 (%) 3139 (28.0) 466 (24.4) 2103 (29.9) 870 (25.1)  
 2 (%) 3438 (30.7) 574 (30.1) 2093 (29.8) 771 (33.9)  
 3 (%) 1481 (13.2) 261 (13.7) 928 (13.2) 292 (12.8)  
 4 (%) 448 (4.0) 79 (4.1) 284 (4.0) 85 (3.7)  
 5 (%) 154 (1.4) 46 (2.4) 83 (1.2) 25 (1.1)  
 6 (%) 32 (0.3) 10 (0.5) 15 (0.2) 7 (0.3)  
 7 (%) 3 (<0.1) 0 (<0.1) 2 (<0.1) 1 (<0.1)  
Creatinine (µmol/L)      
 mean (SD) 89.1 (27.6) 91.8 (26.2) 86.2 (26.8) 95.8 (29.6) <0.001 
eGFR (ml/min/1.73m
2
)      
 median (lower, 
upper quartile) 
81.1 (66.3, 
95.9) 
74.3 (59.7, 
89.8) 
82 (67.4, 
89.8) 
84.2 (70.0, 
98.9) 
<0.001 
 >120 (%) 611 (5.5) 67 (3.5) 380 (5.4) 164 (7.2) <0.001 
 90-120 (%) 3234 (28.9) 404 (21.2) 2091 (29.8) 739 (32.5)  
 60-89 (%) 5451 (48.6) 953 (49.9) 3453 (49.2) 1045 
(45.9) 
 
 45-59 (%) 1300 (11.6) 323 (16.9) 750 (10.7) 227 (10.0)  
 30-44 (%) 487 (4.3) 131 (6.9) 274 (3.9) 82 (3.6)  
 15-29 (%) 122 (1.1) 30 (1.6) 74 (1.1) 18 (0.8)  
ACR (mg/mmol)      
 median (lower, 
upper quartile) 
1.1 (0.4, 3.4) 1.0 (1.4, 
2.8) 
1.2 (0.5, 3.8) 1.0 (0.3, 
2.9) 
<0.001 
 Optimal (<1.1) 
(%) 
5641 (50.3) 1026 
(53.8) 
3400 (48.4) 1214 
(53.4) 
<0.001 
 High Normal (1.1-
2.99) (%) 
2485 (22.2) 426 (22.3) 1560 (22.2) 499 (21.9)  
 High (3.0-29.99) 
(%) 
2594 (23.2) 402 (21.1) 1717 (24.4) 475 (20.9)  
 Very High (30 - 
200) (%) 
413 (3.7) 49 (2.6) 287 (4.1) 77 (3.4)  
 Nephrotic (>200) 
(%) 
73 (0.7) 5 (0.3) 58 (0.8) 10 (0.4)  
Died      
  n (%) 484 (4.3) 149 (7.8) 250 (3.6) 85 (3.7) <0.001 
Abbreviations: ACR, albumin creatinine ratio; AF, atrial fibrillation; CKD, chronic 
kidney disease; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart 
disease; IMD, index of multiple deprivation.   
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3.5.3 Univariable Analysis 
The univariable analysis for the complete cohort (Table 3-3) demonstrated unadjusted 
HRs for death of 0.42 (95% CI 0.38 – 0.47, P<0.001) for people of South Asian 
ethnicity and 0.52 (95% CI 0.45 – 0.61, P<0.001) for people of black ethnicity, 
compared to people of white ethnicity. The mortality rate increased exponentially 
with age and a higher HR was observed for male gender, current smokers and total 
number of comorbidities. No difference in mortality was found between deprivation 
quintiles. Using an eGFR of 90-119 ml/min/1.73m
2
 as reference, a J-shaped 
relationship was observed with a higher risk of death seen for both higher and lower 
eGFR values. The HR for death increased progressively by stage of CKD with an 
eGFR <90 ml/min/1.73m
2
.  
 
The univariable analysis was repeated for those individuals who had their ACR 
reported (Table 3-3) with similar trends identified to the whole population analysis 
with the exception of no observed difference between individuals with an eGFR of 
≥120 ml/min/1.73m2 compared to 90-119 ml/min/1.73m2. A progressive increase in 
HR for death was seen with each increasing category for ACR. 
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Table 3-3. Cox Proportional Hazard Regression Analysis. Univariable analyses.  
    Complete Cohort  ACR Tested Cohort 
    HR (95% CI) P-value HR (95% CI) P-value 
Ethnicity     
 
White 1 (<0.001*) 1 (<0.001*) 
 
South Asian 0.42 (0.38 - 0.47) <0.001 0.44 (0.36 - 0.55) <0.001 
 
Black 0.52 (0.45 - 0.61) <0.001 0.47 (0.36 - 0.61) <0.001 
Age (years)     
 
50 and under 1 (<0.001*) 1 (<0.001*) 
 
51-60 2.13 (1.55 - 2.91) <0.001 1.76 (1.06 - 2.92) 0.03 
 
61-70 5.43 (4.08 - 7.23) <0.001 4.65 (2.93 - 7.35) <0.001 
 
71-80 12.97 (9.89 - 17.02) <0.001 11.36 (7.38 - 17.51) <0.001 
 
81-90 32.86 (29.95 - 43.26) <0.001 24.73 (15.77 - 38.77) <0.001 
 
>90 90.90 (65.10 - 126.94) <0.001 82.73 (46.68 - 146.61) <0.001 
Gender     
 
Female as reference 1.38 (1.24 - 1.53) <0.001 1.40 (1.16 - 1.70) 0.001 
Smoker     
 
Non-smoker as reference 1.15 (1.01 - 1.32) 0.036 1.26 (1.01 - 1.57) 0.044 
IMD Rank     
 
Quintile 1 (least deprived) 0.86 (0.39 - 1.92) 0.713 <0.001 (<0.001 - >10^5) 0.939 
 
Quintile 2 0.82 (0.47 - 1.45) 0.501 <0.001 (<0.001 - >10^5) 0.897 
 
Quintile 3 1.00 (0.85 - 1.19) 0.983 1.15 (0.82 - 1.62) 0.419 
 
Quintile 4 0.93 (0.80 - 1.07) 0.297 0.77 (0.58 - 1.04) 0.088 
  Quintile 5 (most deprived) 1 (0.802*) 1 (0.42*) 
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Table 3-3 continued… 
 
    Complete Cohort  ACR Tested Cohort  
    HR (95% CI) P-value HR (95% CI) P-value 
AF  5.59 (4.76 - 6.57) <0.001 6.12 (4.57 - 8.21) <0.001 
CKD 3.44 (3.07 - 3.85) <0.001 3.50 (2.90 - 4.21) <0.001 
Diabetes 1.35 (1.21 - 1.50) <0.001 1.94 (1.58 - 2.39) <0.001 
Heart Failure 7.62 (6.60 - 8.80) <0.001 7.28 (5.68 - 9.33) <0.001 
Hypertension 2.08 (1.86 - 2.33) <0.001 2.05 (1.68 - 2.50) <0.001 
IHD  2.80 (2.50 - 3.13) <0.001 3.14 (2.59 - 3.80) <0.001 
Stroke 3.65 (3.15 - 4.23) <0.001 3.71 (2.86 - 4.82) <0.001 
Comorbidities     
 
0 1 (<0.001*) 1 (<0.001*) 
 
1 1.78 (1.49 - 2.12) <0.001 1.63 (1.09 - 2.43) 0.016 
 
2 2.93 (2.46 - 3.49) <0.001 2.92 (2.02 - 4.21) <0.001 
 
3 5.49 (4.55 - 6.62) <0.001 5.58 (3.84 - 8.11) <0.001 
 
4 9.58 (7.69 - 11.94) <0.001 9.86 (6.51 - 14.92) <0.001 
 
5 17.59 (13.49 - 22.94) <0.001 21.09 (13.48 - 33.00) <0.001 
 
6 28.39 (18.41 - 43.78) <0.001 33.67 (17.52 - 64.72) <0.001 
  7 11.87 (1.66 - 84.73) 0.014 29.40 (4.03 - 214.46) 0.001 
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Table 3-3 continued… 
 
    Complete Cohort  ACR Tested Cohort  
    HR (95% CI) P-value HR (95% CI) P-value 
eGFR (ml/min/1.73m
2
)     
 
>120 1.49 (1.11 - 2.01) 0.008 1.07 (0.60 - 1.90) 0.813 
 
90-120 1 (<0.001*) 1 (<0.001*) 
 
60-89 1.36 (1.16 - 1.59) <0.001 1.50 (1.14 - 1.99) 0.04 
 
45-59 3.85 (3.24 - 4.57) <0.001 4.26 (3.16 - 5.74) <0.001 
 
30-44 6.59 (5.40 - 8.04) <0.001 7.72 (5.56 - 10.70) <0.001 
 
15-29 14.47 (11.34 - 18.45 ) <0.001 15.05 (9.94 - 22.80) <0.001 
ACR (mg/mmol)     
 
Optimal (<1.1)   1 (<0.001*) 
 
High Normal (1.1-2.99)   1.36 (1.04 - 1.79) 0.026 
 
High (3.0-29.99)   2.97 (2.38 - 3.70) <0.001 
 
Very High (30 - 200)   6.25 (4.49 - 14.01) <0.001 
  Nephrotic (>200)     7.93 (4.49 - 14.01) <0.001 
 
Abbreviations: ACR, albumin creatinine ratio; AF, atrial fibrillation; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; IMD, index of multiple deprivation.  
 
* P-value for overall effect 
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3.5.4 Multivariable Analysis 
Following adjustment for covariates the differences in ethnicity remained; people of 
South Asian and black ethnicities had a lower HR for death in all analyses. 
 
Model 1 (complete cohort, incorporating the number of identified comorbidities) 
analysed the complete cohort (Table 3-4) and showed an adjusted HR for death of 
0.67 (95% CI 0.60 – 0.76, P<0.001) for people of South Asian ethnicity and 0.59 
(95% CI 0.50 – 0.70, P<0.001) for people of black ethnicity compared to people of 
white ethnicity. When the analysis was restricted to the cohort with ACR tests 
available (Table 3-4) the HR for death was 0.76 (95% CI 0.61 – 0.94, P=0.011) for 
people of South Asian ethnicity and 0.53 for people of black ethnicity (95% CI 0.4 – 
0.69, P<0.001) compared to people of white ethnicity. For the complete cohort, 
mortality risk was lower in IMD quintiles 3 and 4 (compared to the most deprived 
quintile 5). No significant difference between IMD quintiles was identified in the 
ACR cohort. Increasing age (51 years and over in complete cohort, 61 years and over 
in ACR cohort), smoking status and male gender was significant in analyses for both 
cohorts. An increased HR for death was observed for two or more comorbidities, with 
the HR increasing as the number of comorbidities increased. 
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Table 3-4. Cox Proportional Hazard Regression Analysis. Multivariable Analyses. Model 1. (incorporating the number of identified 
comorbidities but not including any measurements of renal function). 
    Complete Cohort  ACR Tested Cohort 
    HR (95% CI) P-value HR (95% CI) P-value 
Ethnicity     
 White 1 (<0.001*) 1 (<0.001*) 
 South Asian 0.67 (0.56 - 0.76) <0.001 0.76 (0.61 - 0.94) 0.011 
 Black 0.59 (0.50 - 0.70) <0.001 0.53 (0.4 - 0.69) <0.001 
Age (years)     
 50 and under 1 (<0.001*) 1 (<0.001*) 
 51-60 1.96 (1.43 - 2.69) <0.001 1.54 (0.92 - 2.57) 0.101 
 61-70 4.51 (3.36 - 6.06) <0.001 3.63 (2.25 - 5.87) <0.001 
 71-80 10.08 (7.57 - 13.41) <0.001 8.12 (5.12 - 12.89) <0.001 
 81-90 23.97 (17.84 - 32.22) <0.001 17.02 (10.44 - 27.73) <0.001 
 >90 68.62 (48.17 - 97.76) <0.001 61.22 (33.37 - 112.31) <0.001 
Gender     
 Female as reference 1.45 (1.30 - 1.62) <0.001 1.81 (1.48 - 2.20) <0.001 
Smoker     
 Non-smoker as reference 1.72 (1.50 - 1.98) <0.001 1.99 (1.57 - 2.52) <0.001 
IMD Rank     
 Quintile 1 (least deprived) 1.08 (0.48 - 2.42) 0.849 <0.001 (<0.001 - >10^5) 0.951 
 Quintile 2 0.91 (0.51 - 1.60) 0.734 <0.001 (<0.001 - >10^5) 0.916 
 Quintile 3 0.82 (0.69 - 0.98) 0.028 0.98 (0.69 - 1.39) 0.907 
 Quintile 4 0.73 (0.63 - 0.85) <0.001 0.75 (0.56 - 1.02) 0.062 
  Quintile 5 (most deprived) 1 (0.001*) 1 (0.478*) 
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Table 3-4 continued… 
    Complete Cohort ACR Tested Cohort 
    HR (95% CI) P-value HR (95% CI) P-value 
Comorbidities     
 0 1 (<0.001*) 1 (<0.001*) 
 1 1.05 (0.87 - 1.25) 0.64 1.39 (0.93 - 2.10) 0.112 
 2 1.26 (1.05 - 1.52) 0.014 1.83 (1.24 - 2.70) 0.002 
 3 1.82 (1.50 - 2.23) <0.001 2.55 (1.72 - 3.81) <0.001 
 4 2.72 (2.16 - 3.44) <0.001 3.87 (2.48 - 6.03) <0.001 
 5 3.89 (2.95 - 5.14) <0.001 6.25 (3.88 - 10.06) <0.001 
 6 6.54 (4.20 - 10.16) <0.001 10.83 (5.53 - 21.22) <0.001 
  7 3.09 (0.43 - 22.08) 0.262 8.97 (1.22 - 66.15) 0.031 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; IMD, index of multiple deprivation.  
 
* P-value for overall effect  
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Kidney function (eGFR) was incorporated into Model 2 (with the removal of CKD 
from the comorbidity score) and in the complete cohort (Table 3-5) the HR for people 
of South-Asian ethnicity was 0.68 (95% CI 0.6 – 0.77 P<0.001) and for people of 
black ethnicity was 0.79 (95% CI 0.64 – 0.98, P=0.032) compared to people of white 
ethnicity. Similarly, when the analysis was restricted to the cohort of patients with 
ACR tests available (Table 3-5), people of South Asian and Black ethnicity had a 
lower proportion of deaths compared to people of white ethnicity with HRs of 0.61 
(95% CI 0.52 – 0.72, P<0.001) and 0.58 (95% CI 0.44 – 0.76, P<0.001) respectively. 
In the complete cohort mortality risk was lower in the IMD quintile 4. More than two 
comorbidities were associated with an increasing HR and an increased HR of death 
compared to the reference eGFR range (90-119 ml/min/1.73m
2
) was seen with an 
eGFR ≥120 ml/min/1.73m2 and ≥45 ml/min/1.73m2. An eGFR of 60-89 
ml/min/1.73m
2
  was associated with a lower HR. In the analysis of those with ACR 
tested, an eGFR <60 ml/min was associated with progressively higher HR by CKD 
stage. 
 
In Model 3 (all vascular comorbidities except CKD and the addition of eGFR and 
ACR, Table 3-6) the HR for death for people of South Asian ethnicity was 0.70 (95% 
CI 0.56 – 0.87, P=0.001) and for people of black ethnicity was 0.53 (95% CI 0.40 – 
0.70, P<0.001) compared to people of white ethnicity (Figure 3-2). Older age, male 
gender, being a current smoker and increasing comorbidity (two or more) were 
associated with an increased HR of death (Figure 3-3). An ACR of ‘high’ or greater 
(i.e. ≥3.0 mg/mmol) and an eGFR <45 ml/min/1.73m2 was also associated with an 
increased HR for death. No significant differences in HRs were observed between 
deprivation quintiles. 
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Table 3-5. Cox Proportional Hazard Regression Analysis. Multivariable Analyses. Model 2. (incorporating the number of identified 
comorbidities excluding CKD, and eGFR). 
    Complete Cohort ACR Tested Cohort 
    HR (95% CI) P-value HR (95% CI) P-value 
Ethnicity     
 White 1 (<0.001*) 1 (<0.001*) 
 South Asian 0.68 (0.6 - 0.77) <0.001 0.79 (0.64 - 0.98) 0.032 
 Black 0.61 (0.52 - 0.72) <0.001 0.58 (0.44 - 0.76) <0.001 
Age (years)     
 50 and under 1 (<0.001*) 1 (<0.001*) 
 51-60 2.09 (1.52 - 2.87) <0.001 1.57 (0.94 - 2.63) 0.086 
 61-70 4.92 (3.65 - 6.63) <0.001 3.70 (2.28 - 6.00) <0.001 
 71-80 10.90 (8.15 - 14.58) <0.001 7.95 (4.96 - 12.74) <0.001 
 81-90 25.20 (18.63 - 34.10) <0.001 16.16 (9.79 - 26.66) <0.001 
 >90 68.19 (47.55 - 97.78) <0.001 52.70 (28.40 - 97.77) <0.001 
Gender     
 Female as reference 1.45 (1.30 - 1.61) <0.001 1.82 (1.49 - 2.22) <0.001 
Smoker     
 Non-smoker as reference 1.69 (1.47 - 1.95) <0.001 1.96 (1.55 - 2.48) <0.001 
IMD Rank     
 Quintile 1 (least deprived) 1.12 (0.50 - 2.49) 0.79 <0.001 (<0.001 - >10^5) 0.951 
 Quintile 2 0.90 (0.51 - 1.59) 0.707 <0.001 (<0.001 - >10^5) 0.917 
 Quintile 3 0.84 (0.71 - 1.00) 0.054 0.98 (0.69 - 1.40) 0.929 
 Quintile 4 0.74 (0.63 - 0.86) <0.001 0.78 (0.58 - 1.05) 0.096 
  Quintile 5 (most deprived) 1 (0.002*) 1 (0.592*) 
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Table 3-5 continued… 
    Complete Cohort ACR Tested Cohort 
    HR (95% CI) P-value HR (95% CI) P-value 
Comorbidities 
    
 
0 1 (<0.001*) 1 (<0.001*) 
 
1 1.02 (0.86 - 1.22) 0.788 1.46 (0.99 - 2.15) 0.055 
 
2 1.21 (1.10 - 1.45) 0.039 1.70 (1.17 - 2.47) 0.006 
 
3 2.12 (1.74 - 2.58) <0.001 2.72 (1.82 - 4.06) <0.001 
 
4 2.64 (2.06 - 3.40) <0.001 3.71 (2.36 - 5.84) <0.001 
 
5 3.64 (2.52 - 5.27) <0.001 6.20 (3.46 - 11.12) <0.001 
 
6 5.07 (1.62 - 15.91) 0.005 10.02 (2.40 - 41.90) 0.002 
eGFR (ml/min1.73m
2
) 
    
 
>120 2.02 (1.5 - 2.72) <0.001 1.47 (0.82 - 2.62) 0.195 
 
90-120 1 (<0.001*) 1 (<0.001*) 
 
60-89 0.82 (0.70 - 0.96) 0.015 0.94 (0.70 - 1.25) 0.649 
 
45-59 1.10 (0.92 - 1.32) 0.301 1.40 (1.01 - 1.92) 0.041 
 
30-44 1.34 (1.08 - 1.66) 0.007 1.95 (1.37 - 2.78) <0.001 
  15-29 2.93 (2.27 - 3.78) <0.001 3.26 (2.10 - 5.06) <0.001 
 
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IMD, index of multiple deprivation.  
 
* P-value for overall effect 
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Table 3-6. Cox Proportional Hazard Regression Analysis. Multivariable analyses. Model 3. (incorporating the number of identified 
comorbidities excluding CKD, and eGFR and ACR)  
    Complete Cohort 
    HR (95% CI) P-value 
Ethnicity   
 White 1 (<0.001*) 
 South Asian 0.70 (0.56 - 0.87) 0.001 
 Black 0.53 (0.40 - 0.70) <0.001 
Age (years)   
 50 and under 1 (<0.001*) 
 51-60 1.52 (0.91 - 2.55) 0.112 
 61-70 3.52 (2.17 - 5.71) <0.001 
 71-80 7.38 (4.61 - 11.82) <0.001 
 81-90 15.72 (9.53 - 25.92) <0.001 
 >90 51.64 (27.89 - 95.62) <0.001 
Gender   
 Female as reference 1.78 (1.46 - 2.18) <0.001 
Smoker   
 Non-smoker as reference 1.89 (1.49 - 2.39) <0.001 
IMD Rank   
 Quintile 1 (least deprived) <0.001 (<0.001 - >10^5) 0.952 
 Quintile 2 <0.001 (<0.001 - >10^5) 0.913 
 Quintile 3 0.98 (0.68 - 1.39) 0.902 
 Quintile 4 0.79 (0.59 - 1.06) 0.118 
  Quintile 5 (most deprived) 1 (0.65*) 
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Table 3-6 continued… 
    Complete Cohort 
    HR (95% CI) P-value 
Comorbidities   
 0 1 (<0.001*) 
 1 1.37 (0.93 - 2.02) 0.109 
 2 1.49 (1.02 - 2.17) 0.039 
 3 2.29 (1.53 - 3.43) <0.001 
 4 3.15 (2.00 - 4.96) <0.001 
 5 5.14 (2.87 - 9.21) <0.001 
 6 10.54 (2.52 - 44.08) 0.001 
eGFR (ml/min/1.73m
2
)   
 >120 1.40 (0.78 - 2.49) 0.26 
 90-120 1 (<0.001*) 
 60-89 0.91 (0.98 - 1.21) 0.505 
 45-59 1.28 (0.93 - 1.76) 0.126 
 30-44 1.57 (1.10 - 2.24) 0.014 
 15-29 2.07 (1.32 - 3.27) 0.002 
ACR (mg/mmol)   
 Optimal (<1.1) 1 (<0.001*) 
 High Normal (1.1-2.99) 1.03 (0.78 - 1.36) 0.821 
 High (3.0-29.99) 1.84 (1.46 - 2.31) <0.001 
 Very High (30 - 200) 2.96 (2.13 - 4.10) <0.001 
  Nephrotic (>200) 3.84 (2.11 - 6.99) <0.001 
 Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IMD, index 
of multiple deprivation. * P-value for overall effect 
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Figure 3-2. Cox Regression Survival Plot indicating cumulative survival between 
ethnicities in Model 3 (comorbidities, eGFR and ACR).  
Table below survival plot demonstrates number of individuals who remained in 
follow up at each time-point. 
 
 
 
Subjects remaining in follow up 
Time from Recruitment (days) 
 
0 200 400 600 800 1000 end 
White 1908 1896 1864 1835 1798 1764 1760 
South Asian 7022 6981 6938 6891 6840 6783 6775 
Black 2275 2266 2251 2228 2208 2192 2191 
All 11205 11143 11053 10954 10846 10739 10726 
 
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration 
rate 
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Figure 3-3. Hazard ratio (HR) for death by number of comorbidities. 
Multivariate analysis: Model 3. 
 
HR not illustrated for 6 comorbidities; HR 10.54 (95% CI 2.52 - 44.084) 
Abbreviations: CI, confidence interval; HR, hazard ratio 
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3.6 Discussion 
The results presented in this chapter utilised routinely available clinical and laboratory 
data, including kidney function assessed by eGFR and ACR, from a large primary 
care population. Detailed SES was included in the analyses and, importantly, three 
ethnic groups, South-Asian, black and white, were studied. Prior to this research, 
there has been uncertainty about the impact of ethnicity and SES on clinical outcomes 
in people with significant comorbidities including CKD. The comprehensive nature of 
the dataset coupled with the ability to utilise the Primary Care Mortality Database has 
allowed me to assess the relative impact of these factors on survival. 
 
The previously identified associations between lower eGFR, higher ACR and 
increased mortality applied to this population. Furthermore, these associations 
remained significant when adjusted for ethnicity, age, gender, cardiovascular risk 
factors and SES. These results add weight to the risk stratification benefit of 
measuring ACR has in high risk groups.  
 
A strong cumulative impact of comorbidity on CKD and ethnicity was shown. 
Whereas traditional comorbidity scores such as the Charlson Comorbidity Index (216) 
are difficult to calculate accurately in a large primary care setting, this study 
demonstrates that a simple cumulative score provides prognostic information. 
Individual comorbidities were present in varying frequencies within different ethnic 
groups, a finding consistent with that found in other ethnically diverse populations 
(238). Whilst individual comorbidities were associated with different mortality risks, 
it was the cumulative effect of comorbidities conveyed the greatest prognostic 
implication. A similar approach, but also including non-cardiovascular risk factors has 
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recently been described (239).  Our study suggests that routinely collected clinical 
data concerning cumulative comorbidity may be utilised to quantify risk, however 
further work would be required to validate this as a tool for use in clinical care.  
 
Socio-economic status was measured by the IMD 2007 score; a cumulative 
deprivation index score incorporating seven areas of deprivation which has been 
validated as superior to other deprivation scores (187). One notable finding is that 
there was no demonstrable association between SES and mortality when corrected for 
all other factors including comorbidity and ethnicity. This is in contrast to the 
evidence presented in Section 1.5.2, which demonstrates that there is frequently an 
independent relationship between SES and mortality across disease states and ethnic 
groups within the UK (240-243). This relationship varies by population group studied 
(244) and there have been limited studies investigating health disparities in similar, 
inner-city populations. Whilst we studied a health care system that is free at the point 
of care, limiting possible health access issues, the majority of individuals were from 
the most deprived national quintile and this study may therefore underestimate the 
influence of the complete spectrum of SES on mortality. To attempt to correct for this, 
analyses were re-run, dividing the cohort into equal quintiles. All analyses continued 
to indicate the effect of ethnicity and the importance of cardiovascular comorbidity 
and renal function. The univariable analysis and the most comprehensive 
multivariable analysis (data not shown) did not show any differences between most 
and least deprived quintiles.  
 
One of the seven areas included in the IMD is health deprivation, raising the 
possibility of an inbuilt relationship between deprivation and health even before 
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analyses are undertaken. The possible implication of this was investigated by Adams 
and White (245) who analysed data having removed the health domain from IMD 
2004 and found that its removal had little, practical, effect. This suggests the presence 
of the health domain is unlikely to influence the results. 
 
Risk of death was lower for people of South Asian and black ethnicity compared to 
people of white ethnicity, and this remained in all analyses (univariable and 
multivariable) performed. Previous studies comparing the outcomes of different 
ethnic groups have been limited in their generalisability. They have either looked at 
disease specific mortality (11, 96, 98, 99) or have been based in populations that do 
not have access to free comprehensive healthcare. The finding that differences in 
mortality risk between ethnic groups is independent of age, gender, SES, kidney 
function and comorbidities require further work. Variables, such as health promotion 
targeted at specific groups, differences in medication usage or factors related to 
genetic diversity may offer potential explanations for this variation (246, 247). 
 
3.6.1 Potential Utility of Alternative Statistical Techniques  
Tables 3-1 and 3-2 demonstrate the baseline characteristics of the cohort split by 
ethnicity. As highlighted earlier in this chapter, differences were demonstrated 
between ethnicities; for example, median age was youngest in the South Asian cohort, 
and there were differences in SES and frequency of individual comorbidities. These 
variables were incorporated into the multivariable Cox regression analyses and, in 
recognition that certain variables (e.g. age) may not have a linear relationship with 
age, some were categorised. Whilst Cox modelling should correct for these 
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differences, one concern may be that comparing outcomes in disparate populations 
may lead to statistically unsafe results. In order to corroborate the results described in 
this chapter, an alternative statistical technique, such as propensity score matching 
(PSM), could be applied.  
 
Propensity score matching is a statistical technique, most frequently using logistic 
regression, which provides information on the probability of receiving a treatment, or 
experiencing an outcome, conditional on the patient’s observed characteristics (248, 
249). The goal is to balance these characteristics (e.g. age, renal function, 
comorbidities) in the individual groups to assess whether any observed difference is 
due to the exposure (ethnicity in this case) or other factors. The benefits of PSM over 
other multiple regression techniques is not universally acknowledged, but is likely to 
be of most benefit when the outcome is rare and the number of observed 
characteristics is large (250). Propensity score matching would not account for any 
unmeasured characteristics. 
 
Unfortunately, owing to an inability to access the data once a query about alternative 
statistical modelling was raised, I have been unable to perform PSM on these data, but 
acknowledge this would provide statistical weight to the results presented in this 
chapter. 
 
3.6.2 Strengths and Weaknesses 
A major strength in this study is the sample size, which included sixty-two practices 
of varying list size and number of practitioners. Ethnicity was documented in over 
 109 
80% of the population studied; this is much higher than normally found in primary 
care records (251). Self-reporting is considered the ‘gold standard’ method of 
assessing ethnicity (184), taking into account an individual’s culture and self-identity. 
Renal function was described in terms of eGFR and ACR. 
 
These analyses have used data from primary care coding and recording systems, 
which formed part of the electronic downloads. These downloads indicate who is on a 
specific cardiovascular risk register and therefore may not classify people correctly. 
There is a relative paucity of published literature regarding the correct identification 
of people onto the correct cardiovascular risk registers (167, 235, 252, 253), although 
analysis of The Health Improvement Network database has demonstrated 
discrepancies between biochemically defined CKD and appearances on practice 
registers (1). Other surrogate measures of accuracy of the data include previous 
studies looking at gaming for QOF points (falsely classifying people with conditions 
they do not have thereby increasing revenue) or exception reporting (excluding 
individuals who have not had the appropriate monitoring completed) suggest that both 
these are rare (235, 254, 255). 
 
When comparing the breakdown of the population studied in these analyses to the 
source population, it is important to highlight two key differences. Firstly, there is a 
relative underrepresentation of individuals of white ethnicity, consistent with previous 
research (256). This is most marked in those who had their ACR measured; a higher 
number of males and individuals with diabetes or of South Asian ethnicity had an 
ACR measured. Comparing the whole cohort to those who had their ACR reported 
showed similar trends for mortality in respect of age, eGFR, smoking status and SES, 
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suggests a generalisability of results. Secondly one criterion for inclusion was the 
recording of renal function within the previous twelve months. This is likely to have 
resulted in an overrepresentation of comorbidity as people with CV conditions would 
be more likely to have their renal function checked. A further consideration is that the 
accuracy and applicability of creatinine based eGFR equations, such as the formula 
used in this analysis, in non-white ethnic groups is a subject of ongoing research (257-
259). Cystatin C based equations may be more accurate (260), but are not routinely 
measured in clinical practice.  
 
It was not possible to assess the number of people who progressed to ESRD in the 
cohort during the study period, as the anonymous nature of the data did not allow 
linkage to secondary care renal data. 
 
3.7 Conclusion to Chapter 3 
These analyses show the determinants of mortality were multifactorial in a high risk 
population and that ethnicity should be considered as a non-traditional risk factor for 
mortality; the HR for death was lower for South Asian and black individuals 
compared to white individuals which was, in part, independent of age, gender, SES, 
renal function and comorbidities. Furthermore, a simple cumulative comorbidity 
system may have prognostic utility. Renal function (eGFR and ACR) provided 
additional information and gender, age and smoking status remained significant risk 
factors for mortality. 
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Further work will now be performed investigating the impact of ethnicity within a 
secondary care nephrology setting. 
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4 RESULTS 2. The impact of ethnicity on progression to end-stage 
renal disease in pre-dialysis chronic kidney disease. 
 
4.1 Preface 
The previous chapter investigated the impact of ethnicity and chronic kidney disease 
(CKD) on mortality in a the diverse central Birmingham primary care population, and 
demonstrated that hazard ratios for death were lower for South Asian and black 
individuals compared to white individuals in univariable and multivariable analyses.  
 
Whilst the analyses intentionally did not include individuals with an estimated 
glomerular filtration rate (eGFR) below 15ml/min/1.73m
2
, and were unable to 
investigate progression to end stage renal disease (ESRD) directly, the findings may 
impact on the secondary care nephrology population as white individuals may have an 
increased competing risk (i.e. death) which means they will not reach ESRD or, 
potentially, the need for secondary care nephrology input. 
 
This work, coupled with evidence of higher rates of progression to ESRD in non-
white ethnicities, led to an evaluation of ethnicity as a potential risk factor associated 
with accelerated progression of CKD in the Renal Impairment in Secondary Care 
(RIISC) CKD cohort. Whilst this chapter investigates the impact of both South Asian 
and black ethnicities compared to white ethnicity, the predominant focus is on South 
Asian ethnicity as there is a little published literature on the factors that influence 
progression in this group. To include the impact of any difference in mortality 
between ethnicities, competing risk regression (Section 2.4.3.3) was performed.  
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4.2 Abstract 
Background. People of South Asian ethnicity have a higher rate of progression to 
ESRD compared to white individuals. A United Kingdom (UK) based, CKD cohort 
was utilised to assess for modifiable risk factors for accelerated progression of CKD 
in people of South Asian ethnicity.  
  
Methods. 727 (white 507, South Asian 150, black 70) individuals in the Renal 
Impairment in Secondary Care study were included. Primary end-points included 
progression to ESRD or death. Survival analyses, including Cox proportional hazards 
and competing risk regression were performed. 
  
Results. Median eGFR was 25.7ml/min/1.73m
2
 (IQR 19.5-33.5) and median urine 
albumin creatinine ratio (ACR) was 32.8mg/mmol (IQR 6.7-127.6). During the 
follow-up period, 151 (20.8%) individuals reached ESRD and 76 (10.5%) died. 
  
There was no difference in eGFR between ethnic groups. However there were major 
differences in albuminuria as measured by ACR; this was highest in South Asian 
participants (median 84.1mg/mmol, interquartile range (IQR) 25.9-170.2), compared 
to black (53.2mg/mmol, IQR 9.9-137.3) and white ethnicities (20.0mg/mmol, IQR 
4.5-101.4) (P=0.0001). 
  
By Cox survival analysis, individuals of South Asian (Hazard Ratio (HR) 1.62, 95% 
Confidence Interval (CI) 1.11-2.35, P=0.012) and black ethnicities (HR 1.79, 95% CI 
01.10-2.90, P=0.019) had an increased risk of ESRD compared to individuals of white 
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ethnicity. Multivariable analyses attenuated this difference and ACR was the major 
modifiable risk factor. Other variables independently associated with worse outcome 
were lower age, male gender, lower eGFR, higher diastolic blood pressure, lower 
serum albumin, lower haemoglobin and lower triglycerides. 
  
Conclusions. Albuminuria is the principal modifiable risk factor for progression to 
ESRD in people of South Asian ethnicity. Treatments to reduce albuminuria should 
be optimised and research is needed into why albuminuria is typically higher in this 
ethnic group. 
 
4.3 Introduction 
People of South Asian ethnicity are a large ethnic group in the UK. Despite a similar 
or lower overall prevalence of CKD compared with individuals of white ethnicity, 
there is both a higher rate of progression to ESRD (2, 6, 39) and a lower median age 
of starting renal replacement therapy (RRT) compared to people of white ethnicity 
(57.0 years for non-White patients compared to 66.0 years for White patients) (103).  
 
In patients with CKD there is intense interest on risk stratification through the 
identification of factors that are associated with adverse outcomes. Whilst there have 
been many studies looking at the impact of black ethnicity on ESRD, including 
identification of potential genetic explanations of any differences (261), there has 
been no analysis specific for those of South Asian ethnicity. Consequently little is 
known about how risk factors for progression to ESRD in this ethnic group differ 
from other ethnic groups. 
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If differences in ESRD by ethnicity exist, potential explanations include: differences 
in the intrinsic characteristics of specific populations; a variation in the rate of 
established risk factors (12); or a competing event which prevents an individual 
reaching ESRD. For example, previous studies, including the analyses described in 
Chapter 3, have identified a lower rate of death in non-white ethnic groups (11, 262) 
and, if there is a different mortality rate by ethnicity, this competing risk may 
influence the total numbers reaching ESRD.  
 
In order to clarify the relationships between ethnicity and established risk factors on 
progression to ESRD in people of South Asian ethnicity this chapter utilises the 
socioeconomically and ethnically diverse RIISC prospective cohort study of pre-
dialysis CKD in a country with universal health coverage.  
 
The analyses presented explore demographic, clinical and laboratory determinants on 
progression to ESRD for people with South Asian ethnicity, compared to people of 
white and black ethnicity. They focus on routinely collected clinical and laboratory 
data and selected additional novel risk factors to assess the relative impact of these 
factors on the risk of progression to ESRD. In addition to traditional survival 
analyses, we performed competing risk analyses to mitigate any impact of different 
mortality rates on ESRD. 
 
4.4 Methods 
A comprehensive description of the RIISC study and its methodology is presented in 
Chapter 2 (Section 2.3) and have previously been published (73, 180).  
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4.4.1 Ethnicity 
Ethnicity and country of birth were self-reported and documented at time of 
recruitment. For the analyses that follow, individuals are grouped into white, South 
Asian (individuals of Bangladeshi, Indian and Pakistani descent) or black (individuals 
from or who have ancestors from Africa or the Caribbean) ethnicity; ethnicities 
classified as other are not included in the analyses. 
 
4.4.2 Specific Statistical Analyses Related to this Chapter 
Analyses were performed using Stata 13.1 (Statacorp, College Station, Texas, USA). 
 
Techniques for the analysis of descriptive statistics and survival analyses are 
described in Section 2.4. Whilst competing risk analyses is also described in the 
methods section, I have included a short summary below to aid interpretation of the 
data. 
 
4.4.2.1 Competing Risk Analyses 
Survival analyses including Cox proportional hazard analyses (Section 2.4.3.2) treat 
all censored events as ‘uninformative’. A patient may be censored at the end of their 
follow up or when they reach another end-point (death); both situations are treated 
equally but are of different clinical (and statistical) importance. To adjust for this, a 
competing risk analyses according to the method described by Fine and Gray (Stata 
command stcrreg) was performed (223). Data are presented using subdistribution 
hazard ratios (SHR) with 95% confidence interval (CI) and P-values. 
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4.4.2.2 Univariable and Multivariable Analyses 
Ethnicity was initially analysed in univariable analyses. Multivariable analyses were 
then performed to include a priori variables (known confounding factors of age, 
gender, comorbidity assessed by CCI, eGFR and ACR); Model 1. Further candidate 
variables included any baseline characteristics demonstrating differences by ethnicity 
(P<0.1); Model 2. A backwards selection model was used to produce the final 
multivariable model; Model 3. 
 
The a priori variables were chosen as international prediction equations identify age, 
gender, eGFR and ACR and being associated with the greatest risk of ESRD in (see 
Section 1.4 and (85-87)). Additionally Chapter 3 demonstrated the impact of 
comorbidity on mortality and I therefore included the Charlson Comorbidity Index as 
a validated cumulative score (216). 
 
The censor date used in the analysis of these data is 24
th
 February 2016. 
 
4.5 Results 
All participants recruited to end March 2014 (n=745) were evaluated for inclusion in 
this study. Eighteen patients were excluded from the analyses as they were not 
categorised within White (507, 68.1%), South Asian (150, 20.1%) or Black (70, 
9.4%) ethnic groups. Figure 4-1 indicates the number of individuals at each stage of 
evaluation. 
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Figure 4-1. Flow diagram of study participants and outcomes. 
 
Abbreviations: ESRD, end-stage renal disease. 
 
Median age at recruitment was 64 years (IQR 50-77 years) and 61.1% were male. The 
most common primary renal diagnoses were ischaemic/hypertensive nephropathy in 
25.9%, glomerulonephritis in 13.5%, diabetic kidney disease in 11.3%, polycystic 
kidney disease in 5.0% and not known/ other in 23.1% (Table 4-1).  
 
Median eGFR was 25.7 ml/min/1.73m
2 
(IQR 19.5-33.5)
 
and median ACR was 32.8 
mg/mmol (IQR 6.7-127.6). Table 4-2 illustrates the study population by KDIGO 
classification (42). 
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Table 4-1. Aetiology of renal disease, split by ethnicity.  
  
Complete 
Cohort White Black South Asian P-value 
  n (%) n (%) n (%) n (%)   
Ischaemic/ hypertensive 
nephropathy 188 (25.9) 129 (25.4) 19 (27.1) 40 (26.7) 0.1 
Primary glomeulonephritides 92 (12.7) 65 (25.8) 11 (15.7) 16 (10.7) 
 Diabetic kidney disease 82 (11.3) 47 (9.3) 11 (15.7) 24 (16.0) 
 Polycystic kidney disease 36 (5.0) 27 (5.3) 4 (5.7) 5 (3.3) 
 Interstitial nephropathy 34 (4.7) 27 (5.3) 1 (1.4) 6 (4.0) 
 Obstructive uropathy 24 (3.3) 20 (3.9) 1 (1.4) 3 (2.0) 
 Reflux nephropathy 19 (2.6) 10 (2.0) 0 (0) 9 (6.0) 
 Hereditary nephropathies 7 (1.0) 6 (1.2) 1 (1.4) 0 (0) 
 Other cystic renal diseases 6 (0.8) 6 (1.2) 0 (0) 0 (0) 
 Secondary glomerulonephritides 6 (0.8) 6 (1.2) 0 (0) 0 (0) 
 Not known and other 168 (23.1) 114 (22.5) 18 (25.7) 36 (24.0) 
 Not stated 65 (8.9) 50 (9.9) 4 (5.7) 11 (7.3) 
 
      Total 727 (100) 507 (100) 70 (100) 150 (100)   
 
 
  
 120 
Table 4-2. Renal function of study population stratified by Kidney Disease 
Improving Global Outcomes (KDIGO) classification. 
 
      ACR (mg/mmol)   
 
  <3 3-30 >30 ACR not 
stated 
N (%) 
A1 
N (%) 
A2 
N (%) 
A3 
N (%) 
eGFR 
(ml/min/1.73m
2
) 
≥60 G1/G2 1 (0.1) 1 (0.1) 22 (3.0) 2 (0.3) 
45-59 G3a 8 (1.1) 13 (1.8) 23 (3.1) 0 (0) 
30-44 G3b 26 (3.6) 59 (8.1) 76 (10.5) 8 (1.1) 
15-29 G4 64 (8.8) 136 (18.7) 188 (25.9) 26 (3.6) 
<15 G5 5 (6.9) 19 (2.6) 47 (6.5) 3 (0.4) 
 
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration 
rate 
 
During the follow-up period 151 (20.8%) individuals reached ESRD and 76 (10.5%) 
died. One-hundred and six (14.6%) withdrew from follow up. 
 
4.5.1 Baseline demographic, clinical and biochemical factors 
Baseline demographic, clinical and laboratory data, split by ethnicity, are shown in 
Table 4-3. White participants were older, less socio-economically deprived and more 
likely to smoke tobacco and drink alcohol compared to participants of South Asian 
and black ethnicities. No difference was demonstrated between gender split or in 
perceived HRQL. No difference was seen in aetiology of renal disease (P=0.1). 
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Table 4.3. Baseline characteristics of cohort, split by ethnicity. 
    Complete Cohort White South Asian Black P-value Completeness 
of data (%) 
   N (%) 727 (100) 507 (69.7) 150 (20.6) 70 (9.6)     
Demographics       
 Age (years) * 64 (50-77) 68 (55-78) 57 (44-69.3) 53.5 (46.5-75) 0.0001 100 
 Gender - Female n(%) 283 (38.9) 193 (38.1) 63 (42.0) 27 (38.5) 0.685 100 
 IMD Score * 31.9 (17.6-46.7) 26.0 (15.4-42.9) 38.2 (22.5-50.8) 51.1 (36.3-59.6) 0.0001 99.2 
 Most deprived quintile 
nationally n(%) 
345 (47.8) 203 (40.1) 87 (58.8) 55 (79.7) <0.001 99.4 
 BMI (kg/m
2
) * 28.6 (24.9-33.0) 28.6 (24.7-33.3) 28 (24.9-32) 30.3 (26.2-35.3) 0.0435 98.5 
Renal Function       
 Creatinine (μmol/L) * 213 (167-272) 210 (167.5-263) 221 (163-289) 250.5 (173.3-332.5) 0.0305 98.5 
 eGFR (ml/min/1.73m
2
) * 25.7 (19.5-33.5) 25.5 (10.2-33.1) 25.3 (18.3-34.8) 26.8 (19.5-38.7) 0.6011 98.5 
 ACR (mg/mmol) * 32.8 (6.7-127.6) 20 (4.5-101.4) 84.1 (25.9-170.2) 53.2 (9.9-137.3) 0.0001 94.9 
Comorbidities       
 Malignancy n(%) 110 (15.1) 96 (18.9) 6 (4.0) 8 (11.4) <0.0001 100 
 Diabetes n(%) 265 (36.5) 173 (34.1) 62 (41.3) 30 (42.8) 0.137 100 
 COPD n(%) 78 (10.7) 65 (12.8) 9 (6.0) 4 (5.7) 0.022 100 
 Cerebrovascular n(%) 89 (12.2) 64 (25.4) 19 (12.7) 6 (8.6) 0.615 100 
 Cardiovascular n(%) 165 (22.7) 125 (24.5) 33 (22.0) 7 (10.0) 0.023 100 
 PVD n(%) 73 (10.0) 55 (10.8) 10 (6.7) 8 (11.4) 0.3 100 
  CCI * 3 (1-5) 3 (1-5) 3 (1-4) 3 (1-5) 0.0213 99.9 
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Table 4-3 continued… 
    Complete Cohort White South Asian Black P-value Completeness 
of data (%) 
Health Related Quality of Life       
 Eq5D score * 0.743 (0.656-
0.883) 
0.753 (0.656-
0.883) 
0.727 (0.636-
0.858) 
0.727 (0.630-1) 0.9039 98.3 
Smoking Status       
 Never n(%) 348 (48.2) 192 (37.9) 114 (76.0) 42(60.0) <0.0001 99.3 
 Current n(%) 91 (12.6) 72 (14.2) 12 (8.0) 7 (10.0)   
 Previous n(%) 283 (39.2) 238 (46.9) 24 (16.0) 21 (30.0)   
Alcohol (weekly)       
 None n(%) 418 (57.5) 246 (48.5) 129 (86.0) 43 (61.4) <0.0001 100 
 1-10 units n(%) 216 (29.7) 179 (35.3) 16 (10.7) 21 (30.0)   
 11-20 units n(%) 63 (8.7) 55 (10.8) 5 (3.3) 3 (4.3)   
 more than 20 units n(%) 30 (4.1) 27 (5.3) 0 (0) 3 (4.3)   
Blood Pressure       
 Systolic BP (mmHg) ** 130.4 (20.5) 130.0 (21.1) 131.6 (18.9) 131.4 (19.7) 0.6045 98.6 
 Diastolic BP (mmHg) ** 78.8 (12.3) 75.2 (12.4) 78.8 (23.3) 79.8 (14.1) 0.0007 98.6 
 Mean Arterial Pressure 
(mmHg) ** 
106.1 (13.8) 104.9 (13.3) 108.2 (13.2) 110.5 (16.7) 0.0011 92.4 
Medication       
 ACEi/ARB n(%) 426 (58.7) 282 (55.7) 94 (62.7) 50 (71.4) 0.024 99.9 
 Allopurinol n(%) 131 (18.1) 102 (20.2) 22 (14.7) 7 (10.0) 0.056 99.9 
 Bicarbonate n(%) 107 (14.8) 70 (13.8) 25 (16.7) 12 (17.1) 0.578 99.9 
 Lipid Lowering medication 
n(%) 
453 (62.4) 317 (62.6) 100 (66.7) 36 (51.4) 0.092 99.9 
  No. antihypertensives * 2 (1-3) 2 (1-3) 2 (1-3) 3 (2-4) 0.598 99.9 
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Table 4-3 continued… 
    Complete Cohort White South Asian Black P-value Completeness 
of data (%) 
Biological markers       
 Albumin (g/L) * 43 (40-46) 43 (41-46) 42 (38-45) 42.5 (39-44.75) 0.0006 97.9 
 Albumin - under 30 g/L n(%) 7 (1.0) 5 (1.0) 2 (1.4) 0 (0) 0.64 97.9 
 Bicarbonate (mmol/L) ** 24.0 (3.7) 24.1 (3.6) 23.0 (3.8) 24.8 (4.0) 0.0006 97.2 
 Bicarbonate - under 20 
mmol/L n(%) 
104 (14.7) 67 (13.5) 30 (20.4) 7 (10.8) 0.076 97.2 
 Calcium (mmol/L) ** 2.3 (0.1) 2.3 (0.1) 2.3 (0.2) 2.3 (0.2) 0.1653 97.5 
 Uncorrected calcium 
(mmol/L) ** 
2.3 (0.2) 2.3 (0.1) 2.3 (0.1) 2.3 (0.2) 0.4059 97.5 
 Cholesterol (mmol/L) * 4.5 (3.8-5.5) 4.5 (3.8-5.4) 4.7 (3.9-5.7) 4.4 (4-5.4) 0.4584 97.4 
 CRP (mg/L) * 3.0 (1.4-7.3) 3.5 (1.5-7.8) 2.7 (1.4-5.6) 2.2 (0.8-7.2) 0.0277 93.8 
 Ferritin (ng/mL) * 118 (58-216.5) 116 (58-208) 114 (55-199) 146 (67-247) 0.1847 94.8 
 Glucose (mmol/L) * 5.3 (4.7-6.8) 5.2 (4.7-6.5) 5.3 (4.6-8.2) 5.3 (4.7-7.1) 0.4961 95.9 
 HbA1c (IFCC; mmol/mol) * 43 (39-53) 43 (39-52) 44 (40-58) 42.5 (38.25-50) 0.1075 94.8 
 Haemoglobin (g/L) ** 124.4 (17.2) 125.8 (16.8) 123.1 (17.1) 117.3 (17.8) 0.0003 96.1 
 Haemoglobin - under 100 g/L 
n (%) 
47 (6.7) 32 (6.6) 7 (4.9) 8 (11.4) 0.197 96.1 
 HDL (mmol/L) * 1.2 (1.0-1.5) 1.23 (0.98-1.5) 1.12 (0.94-1.42) 1.29 (0.94-1.7) 0.0289 97.9 
 Phosphate (mmol/L) ** 1.1 (0.2) 1.1 (0.2) 1.2 (0.3) 1.2 (0.3) 0.4897 97.1 
 Potassium (mmol/L) ** 4.7 (0.6) 4.7 (0.6) 4.7 (0.6) 4.7 (0.5) 0.409 97.1 
 Triglyceride (mmol/L) * 1.6 (1.1-2.4) 1.6 (1.14-2.39) 1.8 (1.2-2.6) 1.2 (0.9-1.7) 0.0001 96.8 
  Uric Acid (μmol/L) * 471.2 (119.7) 469.4 (116.4) 462.6 (135.2) 503.3 (102.9) 0.0604 96.8 
* median (interquartile range) ** mean (standard deviation) 
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Table 4-3 continued… 
 
Abbreviations: ACEi, Angiotensin converting enzyme inhibitor; ACR, Albumin creatinine ratio; ARB, Angiotensin II Receptor Blocker; BMI, 
Body mass index; BP, Blood pressure; CCI, Charlson Comorbidity Index; COPD, Chronic obstructive airways disease; CRP, C-Reactive 
Protein; eGFR, estimated glomerular filtration rate; EQ-5D score, Health dimensions from EQ-5D health related quality of life questionnaire 
were converted into an EQ-5Dindex score ranging from −0.594 to 1.0 (where 1 is full health and lower values indicate worse HRQL) using a set 
of weighted preferences produced from the UK population (Section 2.3.2); HbA1c, Glycated haemoglobin; HDL, High density lipoprotein; 
PVD, Peripheral vascular disease. 
 
 
 
; 
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Comorbidity was more common in participants of white ethnicity, with higher known 
rates of malignancy, chronic obstructive pulmonary disease and cardiovascular 
disease. This equated to a higher CCI in white participants. Whilst there was no 
difference between ethnic groups in the median number of anti-hypertensive agents 
used, angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor 
blockers (ARB) were more frequently prescribed in black (71.4%) and South Asian 
(62.7%) compared to white (55.7%) ethnic groups (P=0.024).  No difference was 
observed in the use of lipid lowering medication or bicarbonate supplementation. 
 
Diastolic Blood Pressure (DBP) was highest in those of non-white ethnicity (mean 
DBP black 79.8 mmHg, South Asian 78.8 mmHg, white 75.2 mmHg, P=0.0007). 
Similar differences were found in the mean arterial pressure (MAP).  
 
No differences were demonstrated in eGFR between ethnicities (P=0.6011). 
Proteinuria, as assessed by urine ACR, was highest in South Asian participants 
(median 84.1 mg/mmol), followed by participants of black ethnicity (53.2 mg/mmol) 
and lowest in white participants (20.0 mg/mmol) (P=0.0001).  
 
Differences in biochemical parameters were noted in triglyceride, high density 
lipoprotein (HDL) and C reactive protein (CRP) concentrations. Albumin, bicarbonate 
and haemoglobin concentrations also varied, but no difference was identified when 
threshold levels were evaluated (albumin less than 30 g/L, bicarbonate less than 20 
mmol/L, haemoglobin less than 100 g/L). 
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4.5.2 Progression to ESRD by ethnicity 
The Kaplan-Meier survival plot illustrating progression to ESRD by ethnicity (log-
rank test P=0.0073) is shown in Figure 4-2. By Cox survival analysis, individuals of 
South Asian ethnicity (HR 1.62, 95% CI 1.11-2.35, P=0.012) and black ethnicity (HR 
1.79, 95% CI 01.10-2.90, P=0.019) had a statistically increased risk of ESRD 
compared to individuals of white ethnicity. 
Figure 4-2. Kaplan-Meier survival plot illustrating progression to end-stage 
renal disease split by ethnicity. Log-rank test comparing ethnicities P=0.0073. 
Life table below survival plot indicates the number of individuals who remained in 
follow-up at each time point. 
 
  
Subjects remaining in follow up 
Time from Recruitment (days) 
  0 250 500 750 1000 1250 1500 1750 
White 507 462 415 358 259 128 66 26 
South Asian 150 132 117 97 65 27 12 5 
Black 70 60 57 42 27 13 7 4 
Total 727 654 589 497 351 168 85 35 
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4.5.3 Competing risk analysis 
No significant difference was found for risk of death between ethnicities using Kaplan 
Meier (Log-rank test P=0.2745) or Cox proportional hazards regression (South Asian 
compared to white HR 0.56, 95% CI 0.28-1.14, P=0.113; black compared to white 
HR 0.96, 95% CI 0.44-2.10, P=0.915). 
 
To adjust the survival analyses for risk of ESRD for the competing risk of death, 
competing risk analyses were performed. In these analyses, individuals of South 
Asian (SHR 1.65, 95% CI 1.13-2.40, P=0.009) and black ethnicity (SHR 1.77, 95% 
CI 1.08-2.91, P=0.023) had a higher risk of ESRD. 
 
4.5.4 The relationship between established risk factors and progression to end-
stage renal disease  
On multivariable Cox regression analysis, after adjusting for age, gender, eGFR, ACR 
and CCI, the impact of ethnicity on ESRD risk was not significant for South Asian 
ethnicity (HR 0.90, 95% CI 0.58-1.38, P=0.625) and of borderline significance for 
black ethnicity (HR 1.67, 95% CI 1.00-2.79, P=0.05) (Table 4-4, Model 1). Lower 
age, lower eGFR and higher ACR were associated with ESRD risk. 
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Table 4-4. Multivariable survival analyses for progression to end-stage renal 
disease. Renal function (eGFR and ACR) analysed as continuous variables. 
Model 1 and 2. 
    Model 1 Model 2 
    Hazard Ratio 
(95% CI) 
P-value Hazard Ratio 
(95% CI) 
P-value 
Ethnicity     
 White 1  1  
 South Asian 0.90 (0.58-1.38) 0.625 1.07 (0.61-1.89) 0.795 
 Black 1.67 (1.00-2.79) 0.05 1.27 (0.65-2.48) 0.478 
Age (per 1 year increase) 0.97 (0.96-0.99) <0.001 0.97 (0.95-0.99) <0.001 
Gender (male as reference) 1.33 (0.93-1.90) 0.12 2.24 (1.31-3.82) 0.003 
eGFR (per 5ml/min/1.73m2 
increase) 
0.57 (0.51-0.64) <0.001 0.52 (0.44-0.60) <0.001 
ACR (per 10mg/mmol increase) 1.03 (1.02-1.04) <0.001 1.03 (1.02-1.04) <0.001 
Charlson Comorbidity Index 1.04 (0.95-1.13) 0.397 1.03 (1.02-1.16) 0.629 
Socioeconomic Status     
 IMD score   0.99 (0.98-1.00) 0.214 
Smoking Status     
 None   1  
 Current   1.28 (0.65-2.51) 0.474 
 Previous   1.44 (0.88-2.36) 0.145 
Alcohol (weekly)     
 None   1  
 Under 10 units   0.88 (0.53-1.44) 0.602 
 11-20 units   0.57 (0.25-1.28) 0.171 
 over 20 units   1.61 (0.61-4.25) 0.338 
Blood Pressure     
 AvgDBP (mmHg)   1.02 (1.00-1.04) 0.121 
 AvgMAP (mmHg)   1.01 (0.99-1.03) 0.419 
Medication     
 ACEi/ARB   1.43 (0.91-2.25) 0.119 
Additional Biological markers     
 Albumin (g/L)   0.93 (0.89-0.98) 0.007 
 Bicarbonate (mmol/L)   1.05 (0.99-1.12) 0.094 
 CRP (mg/L)   0.99 (0.97-1.00) 0.079 
 Haemoglobin (g/L)   0.97 (0.96-0.99) <0.001 
 HDL (mmol/L)   0.96 (0.56-1.67) 0.898 
  Triglycerides (mmol/L)     0.83 (0.67-1.02) 0.078 
 
Abbreviations: ACEi, Angiotensin converting enzyme inhibitor; ACR, Albumin 
creatinine ratio; ARB, Angiotensin II Receptor Blocker; CCI, Charlson comorbidity 
index; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated 
glomerular filtration rate; HDL, high density lipoprotein; MAP; mean arterial 
pressure.  
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To quantify the significance of proteinuria and aid interpretation, the analyses were 
rerun with eGFR and ACR values categorised by KDIGO classification (Table 4-5, 
Model 1). This illustrated the significance of reduced eGFR (<30ml/min/1.73m
2
 with 
30-44ml/min/1.73m
2
 as reference) and proteinuria (>30mg/mmol). In these analyses, 
South Asian ethnicity was not associated with progression to ESRD (HR 1.10, 95% 
CI 0.55-1.26, P=0.384). Black ethnicity remained significantly associated with 
progression (HR 1.78, 95% CI 1.09-2.93, P=0.022). 
 
A further multivariable analysis was performed including a priori variables and 
factors which differed between ethnicities at baseline (Table 4-4, Model 2). A 
backwards stepwise technique was then performed to produce a final model with a 
priori variables and other factors which remained significant with P<0.05 (Table 4-6, 
Model 3 (Cox). In this model, both South Asian and black ethnicity were not 
independently significant variables. Significant factors were lower age, male gender, 
lower eGFR, higher ACR, higher diastolic blood pressure, lower albumin, lower 
haemoglobin, and lower triglycerides.  
 
Findings from a competing risk analysis (with death as the competing risk), using the 
same variables, demonstrated findings consistent with the cox regression (Table 4-6, 
Model 3 (competing risk)). 
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Table 4-5. Multivariable survival analyses for progression to end-stage renal 
disease. Renal function (eGFR and ACR) analysed as categorical variables, 
classified by KDIGO CKD classification. Models 1 and 3. 
 
    Model 1 (categorical) Model 3 (categorical) 
    Hazard Ratio 
(95% CI) 
P-value Hazard Ratio 
(95% CI) 
P-value 
Ethnicity     
 White 1  1  
 South Asian 0.83 (0.55-1.26) 0.384 0.86 (0.56-1.32) 0.496 
 Black 1.78 (1.09-2.93) 0.022 1.19 (0.71-2.02) 0.511 
Age (per 1 year increase) 0.98 (0.96-0.99) <0.001 0.98 (0.96-0.99) 0.001 
Gender (male as reference) 1.32 (0.92-1.87) 0.127 2.02 (1.36-2.99) <0.001 
eGFR - categorical     
 G1/2 (≥60ml/min/1.73m2) no ESRD 1 no ESRD 1 
 G3a (45-59 ml/min/1.73m
2
) 0.23 (0.03-1.73) 0.152 0.21 (0.03-1.64) 0.137 
 G3b (30-44 ml/min/1.73m
2
) 1  1  
 G4 (15-29 ml/min/1.73m
2
) 3.50 (1.97-6.23) <0.001 2.93 (1.63-5.24) <0.001 
 G5 (<15ml/min1.73m
2
) 17.53 (9.05-
33.99) 
<0.001 12.64 (6.32-
25.26) 
<0.001 
ACR - categorical     
 A1 (<3 mg/mmol) 1  1  
 A2 (3-30 mg/mmol) 1.70 (0.78-3.72) 0.183 1.37 (0.61-3.08) 0.443 
 A3 (>30 mg/mmol) 4.67 (2.23-9.79) <0.001 3.69 (1.68-8.13) 0.001 
Charlson Comorbidity Index 1.07 (0.99-1.17) 0.094 1.02 (0.92-1.12) 0.754 
AvgDBP (mmHg) 
  
1.02 (1.00-1.03) 0.045 
Albumin (g/L) 0.95 (0.91-0.99) 0.007 
Haemoglobin (g/L)   0.97 (0.96-0.99) <0.001 
Triglycerides (mmol/L)     0.87 (0.74-1.03) 0.106 
 
Abbreviations: ACR, albumin creatinine ratio; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate. 
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Table 4-6. Multivariable survival analyses for progression to end-stage renal 
disease. Renal function (eGFR and ACR) analysed as continuous variables. 
Model 3.  
 
    Model 3 (Cox) Model 3 (competing risk) 
    Hazard Ratio 
(95% CI) 
P-
value 
Subdistribution 
Hazard Ratio (95% 
CI) 
P-
value 
Ethnicity     
 White 1  1  
 South Asian 0.97 (0.63-1.48) 0.89 0.92 (0.57-1.48) 0.722 
 Black 1.08 (0.63-1.86) 0.779 1.03 (0.58-1.85) 0.913 
Age (per 1 year increase) 0.97 (0.96-0.99) <0.001 0.97 (0.96-0.98) <0.001 
Gender (male as reference) 2.26 (1.51-3.37) <0.001 2.47 (1.60-3.82) <0.001 
eGFR (per 5ml/min/1.73m
2
 
increase) 
0.56 (0.49-0.63) <0.001 0.56 (0.47-0.66) <0.001 
ACR (per 10mg/mmol 
increase) 
1.04 (1.03-1.05) <0.001 1.03 (1.02-1.04) <0.001 
Charlson Comorbidity Index 0.98 (0.89-1.08) 0.664 0.97 (0.88-1.06) 0.463 
AvgDBP (mmHg) 1.02 (1.00-1.03) 0.032 1.02 (1.00-1.04) 0.022 
Albumin (g/L) 0.96 (0.92-1.00) 0.031 0.95 (0.91-0.99) 0.02 
Haemoglobin (g/L) 0.98 (0.97-0.99) 0.002 0.98 (0.97-0.99) 0.002 
Triglycerides (mmol/L) 0.80 (0.66-0.95) 0.016 0.82 (0.68-1.00) 0.046 
 
Abbreviations: ACR, albumin creatinine ratio; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate. 
 
 
Cox regression analysis incorporating variables from the final model (ethnicity, a 
priori variables, diastolic BP, albumin, haemoglobin, triglycerides) but with eGFR 
and ACR categorised was performed (Table 4-5, Model 3). This demonstrated the 
same variables remained significant (lower age, male gender, lower eGFR, higher 
ACR, higher diastolic blood pressure, lower albumin and lower haemoglobin) with 
the exception of triglycerides. Compared to an eGFR 30-44ml/min/1.73m
2
 (G3b; the 
reference category), an eGFR 15-29ml/min/1.73m
2
 (G4; HR 2.93, 95% CI 1.63-5.24, 
P<0.001) and eGFR <15ml/min/1.73m
2
 (G5; HR 12.64, 95% CI 6.32-25.26, P<0.001) 
were associated with a higher HR for ESRD, as was an ACR >30 mg/mmol (A3; HR 
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3.69, 95% CI 1.68-8.13, P=0.001). Consistent with the analyses above, no 
significance was identified for differences by ethnicity. 
 
4.6 Discussion 
Whilst significant emphasis has been placed on risk stratification and identification of 
factors associated with ESRD, the impact of South Asian ethnicity has not been 
explored in detail, even though observational data shows an increased rate of ESRD in 
non-white ethnic groups (39). Previous studies investigating the impact of ethnicity on 
progression of CKD have not included large South Asian populations or have 
investigated the relationship in health care systems where universal coverage is not 
provided and access to healthcare may vary by SES.  
 
Utilising the UK based, prospective observational RIISC study (73), I analysed 
progression to ESRD within the socioeconomically and ethnically diverse RIISC 
study, where over 30% of participants were of self-reported South Asian or black 
ethnicity. Whilst the median eGFR was similar between ethnicities, individuals of 
South Asian or black ethnicity were likely to be younger, more socio-economically 
deprived and have less comorbidity. Furthermore, people of South Asian or black 
ethnicity had higher albuminuria, assessed as urine ACR. No difference was seen in 
reported health-related quality of life between ethnicities. 
 
There was an increased risk of ESRD for South Asian ethnicity compared to their 
white counterparts. This difference persisted in competing risk analyses (with death as 
the competing risk). Subsequent multivariable analyses incorporating established risk 
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factors (age, gender, eGFR, ACR, comorbidity) and candidate variables that differed 
by ethnicity (diastolic blood pressure, serum albumin, haemoglobin and triglycerides 
after backwards step-wise technique) attenuated the difference between ethnicities. 
Similar findings were identified for those of black ethnicity. Socio-economic status 
was not significant in the multivariable model, thereby not suggesting evidence of 
health inequality associated with socio-economic deprivation. 
 
One of the most striking differences in the baseline characteristics between ethnicities 
was the variation in albuminuria. Given the prognostic significance of ACR in our 
analyses, possible explanations for this difference include: 
 
1. The difference in ACR could be a disease specific effect. I did not identify any 
significant difference in overall proportion of renal aetiologies between ethnicities 
(P=0.1). However the proportion of people with diabetic kidney disease (DKD) 
was highest in South Asian (16.0%) and black (15.6%) compared to white 
ethnicities (9.3%). Whilst median ACR for South Asians with DKD was higher 
(155.3 mg/mmol, IQR 65.1-427) than white (64.7 mg/mmol, IQR 23-339.6) and 
black (58.1 mg/mmol, IQR 3.95-240.5) ethnicities, no statistical difference was 
found (P=0.187). 
 
2. The difference in ACR may be explained by BP differences or a differential effect 
of ACEi/ARB. Whilst the median number of antihypertensives used were similar 
for all ethnicities, ACEi/ARBs were more frequently prescribed in the South 
Asian and black ethnic groups, and the baseline diastolic BP and MAP were both 
slightly, but significantly, higher in South Asian (and black) groups. Current 
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guidelines for hypertension suggest the selection of antihypertensive agent by 
ethnicity, in recognition that the pathophysiology of (non-renal) hypertension may 
be different. Previous research has often focused on those of black ethnicity 
compared to white. Data on South Asian ethnicity and response to 
antihypertensive treatments are limited and have not focused on patients with 
CKD. Studies have commented that ‘South Asians appear to respond to 
antihypertensive drug treatment in a similar manner to whites’ but acknowledge 
that ‘there is insufficient information on this point and South Asians are under-
represented in studies’. (263). However, a sub-analysis of the ASCOT trial 
suggested that South Asians may have a greater response to antihypertensives 
(perindopril and amlodipine) than whites (264). Using a stratified medicine 
approach (see Section 1.8 for definition) it may be possible to target treatments 
according to specific biological or risk characteristics (165). This concept will be 
explored further in Chapter 5. 
 
3. There may be a genetic basis for the development of albuminuria within the South 
Asian population. Whilst research is again limited, proteinuria appears to be more 
common in non-white ethnicities within the paediatric and adolescent population, 
suggesting a potential genetic or environmental basis (265, 266). Additionally, 
non-white ethnic groups were more likely to have proteinuric DKD compared to 
non-proteinuria DKD (267). There may also be differences within broad 
categories of ethnicity; Jafar and colleagues studied determinants of proteinuria 
among South Asian subgroups in Pakistan, and concluded that unmeasured 
environmental or genetic factors account for difference in proteinuria (268). 
Studies have looked at variants of the gene encoding apolipoprotein L1 (APOL1), 
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with high risk groups having a higher risk of adverse renal outcome (261). 
However there was no evidence of an interaction between APOL1 and baseline 
proteinuria. 
 
4.6.1 Strengths and Weaknesses 
The major strength of this study is the use of a prospectively recruited, socio-
economically and ethnically diverse cohort of patients with advanced and/or 
progressive pre-dialysis dependent CKD. Detailed demographic and clinical data were 
collected at initial recruitment and the participants were tracked longitudinally to 
record outcomes, including death and ESRD. The study focused on individuals at 
highest risk of ESRD and, in comparison to other studies within CKD populations in 
the UK (269, 270), a higher number of people reached ESRD than died. 
 
Survival analyses were performed using both Cox proportional hazard analyses and 
competing risk analyses. The latter is important, as it enabled the competing risk of 
death to be taken into account when assessing progression to ESRD. Whilst I did not 
demonstrate a significant difference in the study population, the HR for death for 
South Asian and black ethnicities were lower. This would be consistent with the 
primary care data presented in Chapter 3. 
 
A weakness, as with all observational studies, is that I have assessed association 
rather than causation. However, the detailed demographic and bioclinical 
characteristics have enabled multivariable analyses of both a priori and candidate 
variables. Whilst information regarding medication use was collected, the study team 
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did not record whether people had been given, or were intolerant to, medications such 
as ACEi/ARB.  
 
It would have been useful if these analyses could be repeated in a replication cohort 
but I did not identify any national or international cohort with a significant proportion 
of South Asian participants. 
 
4.6.2 Global Significance of These Findings 
CKD is a major public health issue and contributes to the overall burden of non-
communicable disease; this is likely to grow with the increasing prevalence of 
diseases including diabetes mellitus and obesity (80). Individuals of South Asian 
ethnicity account for approximately 25% of the world’s population and international 
studies have identified a high prevalence of CKD within South Asian countries, 
including a high rate of proteinuria (4, 14, 15). Treatment of ESRD is unaffordable to 
many (81). If these results suggesting a higher rate of progression to ESRD, albeit 
explained by known risk factors, are transferable to the wider South Asian population, 
screening and intervention strategies for these high risk groups should be considered 
as part of public health strategies. 
 
4.7 Conclusion to Chapter 4 
In summary, these analyses demonstrate that those of South Asian ethnicity are at a 
higher risk of ESRD than their white counterparts. This difference can be explained 
by known risk factors for renal progression and albuminuria is the principal 
modifiable risk factor.  
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Traditional strategies to reduce albuminuria (blood pressure control, use of 
ACEi/ARB) need to be optimised and ongoing research into why albuminuria is 
typically higher in South Asian and black ethnicities is needed. 
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5 RESULTS 3. Serum tryptase concentration and progression to 
end-stage renal disease 
 
5.1 Preface 
In the previous chapter, I discussed that studies have proposed that different ethnic 
group may have a differential response to antihypertensive treatment (Section 4.6). 
This is an example of how stratified medicine (Section 1.8) may be beneficial, as it 
may be possible to target treatments to those most likely to respond.  
 
I used a stratified medicine approach in the study reported in this chapter, focusing on 
biological determinants of response to angiotensin converting enzyme inhibitor 
(ACEi) and angiotensin II receptor blocker (ARB) therapy in patients with chronic 
kidney disease (CKD). I investigated the relationship of serum tryptase, a product of 
mast cell activation which may be involved in non-classical activation of the Renin-
Angiotensin-Aldosterone System, to progression to end stage renal disease (ESRD) 
and whether this relationship is influenced by participants use of ACEi/ARB. 
 
These analyses utilised the Renal Impairment in Secondary Care (RIISC) cohort and 
the detailed bioclinical information, including medication use, collected and the 
routine collection of additional biological samples (Section 2.3). 
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5.2 Abstract 
Background. Mast cell activation can lead to non-classical activation of the Renin-
Angiotensin-Aldosterone System (RAAS). However the relevance of this to human 
chronic kidney disease is unknown. I assessed the association between serum tryptase, 
a product of mast cell activation, and progression to ESRD or mortality in patients 
with advanced CKD. Patients were stratified by use of ACEi/ARB. 
 
Methods. This was a prospective cohort study of 446 participants recruited into the 
RIISC study. Serum tryptase was measured at recruitment by sandwich immunoassay. 
Cox regression analysis was undertaken to determine variables associated with 
progression to ESRD or death. 
 
Results. Serum tryptase concentration was independently associated with progression 
to ESRD but not with death. In patients treated with ACEi or ARB, there was a strong 
independent association between higher tryptase concentrations and progression to 
end-stage renal disease; when compared to the lowest tertile, tryptase concentrations 
in the middle and highest tertiles had Hazard Ratios (HR) of 5.78 (95% Confidence 
interval (CI) 1.19-28.03, P=0.029) and 6.19 (95% CI 1.49-25.69, P=0.012) 
respectively. The other independent risk factors for progression to end-stage renal 
disease were lower age, male gender, lower estimated glomerular filtration rate, and 
higher urinary albumin creatinine ratio. 
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Conclusion. Elevated serum tryptase concentration is an independent prognostic 
factor for progression to end-stage renal disease in patients with chronic kidney 
disease who are receiving treatment with an ACEi or ARB. 
 
5.3 Introduction 
Identifying patients with CKD at high risk of progression to ESRD is a clinical 
priority. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor II 
blockers (ARB) slow progression of CKD, but some patients treated with these drugs 
remain at high risk of progressing to ESRD (85, 88). 
 
Mast cells may contribute to progressive renal disease through a number of pathways 
(139). Tryptase is an inflammatory and profibrotic protease that is released from mast 
cells (150, 151); it activates protease-activated receptor 2 (PAR2) which stimulates 
tubular epithelial cells to a pro-inflammatory phenotype (271). Serum tryptase 
concentrations have been shown to increase with worsening renal impairment (152), 
but the relationship between tryptase concentration and clinical outcomes in patients 
with CKD has not been explored to date. Chymase, the other major protease produced 
by mast cells, can convert angiotensin (AT)I to ATII and activate transforming 
growth factor beta (TGF) (153, 154).  
 
I therefore analysed data from the RIISC study to explore the relationship between 
serum tryptase concentration, other independent prognostic factors for progression of 
CKD, and clinical outcomes. Given the potential involvement of mast cell proteases 
in the RAAS pathway, the cohort was stratified by ACEi/ARB use. 
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5.4 Methods 
Information regarding the RIISC study can be found in Chapter 2 (Section 2.1). The 
first 503 individuals who were recruited into the RIISC study were evaluated (73). 
RIISC commenced recruitment in October 2010 and the censor date used in these 
analyses was March 24
th
 2014. 
 
5.4.1 Assays Specific to this Chapter 
Serum tryptase concentration was measured by the ImmunoCAP Tryptase sandwich 
immunoassay (Phadia AB, Uppsala, Sweden).  Baseline tryptase levels in healthy 
individuals are reported by the manufacturer of the assay as 1-15 μg/L (214). Sample 
analysis was performed by the Clinical Immunology Service at the University of 
Birmingham (Birmingham, UK). 
 
C-reactive protein (CRP) was measured using the Full Range C-Reactive Protein Kit 
on a SPA
TM
 automated PLUS turbidimeter (The Binding Site Group Ltd, 
Birmingham, UK). The normal range for CRP is between 0.1 and 9 mg/L, with 90 
percent below 3 mg/L (213). 
 
Serum kappa (κ) and lambda (λ) free light chain (FLC) concentrations were measured 
by nephelometry on a Dade-Behring BNTMII Analyser (Siemens AG, Erlangen, 
Germany) using particle enhanced high-specificity homogenous immunoassays 
(Freelite
TM
; The Binding Site Group Ltd, Birmingham, UK). The normal reference 
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ranges for serum FLC concentrations have been previously described as κ: 3.3–19.4 
mg/L and λ: 5.7–26.3 mg/L, with the assay sensitivity being demonstrated as <1 
mg/L. Kappa and Lambda FLC concentrations were combined to calculate the 
combined FLC (cFLC) concentration. For the purpose of analysis, data are presented 
as cFLC and Kappa-Lambda FLC ratio.   
 
Patients with a potential monoclonal gammopathy, as defined by the presence of an 
abnormal κ-λ FLC ratio using the renal reference range (0.37-3.1), were excluded 
(n=12) (131). 
 
CRP and serum FLC analyses were performed by technicians at The Binding Site 
Group Ltd (Birmingham, UK). 
 
5.4.2 Specific Statistical Analyses Related to this Chapter 
Analyses were performed using Stata 13.1 (Statacorp, College Station, Texas, USA). 
 
Techniques for the analysis of descriptive statistics and survival analyses are 
described in Section 2.4. For the survival analyses in this manuscript, tryptase, CRP 
and FLC concentrations have been divided into three groups (tertiles). 
 
Variables significant to P<0.1 by univariable analysis were subsequently included in a 
multivariable analyses together with a priori variables (age, gender, eGFR and ACR), 
chosen as the variables strongly associated with ESRD (Section 1.4). 
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5.5 Results 
Five hundred and three participants had tryptase concentrations measured. Figure 5-1 
indicates the number of individuals at each stage of evaluation. Participants were 
excluded from further analyses if they were taking systemic immunosuppression for a 
non-renal cause (n=21), did not have tryptase, cFLC or CRP data available (n=24) or 
if their κ-λ FLC ratio fell outside of the accepted renal reference range (n=12). 
Therefore 446 individuals were included in the study. The aetiology of participants’ 
kidney disease are stated in Table 5-1. 
 
The baseline characteristics of the cohort are presented in Table 5-2. The median 
follow-up was 628 days (IQR 470-857.3 days) with a follow up period of 3-1243 
days. At recruitment, the median age was 65 years (IQR 50.8-77 years); 60.8% were 
male and 31.9% were non-white (South Asian 20.1%, Black 9.4%, other 2.4%). 
Almost half (46.3%) of participants were in the most deprived SES quintile nationally 
as defined by IMD 2010 score. No difference in SES was seen when analysed by 
CKD stage with IMD Score (P=0.48), IMD rank (P=0.35) or percentage in most 
deprived quintile (P=0.75). Comorbidity was common and increased with advancing 
CKD stage (Table 5-3). 
 
The median eGFR at recruitment was 25.8 ml/min/1.73m
2
 (IQR 19.6-33.7). 56.6% of 
individuals had stage G4 CKD. Median ACR was 33 mg/mmol (IQR 6.6-130.3 
mg/mmol). 
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Figure 5-1. Flow diagram of the participants in the study.  
 
 
Abbreviations; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker; ESRD, end-stage renal disease. 
 
Table 5-1. Aetiology of Chronic Kidney Disease. 
 
Renal Diagnosis N (%) 
Ischaemic/ hypertensive nephropathy 118 (26.5) 
Glomerulonephritis (primary) 70 (15.7) 
Diabetic Nephropathy 49 (11.0) 
Polycystic Kidney Disease 26 (5.8) 
Interstitial nephropathies 21 (4.7) 
Reflux nephropathy 16 (3.6) 
Obstructive uropathy 11 (2.5) 
Hereditary (not otherwise stated) 5 (1.1) 
Other cystic renal disease 4 (0.9) 
Glomerulonephritis (secondary) 2 (0.5) 
Unknown 103 (23.1) 
Not Stated 21 (4.7) 
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Table 5-2. Patient demographics and baseline descriptive statistics.  
 
    All No ACE/ARB ACEi/ARB P-value Data 
completeness 
(%) 
n (%) 446 (100) 179 (40.1) 267 (59.9)     
Renal Function      
 Creatinine (μmol/L) * 208 (164-262) 214 (170-268.5) 202 (155-258) 0.0981 99.3 
 eGFR (ml/min/1.73m2) * 26.8 (20.7-34.9) 25.4 (18.8-31.8) 27.5 (21.6-37.0) 0.0086 99.3 
 ACR (mg/mmol) * 28.8 (6-109.7) 22.6 (5.3-95.1) 36 (6.4-119.7) 0.1131 95.5 
Demographics      
 Age (years) * 65 (50.8-77) 71 (57-80) 62 (48-74) 0.0001 100 
 Gender - Female (%) 39.5 41.3 38.2 0.506 100 
Ethnicity      
 White (%) 71.1 76.5 67.4 0.166 100 
 South Asian (%) 17.7 15.1 19.4 
 Black (%) 8.3 5.6 10.1 
 Other (%) 2.9 2.8 3 
Smoking Status      
 Never (%) 44.6 38 49.1 0.069 100.0 
 Current (%) 14.1 35.4 12.7 
  Previous (%) 41.3 45.8 38.2 
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Table 5-2 continued… 
    All No ACE/ARB ACEi/ARB P-value Data 
completeness 
(%) 
Alcohol Consumption      
 None (%) 54.3 55.3 53.6 0.484 100.0 
 1-10 unit (%) 33.0 33.5 32.6 
 11-20 units (%) 8.1 8.4 7.9 
 >20 units (%) 4.7 2.8 6 
SES      
 Score * 31.2 (17.8-46.3) 33.2 (18.6-47) 28.9 (17.6-45.4) 0.3494 100 
 Rank * 7694.5 (2894.3-
15913) 
6829 (2775-15140) 8695 (3120-15934) 0.3145 
 % in most deprived national quintile 46.9 49.7 44.9 0.322 
Comorbidity      
 Cerebrovascular disease (%) 12.3 16.8 9.4 0.02 100.0 
 COPD (%) 11.0 11.2 10.9 0.918 
 Diabetes (%) 38.6 37.4 39.3 0.687 
 IHD (%) 24.0 29.1 20.6 0.04 
 Malignancy (%) 15.2 23.5 15.2 <0.001 
 PVD (%) 11.7 12.8 10.9 0.521 
 CCI 3 (1-4) 3 (2-5) 2 (0-4) 0.0002 99.8 
Anthropometrics      
 BMI (kg/m
2
) * 28.6 (24.9-33) 27.9 (23.8-31.8) 29.4 (26-33.9) 0.0023 99.6 
Blood Pressure      
 Systolic BP (mmHg) ** 129.7 (21.2) 131.2 (21.7) 128.7 (20.9) 0.2168 98.7 
  Diastolic BP (mmHg) ** 76.0 (12.7) 75.1 (13.3) 76.5 (12.3) 0.2535 98.7 
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Table 5-2 continued… 
    All No ACE/ARB ACEi/ARB P-value Data 
completeness 
(%) 
Medication      
 Alpha Blockers (%) 26.2 25.7 26.2 0.833 100 
 Beta Blockers (%) 30.7 33 29.2 0.4 100 
 Calcium Antagonists (%) 44.4 44.1 60.1 0.928 100 
 Diuretics (%) 48 49.2 47.2 0.683 100 
 Statins (%) 63 65.4 63 0.398 100 
 Number of antihypertensive 
medications (n) 
2 (1-3) 2 (1-2) 3 (2-3) 0.0001 100 
Biomarkers - Traditional      
 Albumin (g/L) * 44 (41-46) 44 (41-46) 44 (41-46) 0.8858 98.9 
 Bicarbonate (mmol/L) ** 25.0 (3.2) 25.1 (3.2) 25.0 (3.2) 0.7315 97.5 
 Calcium (mmol/L) ** 2.3 (0.2) 2.3 (0.2) 2.3 (0.1) 0.8015 98.4 
 Cholesterol (mmol/L) * 4.5 (3.8-5.4) 4.5 (3.7-5.3) 4.5 (3.8-5.5) 0.92 98.0 
 Corrected Calcium (mmol/L) ** 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 0.9447 98.4 
 Ferritin (ng/mL) * 115 (61-218) 119 (64.5-236) 110 (57.8-210.3) 0.5488 96.6 
 Glucose (mmol/L) * 5.2 (4.7-6.6) 5.3 (4.7-7.0) 5.1 (4.6-6.5) 0.1196 96.6 
 Haemoglobin (g/L) * 124.8 (16.3) 122.9 (15.3) 126.1 (16.8) 0.0398 97.3 
 HbA1c (IFCC; mmol/mol) * 43 (39-55) 43 (39-56) 43.5 (39-55) 0.8756 94.8 
 HDL (mmol/L) * 1.2 (1.0-1.5) 1.3 (1.1-1.6) 1.2 (1.0-1.5) 0.0607 100 
 Phosphate (mmol/L) ** 1.14 (0.2) 1.2 (0.2) 1.1 (0.2) 0.5883 98.0 
 Potassium (mmol/L) ** 4.7 (0.6) 4.6 (0.6) 4.8 (0.6) <0.0001 98.0 
 Triglycerides (mmol/L) * 1.5 (1.1-2.3) 1.5 (1.1-2.3) 1.6 (1.1-2.3) 0.4836 97.5 
  Uric Acid (micromol/L) ** 467.2 (119.7) 472.6 (122.1) 463.2 (118.2) 0.4427 97.3 
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Table 5-2 continued… 
 
    All No ACE/ARB ACEi/ARB P-value Data 
completeness 
(%) 
Biomarkers - Non-traditional      
 Tryptase (microgram/L) * 8.2 (5.5-11.3) 8.1 (5.3-11.8) 8.2 (5.7-11) 0.9647 100 
 cFLC (mg/L) * 73.9 (50.4-102.9) 80.2 (51.1-107.0) 69.9 (50.3-96.8) 0.1209 100 
 Kappa (mg/L) * 41.5 (27.1-61.1) 45.8 (26.9-65.7) 38.8 (27.2-57.0) 0.0571 100 
 Lambda (mg/L) * 31.1 (22.2-44.4) 32.5 (20.8-45.8) 30.0 (22.4-42.9) 0.5731 100 
 Kappa-Lambda Ratio ** 1.4 (0.4) 1.4 (0.4) 1.3 (0.4) 0.0099 100 
  CRP (mg/L) * 2.9 (1.4-7.3) 3.4 (1.8-9.5) 2.6 (1.2-5.7) 0.0009 100 
 
* median (interquartile range) ** mean (standard deviation) 
 
Abbreviations: ACR, albumin creatinine ratio; BP, blood pressure; CCI, Charlson comorbidity index; cFLC, combined serum free light chains; 
COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin; HDL, high density lipoprotein; IHD, ischaemic heard disease; PVD, peripheral vascular disease; SES, socioeconomic status 
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Table 5-3. Comorbidity, split by KDIGO eGFR CKD classification 
 
  All Stage 
G1&G2 
Stage G3a Stage G3b Stage G4 Stage G5 P-value 
Cerebrovascular disease (%) 12.3 16.7 6.5 9.6 13.6 15.4 0.615 
COPD (%) 11.0 8.3 16.1 12.3 10.8 5.1 0.615 
Diabetes (%) 38.6 33.3 37.6 36.8 42.0 30.8 0.446 
IHD (%) 24.0 16.7 19.3 24.6 25.2 20.5 0.878 
Malignancy (%) 15.2 0.0 16.1 16.6 16.0 10.3 0.522 
PVD (%) 11.7 8.3 9.5 13.2 11.6 12.8 0.871 
        
CCI 3 (1-4) 0.5 (0-1.8) 1 (0-3) 2 (0-4) 3 (1-4) 4 (3-6) 0.0001 
 
Abbreviations: CCI; Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; PVD, peripheral 
vascular disease  
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Fifty nine point nine percent (n=267) of individuals were prescribed an ACEi/ARB. 
Comparisons between those receiving or not receiving ACEi/ARB are shown in Table 
5-2. Patients prescribed ACEi/ARB were typically younger, had less comorbidity and 
had a higher BMI. Median eGFR, mean potassium and mean haemoglobin were 
higher in the ACEi/ARB prescribed group. Median serum tryptase concentrations 
were similar for those prescribed (median 8.2μg/L, IQR 5.7-11.0) and not prescribed 
(median 8.1μg/L, IQR 5.3-11.8) ACEi/ARB (P=0.9647). 
 
Individuals were prescribed a median of two antihypertensive medications (IQR 1-3) 
with no significant difference between CKD stages in the number of antihypertensive 
agents prescribed (P=0.38).  
 
5.5.1 Laboratory variables 
The results of the laboratory variables are shown in Table 5-2. Serum concentrations 
of tryptase, CRP and cFLC increased with advancing CKD stage (Table 5-4). Kappa-
Lambda FLC ratio increased with CKD stage (Table 5-4).  
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Table 5-4. Novel Biomarkers, split by KDIGO eGFR CKD classification  
 
  All Stage 
G1&G2 
Stage G3a Stage G3b Stage G4 Stage G5 P-value 
Tryptase 
(microgram/L) * 
8.2 (5.5-
11.3) 
4.0 (2.6-5.7) 6.0 (4.2-9.4) 6.7 (5.0-9.1) 8.7 (6.2-
11.8) 
11.3 (6.6-
14.4) 
0.0001 
cFLC (mg/L) * 73.9 (50.4-
102.9) 
35.3 (23.2-
61.6) 
42.4 (34.0-
54.4) 
56.5 (39.7-
82.2) 
84.7 (60.0-
106.0) 
138.5 
(106.5-
165.2) 
0.0001 
Kappa (mg/L) * 41.5 (27.1-
61.1) 
17.1 (11.3-
31.4) 
23.5 (16.0-
29.5) 
29.8 (20.7-
46.9) 
48.3 (33.5-
65.2) 
76.5 (56.5-
104.9) 
0.0001 
Lambda (mg/L) * 31.1 (22.2-
44.4) 
18.7 (11.4-
27.9) 
19.1 (15.5-
24.8) 
24.4 (19.4-
35.0) 
34.0 (25.1-
45.7) 
54.5 (43.3-
67.0) 
0.0001 
Kappa-Lambda  
Ratio ** 
1.4 (0.4) 1.1 (0.2) 1.2 (0.4) 1.3 (0.5) 1.4 (0.4) 1.4 (0.4) 0.0025 
CRP (mg/L) * 2.9 (1.4-7.3) 1.7 (0.9-2.7) 1.6 (0.8-5.0) 3.0 (1.1-6.0) 3.1 (1.5-8.5) 3.5 (2.4-5.9) 0.0031 
 
* median (interquartile range) ** mean (standard deviation) 
 
Abbreviations: cFLC, combined serum free light chains; CRP, C reactive protein  
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5.5.2 Relationship between markers of inflammation 
There were statistically significant but weak correlations between tryptase and cFLC 
(R=0.28, P<0.001) and between cFLC and CRP (R=0.24, P<0.001). There was no 
significant correlation between CRP and tryptase (R=0.08, P=0.11). 
 
The association between tryptase as the dependent variable and cFLC (both variables 
log transformed due to distribution) was maintained in a linear regression model 
incorporating renal function. This model explained 9.4% of the variation of tryptase 
(R
2 
 0.094). 
 
5.5.3 Outcomes 
Fifty-four participants (12.1%) reached ESRD during the follow-up period, at a 
median time of 446 days (IQR 251.3-745.3 days). Thirty-four participants (7.6%) died 
at a median follow-up of 373 days (IQR 197.3-664.3 days). 
 
Time-independent relationships of the biomarkers and outcomes of progression to 
ESRD and death are shown in Table 5-5. In univariable analyses tryptase and cFLC 
were associated with ESRD whilst cFLC and CRP were associated with death.  
 
Time dependent survival analysis for tryptase was subsequently performed with the 
variables divided into tertiles.  Lower and upper limits for boundaries for each tertile 
are provided in Table 5-6. 
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Table 5-5. Time independent analyses of inflammatory biomarkers (tryptase, C-
reactive protein (CRP), combined free light chains (cFLC) and Kappa-Lambda 
FLC ratio) and outcomes of progression to End Stage Renal Disease (ESRD) and 
Mortality 
 
End Stage Renal Disease: Categorical Data*     
 n (%)  
  1 2 3 P-value 
Tryptase 10 (6.6) 14 (9.3) 30 (20.4) 0.001 
CRP 17 (11.4) 19 (12.8) 18 (12.2) 0.939 
cFLC 2 (1.3) 16 (10.7) 36 (24.3) <0.0001 
Kappa Lambda Ratio 21 (14.1) 14 (9.4) 19 (12.8) 0.437 
     End Stage Renal Disease: Continuous Data**   
  95% CI   
  Beta lower Upper P-value 
Tryptase § 0.26 0.092 0.429 0.003 
CRP § -0.032 -0.377 0.314 0.857 
cFLC
 
§ 0.525 0.385 0.666 <0.001 
Kappa Lambda Ratio -0.016 -0.14 0.108 0.798 
     
Mortality: Categorical Data*       
 n (%)    
  1 2 3  P-value 
Tryptase 11 (7.4) 14 (9.3) 9 (6.1) 0.575 
CRP 8 (5.4) 12 (8.1) 14 (9.5) 0.402 
cFLC 6 (4.2) 10 (6.7) 18 (12.1) 0.027 
Kappa Lambda Ratio 12 (8.1) 5 (3.4) 17 (11.5) 0.03 
     Mortality: Continuous Data**    
  95% CI  
  Beta lower Upper P-value 
Tryptase § 0.034 -0.175 0.243 0.751 
CRP
 
§ 0.468 0.049 0.887 0.029 
cFLC
 
§ 0.309 0.129 0.49 0.001 
Kappa Lambda Ratio 0.099 -0.053 0.252 0.201 
 
Abbreviations: cFLC, combined serum free light chains; CI, confidence interval; 
CRP, C reactive protein 
 
* Comparison performed with Chi-squared test 
** Comparison performed with linear regression 
§ Transformed on a natural log scale due to distribution  
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Table 5-6. Category Boundaries for variables divided into tertiles  
 
    Lower Tertile Middle Tertile Upper Tertile 
    Lower Upper Lower Upper Lower Upper 
Whole cohort       
 Tryptase 
(microgram/L) 
0 6.35 6.37 10.2 10.3 49.5 
 cFLC (mg/L) 20.18 57.16 57.56 93.09 93.18 297.27 
 CRP (mg/L) 0 1.95 1.95 5.15 5.15 137.84 
        
Prescribed ACEi/ARB       
 Tryptase 
(microgram/L) 
0.44 6.35 6.37 9.92 10.1 49.5 
 cFLC (mg/L) 20.18 56.67 56.94 88.56 89.17 245.57 
 CRP (mg/L) 0 1.53 1.54 4.07 4.09 115.571 
        
No ACEi/ARB       
 Tryptase 
(microgram/L) 
0 6.29 6.4 10.6 10.7 30.6 
 cFLC (mg/L) 20.65 57.74 60.88 99.99 100.18 297.27 
  CRP (mg/L) 0 2.34 2.40 7.07 7.08 137.84 
 
Abbreviations: ARB, angiotensin II receptor blocker; ACEi, angiotensin converting 
enzyme inhibitor; cFLC, combined serum free light chains; CI, confidence interval; 
CRP, C reactive protein  
 
 
 
5.5.3.1 End Stage Renal Disease 
No association was identified between aetiology of renal disease and progression to 
ESRD. 
 
Table 5-7 shows the results of univariable and multivariable Cox proportional hazard 
analyses. In univariable analysis, younger age, lower eGFR, higher ACR, highest 
tryptase tertile and highest and middle cFLC tertiles were associated with an increased 
risk of ESRD. In the multivariate analyses, lower age, male gender, lower eGFR and 
higher ACR remained significant. Significance was lost for all tryptase and cFLC 
tertiles.  
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Individuals were then dichotomised according to ACEi/ARB prescription. For those 
participants not prescribed ACEi/ARB, lower age, male gender, lower eGFR, higher 
ACR and highest cFLC tertile was significant but tryptase was not. Combined FLC 
lost significant in the multivariable analysis (Table 5-7). 
 
By univariable analysis of participants prescribed ACEi/ARB, the highest tryptase 
tertile (see Figure 5-2 for Kaplan Meier plot) and middle and highest cFLC tertiles 
were associated with an increased risk of progression to ESRD. In the multivariate 
model with a priori variables, the middle tryptase tertile (HR 5.78, 95% CI 1.19-
28.03, P=0.03) and highest tryptase tertile (6.19, 95% CI 1.49-25.69, P=0.01) were 
significant for progression to ESRD, in addition to all four a priori variables (Table 5-
7). End stage renal disease was reached in 3.4%, 10.5% and 21.4% of the lowest, 
middle and highest tryptase tertiles respectively. Combined FLC tertiles were not 
significantly associated with progression to ESRD. 
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Table 5-7. Cox proportional hazard analysis. Variables associated with progression to end-stage renal disease. 
      Univariable   Multivariable   
      HR (95% CI) P-Value HR (95% CI) P-Value 
Whole cohort      
 Tryptase Lowest Tertile ref  ref  
  Middle Tertile 1.35 (0.60-3.04) 0.468 1.40 (0.58-3.38) 0.45 
  Highest Tertile 3.44 (1.68-7.05) 0.001 1.58 (0.74-3.38) 0.242 
 cFLC Lowest Tertile ref  ref  
  Middle Tertile 8.47 (1.95-36.85) 0.004 3.38 (0.75-15.21) 0.112 
  Highest Tertile 24.35 (5.85-101.29) <0.001 3.19 (0.68-14.96) 0.141 
 CRP Lowest Tertile ref  .  
  Middle Tertile 1.18 (0.61-2.28) 0.614 . . 
  Highest Tertile 1.34 (0.69-2.31) 0.392 . . 
 Age (per 10 year increase) 0.83 (0.71-0.97) 0.021 0.70 (0.58-0.85) <0.001 
 Gender (female as reference) 1.24 (0.71-2.18) 0.442 2.05 (1.09-3.87) 0.027 
 eGFR (per 5ml/min increase) 0.47 (0.38-0.58) <0.001 0.47 (0.37-0.60) <0.001 
  ACR (per 10mg/mmol rise) 1.04 (1.03-1.05) <0.001 1.04 (1.03-1.05) <0.001 
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Table 5-7 continued… 
      Univariable   Multivariable   
      HR (95% CI) P-Value HR (95% CI) P-Value 
Prescribed ACEi/ARB     
 Tryptase Lowest Tertile ref  ref  
  Middle Tertile 3.02 (0.82-11.17) 0.097 5.78 (1.19-28.03) 0.029 
  Highest Tertile 7.79 (2.30-26.36) 0.001 6.19 (1.49-25.69) 0.012 
 cFLC Lowest Tertile ref  ref  
  Middle Tertile 8.48 (1.06-67.82) 0.044 2.27 (0.26-19.76) 0.457 
  Highest Tertile 28.53 (3.84-211-97) 0.001 1.42 (0.15-13.21) 0.756 
 CRP Lowest Tertile ref  .  
  Middle Tertile 1.30 (0.57-2.97) 0.531 . . 
  Highest Tertile 0.88 (0.35-2.23) 0.788 . . 
 Age (per 10 year increase) 0.83 (0.67-1.03) 0.087 0.67 (0.51-0.89) 0.005 
 Gender (female as reference) 1.13 (0.54-2.35) 0.75 4.04 (1.52-10.69) 0.005 
 eGFR (per 5ml/min) 0.44 (0.33-0.57) <0.001 0.32 (0.21-0.49) <0.001 
  ACR (per 10mg/mmol rise) 1.04 (1.02-1.05) <0.001 1.04 (1.02-1.06) <0.001 
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Table 5-7 continued… 
      Univariable   Multivariable   
      HR (95% CI) P-Value HR (95% CI) P-Value 
No ACEi/ARB      
 Tryptase Lowest Tertile ref  .  
  Middle Tertile 0.65 (0.21-2.05) 0.461 . . 
  Highest Tertile 1.48 (0.56-3.90) 0.426 . . 
 cFLC Lowest Tertile ref  ref  
  Middle Tertile 9.42 (1.19-74.40) 0.033 3.05 (0.33-28.23) 0.325 
  Highest Tertile 15.56 (2.02-119.89) 0.008 3.90 (0.44-34.83) 0.223 
 CRP Lowest Tertile ref  .  
  Middle Tertile 0 (0-.) 1 . . 
  Highest Tertile 1.19 (0.51-2.79) 0.688 . . 
 Age (per 10 year increase) 0.73 (0.57-0.95) 0.017 0.64 (0.46-0.88) 0.005 
 Gender (female as reference) 1.38 (0.58-3.29) 0.468 1.43 (0.57-3.62) 0.446 
 eGFR (per 5ml/min) 0.49 (0.34-0.69) <0.001 0.53 (0.36-0.77) 0.001 
  ACR (per 10mg/mmol rise) 1.05 (1.02-1.08) 0.001 1.06 (1.02-1.09) 0.001 
 
Abbreviations: ARB, angiotensin II receptor blocker; ACEi, angiotensin converting enzyme inhibitor; ACR, albumin creatinine ratio; cFLC, 
combined serum free light chains; CI, confidence interval; CRP, C reactive protein; eGFR, estimated glomerular filtration rate   
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Figure 5-2. Kaplan-Meier plot demonstrating increased risk for progression to 
ESRD by Tryptase tertile for individuals prescribed ACEi/ARB.  
The y-axis shows probability of event free survival. The x axis shows time in days 
from study recruitment. Statistical significance was determined using the log-rank test 
(P=0.002). 
 
 
  Subjects remaining in follow up 
Time from Recruitment (days) 
  0 100 200 300 400 500 600 700 800 900 1000 1100 1200 
Lowest 
Tertile 
89 89 89 88 85 74 59 48 36 24 16 8 1 
Middle 
Tertile 
89 89 87 86 81 70 55 48 37 21 17 11 3 
Upper 
Tertile 
89 86 81 78 72 54 39 32 28 18 13 11 5 
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5.5.3.2 Death 
No relationship was seen between tryptase concentration and death, both when 
analysed as a whole cohort or according to ACEi/ARB usage. 
 
The highest cFLC tertile was associated with an increased HR for death in univariable 
Cox regression analysis for the whole cohort (HR 4.13 95% CI 1.63-10.47 P=0.003) 
and both the ACEi/ARB subset (HR 3.99 95% CI 1.08-14.82 P=0.039) and no 
ACEi/ARB subset (HR 4.23 95% CI 1.16-15.41 P=0.029). 
 
The relationship between cFLC tertiles and mortality was lost in multivariable 
analysis with a priori variables for complete cohort; increasing age and elevated ACR 
were the only significant a priori variables associated with an increased HR for death. 
These data are presented in Table 5-8. Multivariable analyses were not performed 
with the group separated into ACEi/ARB usage due to limited event numbers (16 in 
ACEi/ARB group, 23 in non ACEi/ARB group). 
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Table 5-8. Cox proportional hazard analysis. Variables associated with mortality. 
      Univariable   Multivariable   
      HR (95% CI) P-Value HR (95% CI) P-Value 
Whole cohort   
    Tryptase Lowest Tertile ref 
 
. 
   Middle Tertile 1.23 (0.56-2.71) 0.611 . . 
  Highest Tertile 0.89 (0.37-2.16) 0.799 . . 
 cFLC Lowest Tertile ref 
 
ref 
   Middle Tertile 1.71 (0.62-4.73) 0.299 0.96 (0.29-3.18) 0.941 
  Highest Tertile 4.13 (1.63-10.47) 0.003 1.64 (0.50-5.42) 0.417 
 CRP Lowest Tertile ref 
 
ref 
   Middle Tertile 1.57 (0.64-3.83) 0.327 1.14 (0.41-3.13) 0.806 
  Highest Tertile 2.16 (0.90-5.17) 0.084 1.63 (0.64-4.20) 0.307 
 Age (per 10 year increase) 2.42 (1.70-3.46) <0.001 2.64 (1.72-4.05) <0.001 
 Gender (female as reference) 1.41 (0.69-2.89) 0.351 1.30 (0.54-3.14) 0.553 
 eGFR (per 5ml/min increase) 0.75 (0.61-0.91) 0.005 0.83 (0.64-1.08) 0.159 
  ACR (per 10mg/mmol rise) 1.02 (0.99-1.04) 0.199 1.04 (1.01-1.06) 0.003 
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Table 5-8 continued… 
      Univariable   
      HR (95% CI) P-Value 
Prescribed ACEi/ARB  
  Tryptase Lowest Tertile ref 
   Middle Tertile 1.73 (0.50-5.91) 0.385 
  Highest Tertile 1.42 (0.37-5.34) 0.608 
 cFLC Lowest Tertile ref 
   Middle Tertile 1.33 (0.30-5.98) 0.707 
  Highest Tertile 3.99 (1.08-14.82) 0.039 
 CRP Lowest Tertile ref 
   Middle Tertile 1.78 (0.52-6.07) 0.36 
  Highest Tertile 1.35 (0.36-5.05) 0.652 
 Age (per 10 year increase) 2.63 (1.56-4.45) <0.001 
 Gender (female as reference) 0.80 (0.30-2.14) 0.653 
 eGFR (per 5ml/min) 0.71 (0.53-0.96) 0.027 
  ACR (per 10mg/mmol rise) 1.02 (1.00-1.05) 0.064 
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Table 5-8 continued… 
      Univariable   
      HR (95% CI) P-Value 
No ACEi/ARB   
  Tryptase Lowest Tertile ref 
   Middle Tertile 0.80 (0.27-2.37) 0.681 
  Highest Tertile 0.74 (0.24-2.35) 0.613 
 cFLC Lowest Tertile ref 
   Middle Tertile 1.79 (0.43-7.51) 0.425 
  Highest Tertile 4.23 (1.16-15.41) 0.029 
 CRP Lowest Tertile ref 
   Middle Tertile 2.21 (0.52-9.40) 0.281 
  Highest Tertile 4.95 (1.34-18.30) 0.016 
 Age (per 10 year increase) 2.08 (1.25-3.46) 0.005 
 Gender (female as reference) 2.79 (0.92-8.48) 0.071 
 eGFR (per 5ml/min) 0.81 (0.61-1.07) 0.135 
  ACR (per 10mg/mmol rise) 1.00 (0.95-1.05) 0.982 
 
Abbreviations: Abbreviations: ARB, angiotensin II receptor blocker; ACEi, angiotensin converting enzyme inhibitor; ACR, albumin creatinine 
ratio; cFLC, combined serum free light chains; CI, confidence interval; CRP, C reactive protein; eGFR, estimated glomerular filtration rate 
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5.6 Discussion 
The identification of CKD patients at high risk of progression to ESRD enables timely 
preparation for renal replacement therapy and accurate allocation of resources (88, 
272). Furthermore, identifying the mechanisms associated with high risk of 
progression may lead to the development of better targeted therapies. 
 
In these analyses of participants recruited in the RIISC observational study, higher 
baseline tryptase concentrations were associated with increased risk of progression to 
ESRD for individuals prescribed an ACEi/ARB. Furthermore, this association (HR 
for middle tertile 5.78, upper tertile 6.19) remained after correction for age, gender, 
eGFR and ACR. Whilst previous studies have described a rise in tryptase 
concentration by CKD stage, this is the first study to explore an association between 
higher serum concentrations of tryptase and progression to ESRD. 
 
Tryptase is released from mast cells and the number of these cells increase at tissue 
sites of chronic inflammation (273). Few mast cells are found in the renal parenchyma 
of normal kidneys and the concentration of mast cells increases in diseases associated 
with chronic inflammation and have been associated with the severity of interstitial 
fibrosis in patients with progressive CKD due to a variety of aetiologies (140-149) 
and renal allograft dysfunction (274).  
 
There are a number of putative mechanisms for an association between mast cells and 
progression of CKD; these include the release of proteases that promote 
inflammation, fibrosis and haemodynamic stress within the kidney. Tryptase activates 
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PAR2 expression, upregulating TGF-beta and protein expression within mesangial 
and tubular epithelial cells to induce synthesis of pro-fibrotic cytokines and 
extracellular matrix deposition resulting in interstitial fibrosis (149, 271).  
 
Multivariable analysis demonstrated significance in the group prescribed ACEi/ARB 
despite both groups having similar median tryptase concentrations. ACEi/ARB 
exhibit class effects over and above their BP lowering properties for proteinuric CKD 
and cardiovascular disease (275), likely linked to RAAS blockade and the inhibition 
of angiotensin II formation.  Chymase, the other major mast cell protease, acts as the 
main ACE independent pathway of angiotensin II production (276, 277). Mast cell 
activation as measured by mast cell protease levels, in patients receiving ACEi/ARB, 
may define patients at increased risk of progression to ESRD as a consequence of 
pathways that bypass the protective effects of ACEi/ARB. 
 
The results presented in this chapter support the development of early phase studies to 
assess whether mast cell directed therapies have the potential to slow CKD 
progression in patients at high risk of ESRD. Animal models indicate that targeting 
specific mast cell pathways can attenuate renal fibrosis (150). In particular, chymase 
inhibition has been demonstrated to prevent myocardial fibrosis and preserve cardiac 
function after cardiac left ventricular repair surgery in rats (278). Additionally, Wei 
and colleagues, found that combined chymase and ACE inhibition, compared to ACE 
inhibition alone, improved left ventricular function, decreased adverse cardiac 
remodelling, and improved survival after myocardial infarction in hamsters (279). 
Inhibitors of tryptase and chymase have been developed, but have not been trialled to 
date in patients with CKD (280-282).  
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5.6.1 Strengths and Weaknesses 
A major strength of this study is the use of the RIISC study for the recruitment of a 
socioeconomically diverse advanced CKD cohort. Median MDRD eGFR was 25.8 
ml/min/1.73m
2
 and median ACR was 33 mg/mmol at recruitment and, during the 
observation period, 12.1% people reached ESRD.  Data, including SES and 
medication use, were collected prospectively and laboratory samples collected 
according to strict standard operating procedures (73). This enabled the investigation 
of serum tryptase and other non-traditional biological markers including CRP and 
polyclonal cFLCs. Notably, both these are routinely available laboratory tests that 
have been shown, in other cohorts, to be independently associated with progression to 
ESRD (134) and death (133, 283). Exploring the relationship between cFLC and 
tryptase was of particular interest as mast cells can be activated by immunoglobulin 
light chains (284, 285); recent studies have consistently show that in patients with 
CKD, high cFLC are an independent determinant of progression to ESRD and 
mortality (133, 134, 286). This work showed a similar HR for these end-points for 
cFLC, but recruited smaller numbers and was therefore not powered to confirm this 
relationship. 
 
Whilst a substantial proportion of participants reached end-points of ESRD or death, 
the absolute numbers limited the range of dependent variables that could be studied. 
Recognising this we focused on the a priori variables of age, gender, eGFR and ACR; 
which are the cornerstone of risk prediction models for both progression to ESRD and 
mortality (44, 85, 86). The addition of further biological markers may have increased 
the possibility of overfitting. 
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As with all observational studies this work assessed association rather than causation. 
Tryptase was used as a marker of mast cell activation. As discussed earlier, there are 
biologically plausible pathways linking mast cell proteases to tissue fibrosis and CKD 
progression. However, I acknowledge there are other substances released by mast 
cells whose impact on progression of ESRD is unclear (287). This study, in 
conjunction with available animal data, provides a basis for further elucidation of 
mechanisms linking tryptase to CKD progression and consideration of studies 
investigating the therapeutic benefits of mast cell protease inhibition. 
 
5.7 Conclusion to Chapter 5 
In summary this chapter presents the first data to demonstrate serum tryptase 
concentration is an independent prognostic factor for progression to ESRD in patients 
with CKD receiving treatment with an ACEi or ARB. 
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6 RESULTS 4. The impact of Health Related Quality of Life on 
mortality and progression to end-stage renal disease in pre-
dialysis chronic kidney disease. 
 
6.1 Preface 
The previous chapters have investigated the impact of ethnicity (Chapters 3 and 4) on 
outcomes and, using a stratified medicine approach, have identified elevated serum 
tryptase concentration an independent prognostic factor for progression to end-stage 
renal disease (ESRD) in patients with chronic kidney disease (CKD) who are 
receiving treatment with an angiotensin converting enzyme inhibitor (ACEi) or 
angiotensin receptor blockers (ARB) (Chapter 5).  
 
Whilst the end points of death and progression to ESRD are of key importance to 
patients and clinicians, discussion and management of health related quality of life 
(HRQL) are, arguably, as important: impaired HRQL profoundly influences patient 
well-being. As an article by Kimmel and colleagues states ‘survival is not enough’ 
(288). 
 
I therefore investigated the impact of CKD on HRQL and whether there was an 
association between HRQL on the clinical end-points. These analyses utilised the 
RIISC cohort and the HRQL information gathered using the EuroQol EQ-5D 
questionnaire (Section 2.4.2). 
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6.2 Abstract 
Background. Chronic kidney disease is associated with reduced HRQL. However, 
the relationship between pre-dialysis CKD, HRQL and clinical outcomes, including 
mortality and progression to ESRD is unclear. 
 
Methods. All 745 participants recruited into the Renal Impairment In Secondary Care 
study to end March 2014 were included. Demographic, clinical and laboratory data 
were collected at baseline including an assessment of HRQL using the Euroqol EQ-
5D-3L. Health states were converted into an EQ-5Dindex score using a set of weighted 
preferences specific to the UK population. Multivariable Cox proportional hazards 
regression and competing risk analyses were undertaken to evaluate the association of 
HRQL with progression to ESRD or all-cause mortality. Regression analyses were 
then performed to identify variables associated with the significant HRQL 
components. 
 
Results. Median eGFR was 25.8 ml/min/1.73 m
2
 (IQR 19.6-33.7ml/min) and median 
ACR was 33 mg/mmol (IQR 6.6-130.3 mg/mmol). Five hundred and fifty five 
participants (75.7%) reported problems with one or more EQ-5D domains. When 
adjusted for age, gender, comorbidity, eGFR and ACR, both reported problems with 
self-care (hazard ratio (HR) 2.54, 95% confidence interval (CI) 1.22-5.29, P=0.013) 
and reduced EQ-5Dindex score (HR 0.28, 95% CI 0.10-0.81, P=0.019) were 
significantly associated with an increase in all-cause mortality. Similar findings were 
observed for competing risk analyses. Reduced HRQL was not a risk factor for 
progression to ESRD in multivariable analyses.  
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Conclusions. Impaired HRQL is common in the pre-dialysis CKD population. 
Reduced HRQL, as demonstrated by problems with self-care or a lower EQ-5Dindex 
score, is associated with a higher risk for death but not ESRD. Multiple factors 
influence these aspects of HRQL but renal function, as measured by eGFR and ACR, 
are not among them. 
 
6.3 Introduction 
There is increasing evidence of an association between pre-dialysis CKD and 
impaired HRQL as assessed by a variety of patient reported outcome measures 
(PROMs) (75-78). 
 
Health related quality of life can be assessed using disease specific or generic 
instruments. The use of different PROMs within different populations to evaluate 
HRQL means that it is difficult to assess the relevance of the results reported. 
Furthermore, there are limited quantifiable data on the relationship between HRQL 
scores and clinical outcomes, including mortality and progression to ESRD. Previous 
studies have either been small, investigating these outcomes in a Taiwanese 
population (289), or have focused on individuals of black ethnicity with hypertensive 
CKD in the United States (290). A recently published study investigated the impact of 
HRQL using a kidney disease specific tool (KDQOL-36) and found that low HRQL 
was independently association with CV events and death, but not CKD progression 
(291). 
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A systematic review of PROMs in CKD supported the use of preference-based utility 
measures, favouring the EuroQol, EQ-5D due to ease of use for patients and for the 
ability to derive utility values for health economic evaluation (192).  
 
To date, there have been few studies investigating the relationship between pre-
dialysis CKD and HRQL as measured by EQ-5D (75-77), and no studies examining 
the relationship between EQ-5D scores and clinical outcomes. To address this, this 
chapter presents the results of the evaluation of HRQL within the RIISC study, where 
EQ-5D was collected at recruitment, to assess the relationship between HRQL and 
CKD stage, and the impact of HRQL on risk of death or progression to ESRD. 
 
6.4 Methods 
The methodology, including information about the RIISC cohort, the ethical 
permissions and the study design have been described in detail in the methods section 
of this thesis (Section 2.2).  
 
6.4.1 Quality of life 
Data were collected from participants using the EQ-5D-3L (abbreviated to EQ-5D 
throughout this chapter).  Whilst information is provided in Section 2.3.2 of the 
methods, a succinct summary is provided below. 
 
The EQ-5D is a validated, generic preference-based measure of health status. It 
comprises a 5-question multi-attribute questionnaire and a visual analogue self-rating 
scale (VAS) (193). Respondents are asked to rate severity of their current problems 
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(level 1=no problems, level 2=some/moderate problems, level 3=severe/extreme 
problems) for five dimensions of health: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression).   
 
Health states were converted into an EQ-5Dindex score ranging from −0.594 to 1.0 
(where 1 is full health and lower values indicate worse HRQL) using a set of 
weighted preferences produced from the United Kingdom (UK) population (194). The 
EQ VAS asks respondents to rate their own health state relative to full health 
(score=100) or worst imaginable health state (score=0). A copy of the EQ-5D is 
provided in Appendix 5. 
 
6.4.2 Specific Statistical Analyses Related to this Chapter 
Analyses were performed using Stata 13.1 (Statacorp, College Station, Texas, USA). 
 
Techniques for the analysis of descriptive statistics and survival analyses, including 
competing risks, are described in Section 2.4. The censor date for the analyses was 
March 24
th
 2014. 
 
6.4.2.1 Univariable and Multivariable Analyses 
Individual constituents of the EQ-5D were analysed (univariable analyses). Any 
components demonstrating P<0.1 were then included in multivariable analyses 
together with a priori variables (age, gender, comorbidity assessed by Charlson 
comorbidity index (CCI), eGFR and ACR).  
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A priori variables were selected for the reasons discussed in Section 4.4.2.2. 
 
6.4.2.2 Regression analyses to assess the impact of demographic, clinical and 
laboratory variables on HRQL 
Logistic regression was performed to analyse the relationship between problems in 
each of the five domains with clinical, demographic and laboratory variables using 
dichotomised data (patients with moderate and severe problems in a domain were 
combined and compared to those with no problems). Odds ratios (ORs) with 95% CI 
and two-tailed P-values are presented.  
 
Linear regression was utilised for the calculated EQ-5Dindex score and the EQ VAS 
(coefficient with 95% CI and P-value). Residual plots were evaluated to determine 
appropriateness of linear regression models. 
 
Data were entered into multivariable analyses if P<0.1 and a backwards selection 
model performed until remaining variables had a P<0.05. Goodness-of-fit is indicated 
by pseudo R
2 
(logistic regression) or R
2
 (linear regression) values. 
 
6.5 Results 
6.5.1 Descriptive Statistics 
All participants recruited to end March 2014 (n=745) were included in the study. 
Figure 6-1 indicates the number of individuals at each stage of evaluation. Baseline 
demographic, clinical and laboratory data are shown in Table 6-1. Median age at 
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recruitment was 64 years (IQR 50-76 years) and 60.8% were male. The proportion of 
male participants decreased with lower CKD stage (P=0.045). Sixty eight point one 
percent were of white ethnicity, 20.1% South-Asian, 9.4% black ethnicity, and 2.4% 
from other ethnic groups. There was a borderline difference in ethnicity by CKD stage 
(P=0.052). 
 
Forty-six point three percent of participants were in the most deprived quintile 
nationally (IMD 2010). No difference in SES was seen when analysed by CKD stage 
for IMD score (P=0.517) or comparing the percentage in the most deprived quintile 
(P=0.351).  Comorbidity was common and increased with advancing CKD stage, both 
as assessed by individual comorbidities and the CCI (P=0.007).  
 
Table 6-2 illustrates the study population using the KDIGO CKD classification (292). 
Median eGFR was 25.8 ml/min/1.73 m
2
 (IQR 19.6 - 33.7ml/min/1.73 m
2
) and Median 
ACR was 33 mg/mmol (IQR 6.6-130.3 mg/mmol). 
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Figure 6-1. Flow diagram of the participants in the study. 
 
Abbreviation: ESRD, end stage renal disease 
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Table 6-1. Demographic, clinical and laboratory data.  
Categorical variables are expressed as number (%), and continuous variables as mean (SD) or median (IQR). 
 
    All Stage G1/G2 Stage G3a Stage G3b Stage G4 Stage G5 P-
value 
Data 
completeness 
(%) 
eGFR (ml/min/1.73m
2
)  ≥60 45-59 30-44 15-29 <15 
Number in each group (%) 745 (100) 29 (3.9) 45 (6.0) 173 (23.2) 423 (56.8) 75 (10.1) 
Age (years) * 64 (50-76) 41 (34.5-
55.5) 
55 (45-66.5) 61.5 (48.3-
73.8) 
69 (54-75.5) 64 (53.5-
75.5) 
<0.001 100 
Gender - Female (%) 39.2 34.5 28.9 33.1 41.0 50.6 0.045 100 
Ethnicity         
 White (%) 68.1 44.8 71.1 68.0 70.9 59.7 0.052 100 
 South Asian (%) 20.1 27.6 15.6 20.3 18.0 31.2 
 Black (%) 9.4 17.2 11.1 9.3 9.0 7.8 
 Other (%) 2.4 10.3 2.2 2.3 2.1 1.3 
SES (IMD 2010)         
 
Score * 31.9 (46.7-
35.1) 
35.1 (15.2-
44.4) 
31.9 (16.1-
49) 
29 (17.1-
44.4) 
34.1 (18.6-
47.3) 
30 (17.4-
46.0) 
0.615 99.2 
 
% in most deprived 
national quintile 
46.3 51.7 51.1 43.9 49.5 42.1 0.351 99.5 
Educational Attainment         
 
No formal qualifications 
(%) 
46.5 17.2 18.2 40.7 54.9 40.5 <0.001 100 
 GCSE/ O'level (%) 21.8 41.4 27.3 25.6 18.4 21.6 
 NVQ (%) 9.1 3.4 13.6 7.6 9.3 10.8 
 A'Level (%) 7.5 13.8 20.5 8.7 5.0 8.1 
 Undergraduate (%) 10.0 13.8 13.6 12.2 9.1 6.8 
  Postgraduate (%) 5.1 10.3 6.8 5.2 3.3 12.2 
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Table 6-1 continued… 
 
    All Stage G1/G2 Stage G3a Stage G3b Stage G4 Stage G5 P-
value 
Data 
completeness 
(%) 
eGFR (ml/min/1.73m
2
)  ≥60 45-59 30-44 15-29 <15 
                
Current Employment Status         
 
Not currently in 
employment (%) 
19.1 17.2 20.0 18.5 17.7 28.0 <0.001 100 
 In Employment (%) 28.5 65.5 53.3 34.7 21.3 25.3 
 Retired (%) 52.5 17.2 26.7 46.8 61.0 46.7 
Job Type (when last 
working) 
        
 None (%) 0.2 0.0 0.0 0.6 0.0 0.0 0.128 100 
 Unskilled manual (%) 21.4 20.0 18.6 18.1 23.4 18.3 
 Skilled manual (%) 38.2 24.0 30.2 39.4 40.3 30.5 
 Clerical (%) 12.9 4.0 14.0 12.9 13.6 10.7 
 Managerial (%) 10.0 8.0 11.6 10.3 9.5 10.7 
 Professional (%) 17.4 44.0 25.6 18.7 13.1 21.4 
Smoking Status         
 Never (%) 48.0 75.9 38.6 45.9 48.1 46.8 0.042 99.3 
 Current (%) 12.8 10.3 18.2 17.1 11.0 11.7 
  Previous (%) 39.2 13.8 43.2 37.1 41.0 41.6 
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Table 6-1 continued… 
 
    All Stage G1/G2 Stage G3a Stage G3b Stage G4 Stage G5 P-
value 
Data 
completeness 
(%) 
eGFR (ml/min/1.73m
2
)  ≥60 45-59 30-44 15-29 <15 
                
Alcohol Consumption         
 None (%) 57.7 58.6 42.2 52.9 59.7 66.2 0.034 100 
 1-10 unit (%) 29.7 13.8 44.4 34.3 28.4 23.4 
 11-20 units (%) 8.6 20.7 4.4 8.1 8.5 7.8 
 >20 units (%) 4.0 6.9 8.9 4.7 3.3 2.6 
Anthropometrics         
 
BMI (kg/m
2
) * 28.6 (24.9-
33.21) 
30 (25.3-
33.6) 
27.2 (24.6-
31.7) 
28.5 (24.8-
31.9) 
28.7 (24.9-
34) 
28.6 (24.7-
33.2) 
0.786 98.5 
Individual Comorbidities         
 Malignancy (%) 14.0 14.3 17.6 16.1 13.8 9.1 0.494 100 
 Diabetes (%) 34.0 33.3 32.4 30.6 35.4 33.8 0.043 
 COPD (%) 10.0 9.5 14.7 12.8 9.5 5.2 0.383 
 CVD (%) 11.3 19.0 8.8 8.9 11.3 15.6 0.429 
 IHD (%) 21.2 14.3 17.6 21.1 21.4 23.4 0.219 
 PVD (%) 9.5 9.5 8.8 10.6 8.6 13.0 0.788 
Comorbidity Score         
  CCI * 3 (1-5) 1 (0-2) 1 (0-3) 2 (0-4) 3 (2-5) 5 (3-6) <0.001 99.9 
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Table 6-1 continued… 
 
    All Stage G1/G2 Stage G3a Stage G3b Stage G4 Stage G5 P-
value 
Data 
completeness 
(%) 
eGFR (ml/min/1.73m
2
)  ≥60 45-59 30-44 15-29 <15 
                
Blood Pressure         
 Systolic BP (mmHg) ** 130.5 (20.5) 127.7 (20.2) 124 (18.3) 128.9 (20.6) 130.7 (20.2) 137.5 (21.7) 0.004 98.7 
 Diastolic BP (mmHg) ** 76.5 (12.6) 81.9 (11.7) 77.7 (10.7) 77.6 (12.5) 75.5 (12.4) 76.4 (14.9) 0.057 98.7 
Biological Markers         
 
Creatinine (μmol/L) * 212 (166.5-
271.5) 
91 (66-106.5) 135 (111-
145) 
167 (145.3) 235 (205-
272) 
378 (328.3-
434) 
<0.001 98.4 
 
eGFR (ml/min/1.73m
2
) 
* 
25.8 (19.6-
33.7) 
75.6 (70.5-
96.1) 
49.3 (46.9-
52.6) 
35.8 (32.5-
39.3) 
22.8 (19.4-
26.5) 
12.7 (11.0-
14.2) 
<0.001 98.4 
 
ACR (mg/mmol) * 33 (6.6-
130.3) 
92.4 (47.9-
207.4) 
56.3 (6.7-
259.7) 
24.4 (5.0-
140.3) 
28 (4.8-98.9) 79.6 (16.0-
163.3) 
<0.001 94.5 
 Haemoglobin (g/L) ** 124.3 (17.2) 139.0 (17.5) 136.3 (16.0) 129.1 (17.4) 121.8 (15.8) 114.6 (14.9) <0.001 95.6 
 
Bicarbonate (mmol/L) 
** 
24.0 (3.6) 26.0 (2.8) 25.2 (3.3) 24.9 (3.4) 23.8 (3.6) 21.6 (3.6) <0.001 96.8 
 Albumin (g/L) * 43 (43-46) 41 (36.5-45) 44 (41-46.5) 44 (41-46) 43 (40-46) 42 (48-44) 0.002 98 
  CRP (mg/L) ** 3.0 (1.4-7.2) 2.2 (1.1-4.6) 1.6 (0.8-3.7) 3.0 (1.3-5.9) 3.4 (1.6-7.9) 3.5 (2.0 - 10.3) <0.001 93.8 
 
* median (interquartile range) ** mean (standard deviation) 
 
Abbreviations: ACR, Albumin Creatinine Ratio; BMI, Body Mass Index; BP, Blood Pressure; CCI, Charlson Comorbidity index; CRP, C-
reactive protein; eGFR, estimated Glomerular Filtration Rate; SES, Socio-economic status 
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Table 6-2. Study population by Kidney Disease Improving Global Outcomes (KDIGO) classification. 
      ACR categories (mg/mmol)   
   <3 3-30 >30 ACR not 
stated 
N (%) 
      A1 
N (%) 
A2 
N (%) 
A3 
N (%) 
eGFR 
(ml/min/1.73m
2
) 
≥60 G1/G2 1 (0.1) 1 (0.1) 25 (3.4) 2 (0.3) 
45-59 G3a 8 (1.1) 13 (1.7) 24 (3.2) 0 (0) 
30-44 G3b 28 (3.8) 59 (7.9) 78 (10.5) 8 (1.1) 
15-29 G4 66 (8.9) 138 (18.5) 192 (24.8) 27 (3.6) 
<15 G5 5 (0.7) 19 (2.6) 47 (6.3) 4 (0.5) 
 
Abbreviations: ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration rate  
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6.5.2 Self-Reported HRQL 
Complete HRQL data were available for 733 participants (98.4%). Proportions of 
individuals reporting problems with each of the five domains are shown in Figure 6-2. 
One hundred and seventy eight participants (24.3%) reported no problems within any 
domain. Problems with one, two, three, four and five domains were reported by 136 
(18.6%), 129 (17.6%), 153 (20.9%), 91 (12.4%) and 46 (6.3%) participants, 
respectively.  
 
6.5.3 Associations between HRQL and CKD 
As illustrated in Figure 6-2, statistically significant differences between CKD stages 
were seen in the mobility (P=0.001) and usual activity (P=0.002) domains, with more 
problems reported with a worse CKD stage. No significant difference was found 
between CKD stages and the other domains. 
 
Only a small number of participants described problems in the unable/severe 
category, therefore data were dichotomised to combine the respondents who reported 
moderate problems with those in the severe or unable category.  
 
Health related quality of life for the EQ VAS and calculated EQ-5Dindex score are 
shown in Table 6-3. The EQ-5Dindex score decreased (worsened) with more advanced 
CKD stage (P=0.017). No significant difference was seen between CKD stage and the 
EQ VAS.  
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Figure 6-2. Reported HRQL Problems by EQ-5D domain. Data presented as 
whole cohort (All) and categorised by chronic kidney disease stage (determined 
by eGFR). 
 
* P-value for Chi-squared test comparing each EQ-5D domain by CKD stage. 
 
Table 6-3. Calculated EQ-5D Index Score and Visual Analogue Scale by chronic 
kidney disease stage (determined by eGFR). 
  EQ-5D Index 
Score 
Visual Analogue 
Scale 
All 0.74 (0.66-0.88) 65 (50-80) 
Stage G1/G2 0.85 (0.70-1) 50 (75-82.5) 
Stage G3a 0.80 (0.69-1) 70 (50-80) 
Stage G3b 0.80 (0.68-1) 70 (50-80) 
Stage G4 0.74 (0.62-0.85) 60 (50-80) 
Stage G5 0.73 (0.62-1) 55 (50-80) 
   
P-value 0.0165 0.094 
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6.5.4 Association between HRQL and Clinical end-points 
6.5.4.1 Death 
By March 24
th
 2014, 46 (6.2%) participants had died.  Univariable cox regression 
analysis demonstrated that reported problems with mobility, self-care (Figure 6-3), 
usual activities, lower EQ-5Dindex score, and lower EQ VAS, were all associated with 
an increased risk of death. Table 6-4 indicates univariable cox regression analyses for 
a priori variables and EQ-5D components. 
 
In multivariable analysis, each significant EQ-5D variable was combined with age, 
gender, comorbidity assessed by CCI, eGFR and ACR. Self-care (HR 2.54, 95% CI 
1.22-5.29, P=0.013, Figure 6-4, Table 6-5) and the EQ-5Dindex score (HR 0.28, 95% 
CI 0.10-0.81, P=0.019, Table 6-5) were independently associated with an increased 
risk of death. Fourteen out of 102 (13.7%) participants who reported problems with 
self-care died compared to 32/641 (5.0%) participants who reported no problems (chi-
squared P=0.001).  
 
To adjust the HR associated for death for the competing end-point of ESRD, a 
competing risk analysis was performed. Problems with self-care (sub-distribution 
hazard ratio (SHR) 2.61, 95% CI 1.26-5.60, P=0.01) and a lower EQ-5Dindex score 
(SHR 0.32, 95% CI 0.11-0.96, P=0.042) remained significant in the multivariable 
analysis with age, gender, comorbidity, eGFR and ACR (Table 6-5). 
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Figure 6-3. Cox Proportional Hazards Regression for reported problems with 
self-care and death. Univariable Analyses. 
 
 
Table 6-4. Univariable Survival Analyses (Cox regression) for hazard ratio (HR) 
for death. A priori variables and all components of EQ-5D shown. 
    HR (95% CI) P-Value 
A Priori Variables   
 
Age (per 10 year increase) 2.42 (1.79-3.28) <0.001 
 
Gender (female as reference) 1.38 (0.74-2.55) 0.311 
 
Charlson Comorbidity Index 1.41 (1.25-1.58) <0.001 
 
eGFR (per 5ml/min increase) 0.81 (0.69-0.96) 0.015 
 
ACR (per 10mg/mmol rise) 1.02 (1.00-1.03) 0.065 
 
   
ED5D Components   
 
Mobility 3.72 (1.79-7.73) <0.001 
 
Self-Care 3.04 (1.62-5.71) 0.001 
 
Usual Activities 3.02 (1.59-5.75) 0.001 
 
Pain/Discomfort 1.11 (0.62-1.98) 0.727 
 
Anxiety/ Depression 1.56 (0.86-2.84) 0.146 
 
EQ-5D Index Score 0.20 (0.09-0.45) <0.001 
  Visual Analogue Scale 0.98 (0.96-0.99) <0.001 
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval, eGFR, 
estimated glomerular filtration rate; HR, hazard ratio. 
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Figure 6-4. Cox Proportional Hazards Regression for reported problems with 
self-care and death. Multivariable Analyses.  
Covariates included age, gender, Comorbidity (assessed by Charlson Comorbidity 
Index) and renal function (eGFR and ACR). 
 
 
Table 6-5. Multivariable Survival Analyses (Cox regression and Competing risk) 
for hazard ratio (HR) and subdistribution hazard ratio (SHR) for death. 
  Cox Regression Analyses Competing Risk Analyses 
  HR (95% CI) P-Value SHR (95% CI) P-Value 
Identified problem with self 
care 
2.54 (1.22-5.29) 0.013 2.61 (1.26-5.40) 0.01 
Age (per 10 year increase) 2.04 (1.44-2.88) <0.001 2.24 (1.59-3.16) <0.001 
Gender (female as reference) 1.50 (0.68-3.29) 0.311 1.44 (0.68-3.07) 0.341 
Charlson Comorbidity Index 1.24 (1.06-1.44) 0.006 1.19 (1.04-1.37) 0.01 
eGFR (per 5ml/min increase) 0.85 (0.70-1.05) 0.128 0.90 (0.75-1.10) 0.306 
ACR (per 10mg/mmol rise) 1.02 (1.00-1.03) 0.013 1.02 (1.00-1.03) 0.045 
 
    
EQ-5D index score  0.28 (0.10-0.81) 0.019 0.32 (0.10-0.96) 0.042 
Age (per 10 year increase) 2.09 (1.48-2.95) <0.001 2.31 (1.66-1.66) <0.001 
Gender (female as reference) 1.57 (0.73-3.37) 0.247 1.43 (0.70-2.91) 0.324 
Charlson Comorbidity Index 1.20 (1.03-1.40) 0.02 1.15 (1.01-1.32) 0.032 
eGFR (per 5ml/min increase) 0.85 (0.69-1.05) 0.126 0.91 (0.75-1.11) 0.344 
ACR (per 10mg/mmol rise) 1.02 (1.01-1.04) 0.002 1.02 (1.00-1.03) 0.016 
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval; eGFR, 
estimated glomerular filtration rate 
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These analyses also identify increasing age, comorbidity and higher ACR as being 
associated with death. Estimated GFR was not significant; however a creatinine 
greater than 265 μmol/L (3mg/dL) scores 2 points in the CCI. Reanalysing the data 
for the CCI without the renal disease points results in eGFR demonstrating 
significance in Cox regression but not competing risk analyses (Table 6-6). 
 
Table 6-6. Multivariable Survival Analyses (Cox regression and Competing risk) 
for death – Charlson comorbidity index without renal component. 
 
  Cox Regression Analyses Competing Risk Analyses 
  
HR (95% CI) P-
Value 
SHR (95% CI) P-
Value 
Identified problem with self care 2.49 (1.19-5.20) 0.015 2.57 (1.23-5.36) 0.012 
Age (per 10 year increase) 2.00 (1.41-2.84) <0.001 2.20 (1.55-3.11) <0.001 
Gender (female as reference) 1.82 (0.85-3.92) 0.124 1.68 (0.82-3.44) 0.159 
Charlson Comorbidity Index 
without renal component* 
1.23 (1.04-1.44) 0.013 1.19 (1.02-1.38) 0.03 
eGFR (per 5ml/min increase) 0.78 (0.63-0.97) 0.025 0.84 (0.68-1.04) 0.108 
ACR (per 10mg/mmol rise) 1.02 (1.00-1.03) 0.02 1.02 (1.00-1.03) 0.061 
 
  
  EQ-5D index score  0.29 (0.10-0.84) 0.023 1.32 (0.10-0.99) 0.048 
Age (per 10 year increase) 2.06 (1.46-2.92) <0.001 2.27 (1.63-3.16) <0.001 
Gender (female as reference) 1.86 (0.88-3.92) 0.103 1.62 (0.82-3.22) 0.167 
Charlson Comorbidity Index 
without renal component* 
1.18 (1.00-1.39) 0.051 1.14 (0.98-1.33) 0.095 
eGFR (per 5ml/min increase) 0.79 (0.63-0.98) 0.033 0.86 (0.69-1.06) 0.151 
ACR (per 10mg/mmol rise) 1.02 (1.01-1.04) 0.002 1.02 (1.00-1.03) 0.015 
 
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval; eGFR, 
estimated glomerular filtration rate; HR, hazard ratio; SHR, subdistribution hazard 
ratio 
* Calculated using all Charlson Comorbidity Index components EXCEPT 
moderate/severe renal disease (creatinine >265mmol/L) 
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6.5.4.2 End-Stage Renal Disease 
Seventy-eight participants (10.5%) had reached ESRD by the censor date. Lower EQ 
VAS score was the only component of the EQ-5D associated with an increased HR 
for progression to ESRD (Table 6-7). Significance was lost when the a priori 
variables of age, gender, comorbidity, eGFR and ACR were included in a 
multivariable analysis. Similarly, competing risk analysis indicated an association 
with a lower VAS and ESRD in univariable but not multivariable analysis. 
 
Table 6-7. Univariable survival analyses (Cox regression) for end-stage renal 
disease (ESRD).  
A priori variables and all components of EQ-5D shown. 
 
    HR (95% CI) P-Value 
A Priori Variables   
 
Age (per 10 year increase) 0.84 (0.74-0.96) 0.011 
 
Gender (female as reference) 1.01 (0.64-1.60) 0.955 
 
Charlson Comorbidity Index 1.20 (1.09-1.31) <0.001 
 
eGFR (per 5ml/min increase) 0.41 (0.34-0.49) <0.001 
 
ACR (per 10mg/mmol rise) 1.03 (1.03-1.04) <0.001 
  
  
ED5D Components   
 
Mobility 1.00 (0.64-1.56) 0.998 
 
Self-Care 0.59 (0.26-1.35) 0.211 
 
Usual Activities 1.25 (0.80-1.96) 0.317 
 
Pain/Discomfort 1.09 (0.70-1.71) 0.695 
 
Anxiety/ Depression 1.17 (0.72-1.89) 0.519 
 
EQ-5D Index Score 1.02 (0.44-2.35) 0.958 
  Visual Analogue Scale 0.99 (0.98-1.00) 0.016 
 
Abbreviations: ACR, albumin creatinine ratio; CI, confidence interval, eGFR, 
estimated glomerular filtration rate; HR, hazard ratio. 
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6.5.5 The impact of demographic, clinical and laboratory variables on HRQL 
The analyses above demonstrate the two HRQL factors associated with death in the 
survival analyses were problems with self-care and a lower EQ-5Dindex score. In order 
to explore factors predictive of these two elements, further exploratory analyses were 
performed for self-care (logistic regression) and the EQ-5Dindex score (linear 
regression). 
 
6.5.5.1 Self-care:  
Table 6-8 shows the factors that were associated with (P<0.1) reported problems with 
self-care.  
 
Ethnicity classified as other or not stated, people who were not currently working, 
higher body mass index (BMI), higher bicarbonate concentration, and higher C 
reactive protein (CRP) were statistically significantly associated with reported 
problems with self-care in multivariable analysis (Table 6-8). This model explained 
16.5% of variability with self-care (pseudo R
2
 0.165). Of note, age and renal function 
did not influence this aspect of HRQL. 
 
6.5.5.2 EQ-5Dindex score: 
Table 6-9 shows factors (P<0.1) associated with a higher EQ-5D score (i.e. better 
HRQL).  
 
Multivariable analysis found the following variables remained associated with better 
HRQL: male gender; currently in employment; not smoking in comparison to current 
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smoking; lower BMI; less comorbidity; and lower CRP (Table 6-9). This linear 
regression model explained 20.8% of the variability in HRQL as assessed by the EQ-
5Dindex score (adjusted R
2
 0.208). Again age and renal function were not associated 
with this assessment of overall HRQL. 
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Table 6-8. Variables predictive of reported problems with self-care by logistic regression. 
    Univariable Analyses   Multivariable Analyses*   
    OR (95% CI) SE P-value OR (95% CI) SE P-value 
Age (per 10 year increase) 1.29 (1.12-1.49) 0.09 <0.001 
   Ethnicity (white as reference) 
      
 
South Asian 1.46 (0.88-2.41) 0.38 0.146 1.97 (1.06-3.68) 0.63 0.032 
 
Black 1.36 (0.68-2.72) 0.48 0.391 1.04 (0.41-2.61) 0.49 0.938 
 
Other/ Not stated 2.80 (0.96-8.13) 1.52 0.058 4.30 (1.25-14.76) 2.71 0.021 
SES (most deprived Quintile) 1.51 (0.99-2.30) 0.33 0.058 
   Academic Qualifications (none versus some) 2.16 (1.40-3.32) 0.47 <0.001 
   Employment status (currently employed as reference) 
      
 
Not employed 26.02 (6.09-111.21) 19.28 <0.001 15.22 (3.42-67.79) 11.60 <0.001 
 
Retired 23.77 (5.77-97.94) 17.17 <0.001 19.14 (4.57-80.20) 13.99 <0.001 
Weekly Alcohol Consumption (none as reference) 
      
 
Under 10 units 0.54 (0.32-0.91) 0.14 0.021 
   
 
11-10 units 0.97 (0.47-2.00) 0.36 0.935 
   
 
More than 20 units 0.18 (0.02-1.32) 0.18 0.092 
   BMI (kg/m
2
) 1.07 (1.04-1.11) 0.02 <0.001 1.06 (1.03-1.10) 0.02 0.001 
Charlson Comorbidity Index 1.21 (1.11-1.32) 0.05 <0.001 
   Diabetes 2.41 (1.58-3.68) 0.52 <0.001 
   Chronic obstructive pulmonary disease 2.61 (1.50-4.52) 0.73 0.001 
   Ischaemic Heart disease 1.79 (1.14-2.83) 0.42 0.012 
   Peripheral Vascular Disease 2.15 (1.21-3.83) 0.63 0.009 
   SBP (mmHg) 1.01 (1.00-1.02) 0.01 0.06 
   DBP (mmHg) 0.98 (0.96-1.00) 0.01 0.019       
 
 191 
Table 6-8 continued… 
 
    Univariable Analyses   Multivariable Analyses*   
    OR (95% CI) SE P-value OR (95% CI) SE P-value 
Haemoglobin (g/L) 0.98 (0.97-1.00) 0.01 0.015 
   Bicarbonate (mmol/L) 1.10 (1.04-1.17) 0.03 0.002 1.10 (1.03-1.18) 0.04 0.008 
Albumin (g/L) 0.95 (0.91-0.99) 0.02 0.012 
   CRP (mg/L) 1.02 (1.00-1.03) 0.01 0.007 
   log CRP 1.53 (1.27-1.83) 0.14 <0.001 1.27 (1.03-1.57) 0.14 0.027 
 
Abbreviations; BMI, body mass index; CRP, C-reactive protein; CI, confidence interval; DBP, diastolic blood pressure; OR, odds ratio; SBP, 
systolic blood pressure; SE, standard error; SES, socio-economic status;  
 
* Significant variables removed in a backwards stepwise technique until remaining variables had a P<0.05.   
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Table 6-9. Variables predictive of higher EQ-5D index score by linear regression. 
 
    Univariable Analyses   Multivariable Analyses*   
    Coefficient (95% CI) SE P-value Coefficient (95% CI) SE P-value 
Age (per 10 year increase) -0.03 (-0.05--0.02) 0.01 <0.001    
Gender (male as reference) 0.04 (0.00-0.08) 0.02 0.048 0.05 (0.00-0.10) 0.02 0.042 
SES (most deprived Quintile) -0.06 (-0.10--0.02) 0.02 0.004    
Academic Qualifications (none versus some) -0.01 (-0.14--0.06) 0.02 <0.001    
Employment status (currently employed as 
reference) 
      
 Not employed -0.26 (-0.32--0.21) 0.03 <0.001 -0.19 (-0.26--0.13) 0.03 <0.001 
 Retired -0.21 (-0.25--0.16) 0.02 <0.001 -0.13 (-0.19--0.08) 0.03 <0.001 
Smoking status (non smoker as reference)       
 Current -0.07 (-0.13-0.00) 0.03 0.037 -0.11 (-0.18--0.04) 0.03 0.001 
 Previous -0.07 (-0.11--0.02) 0.02 0.003 -0.03 (-0.08-0.02) 0.02 0.235 
Weekly Alcohol Consumption (none as reference)       
 Under 10 units 0.07 (0.03-0.12) 0.02 0.002 0.03 (-0.02-0.07) 0.02 0.254 
 11-10 units 0.04 (-0.03-0.12) 0.04 0.261 0.01 (-0.07-0.08) 0.04 0.887 
 More than 20 units 0.17 (0.07-0.28) 0.05 0.001 0.11 (0.01-0.22) 0.05 0.033 
BMI (kg/m
2
) -0.01 (-0.01--0.01) 0.00 <0.001 -0.01(-0.01-0.00) 0.00 <0.001 
Charlson Comorbidity Index -0.03 (-0.04--0.02) 0.00 <0.001 -0.02 (-0.03--0.01) 0.01 0.003 
Diabetes -0.11 (-0.15--0.07) 0.02 <0.001    
Chronic obstructive pulmonary disease -0.10 (-0.17--0.04) 0.03 0.001    
Cerebrovascular disease -0.09 (-0.26--0.03) 0.03 0.003    
Ischaemic Heart disease -0.13(-0.18--0.08) 0.03 <0.001    
Peripheral Vascular Disease -0.14 (-0.21--0.08) 0.42 <0.001       
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Table 6-9 continued… 
 
    Univariable Analyses   Multivariable Analyses*   
    Coefficient (95% CI) SE P-value Coefficient (95% CI) SE P-value 
SBP (mmHg) 0.00 (0.00-0.00) 0.00 0.001    
DBP (mmHg) 0.00 (0.00-0.00) 0.00 0.011    
eGFR (per 5ml/min) 0.01 (0.00-0.02) 0.00 0.006    
Haemoglobin (g/L) 0.00 (0.00-0.00) 0.00 <0.001    
Albumin (g/L) 0.01 (0.00-0.01) 0.00 0.001    
CRP (mg/L) -0.05 (-0.07--0.29) 0.01 <0.001    
log CRP 0.00 (-0.01-0.00) 0.00 <0.001 -0.02 (-0.04-0.00) 0.01 0.03 
 
Abbreviations; BMI, body mass index; CRP, C-reactive protein; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated 
glomerular filtration rate; SBP, systolic blood pressure; SE, standard error; SES, socio-economic status;  
 
* Significant variables removed in a backwards stepwise technique until remaining variables had a P<0.05.   
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6.6 Discussion 
The relationship between pre-dialysis CKD, HRQL and clinical outcomes is an 
important aspect of nephrology practice. These analyses, conducted in a cohort of 
people with advanced and/or progressive CKD, demonstrated that reported problems 
with HRQL, as measured by the EQ-5D, were common; only 24.3% of participants 
reported no problem in any EQ-5D domain.  
 
Impaired HRQL was a risk factor for death; problems with self-care and overall 
HRQL, assessed by the EQ-5Dindex score, were associated with an increased HR for 
death when analysed with age, gender, comorbidity, eGFR and ACR. This association 
was present in both cox proportional hazard regression and competing risk regression 
(with ESRD as the competing risk). No element of HRQL was independently 
associated with risk of progression to ESRD. 
 
Until recently, previous studies investigating HRQL in patients with pre-dialysis CKD 
had focused on specific populations (Taiwanese (289) or individuals of black 
ethnicity with hypertensive CKD in the United States(290)). Whilst the 
generalisability of these studies to a multi-ethnic United Kingdom CKD population is 
questionable, both studies identified an association with HRQL and death in similarity 
to the findings presented here. However, the association with HRQL and CKD 
progression was conflicting; Tsai and colleagues identified an association (289) but 
Porter and colleagues only noted an association in a composite of death and CKD 
progression (290).  
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A combined analysis of the Chronic Renal Insufficiency Cohort and Hispanic Chronic 
Renal Insufficiency Cohort has recently been published (291). The disease specific 
KDQOL-36 questionnaire was completed by 3837 patients (of a total of 3939 
enrolled). Consistent with the data presented here, they found that low HRQL was 
independently associated with a higher risk of death but not CKD progression in 
several KDQOL-36 subscales (physical component summary, mental component 
subscale, effects and symptoms). The KDQOL-36 questionnaire is a detailed HRQL 
survey based on a chronic disease core, with added items relevant to patients with 
kidney disease (293). Compared to the EQ-5D, it is more time consuming to 
complete, has some components that apply more to those undergoing RRT than the 
pre-dialysis population, and its utility in health economic evaluations is not as 
established. 
 
To explore further the factors that influence the components of HRQL associated with 
death (self-care and the EQ-5Dindex score), I assessed the relationship between these 
components and demographic, clinical and laboratory variables utilizing regression 
analysis. Not being currently employed, whether young and not working or retired, 
conveyed the highest HR associated with impaired HRQL. Other significant factors 
for a lower HRQL included higher BMI, a higher CRP, and multimorbidity. Further 
research is warranted.  
 
Interestingly, no association was identified between these aspects of HRQL and SES, 
increasing age of the participants or renal function, as measured by eGFR or ACR. 
This lack of association between HRQL and renal function, is a finding variably 
supported by previous studies (76, 294, 295).   
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This work, and that of others, demonstrate that reported problems with HRQL are 
common in this population (192) and I have found an association between impaired 
HRQL and death. It is therefore important to consider what strategies could be used to 
improve HRQL; improving HRQL will not only improve patient well-being but may 
convey a survival advantage. Previous studies have demonstrated that optimisation of 
haemoglobin, psychological interventions and physical exercise may be of benefit 
(296-298). However, the majority of these studies have focused on patients who have 
reached ESRD rather than pre-dialysis CKD. Therefore, the transferability of these, or 
of interventions instigated for other chronic disease states, requires evaluation. 
 
In this study of patients with pre-dialysis CKD, problems with self-care and the EQ-
5Dindex score (194) were both of prognostic significance; in clinical practice problems 
with self-care may be the more useful HRQL screening question to identify patients 
with CKD at an increased risk of death. There are analogies here to the findings of 
O’Hare and colleagues who quantified the impact of age on outcomes in individuals 
with CKD (299); similarly, knowledge about impaired HRQL may help inform 
clinicians and patients about the relative risk of death compared to ESRD. This 
information could inform decision making including when to discuss renal 
replacement therapy options and to help ensure such individuals are adequately 
supported when counselled about their higher mortality risk. Additionally it may 
provide a trigger to enable social care resources to be targeted to those most in need 
and may enable identification of a high-risk group where interventions to improve 
outcomes can be studied. 
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6.6.1 Strengths and Weaknesses 
The major strength of this study is the use of a prospectively recruited, socio-
economically and ethnically diverse cohort of patients with advanced and/or 
progressive pre-dialysis dependent CKD. Detailed demographic and clinical data were 
collected at initial recruitment and the participants were tracked longitudinally to 
record outcomes, including death and ESRD. HRQL was assessed by the EQ-5D tool, 
which is recommended as the preference based measure for HRQL evaluation in CKD 
(192). Survival analyses were performed using both Cox proportional hazard analyses 
and competing risk analyses. The latter is important, though rarely used, as it enabled 
the competing risk of ESRD to be taken into account when assessing death and vice 
versa: both end-points are (separately) of key interest to patients, their families and 
clinicians (222, 300). 
 
A weakness, as with all observational studies, is that these analyses have assessed 
association rather than causation. Whilst the analyses for factors associated with an 
increased risk of death included baseline renal function and progression to ESRD (in 
competing risk analyses), I did not include any other measure of CKD progression.  
 
In addition, whilst considerable demographic and clinical information was collected, 
there was no formal assessment of frailty, depression or nutritional status of the 
participants. These factors have been associated with impairment of HRQL (78, 301-
306).  
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6.7 Conclusion to Chapter 6 
In summary, data presented in this chapter demonstrate that impaired HRQL is 
common in a diverse pre-dialysis CKD population and that impaired HRQL, as 
demonstrated by problems with self-care or a lower EQ-5Dindex score, is associated 
with a higher risk for death but not ESRD. Multiple factors influence these aspects of 
impaired HRQL but renal function, as measured by eGFR and ACR, are not among 
them.  
 
Further studies are recommended to evaluate interventions that may improve HRQL 
within the pre-dialysis CKD population and to investigate whether any improvements 
in HRQL are associated with a survival advantage. 
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7 DISCUSSION 
 
In the results chapters I present data from a series of studies focusing on high-risk 
patients with chronic kidney disease (CKD). In this final chapter, I discuss the key 
findings from each study, highlight the common themes identified throughout this 
thesis and describe potential future directions leading from this research. I examine 
the key strengths and limitations of the work before drawing final conclusions. 
 
7.1 Chapter 3 Summary: The impact of ethnicity, chronic kidney disease 
and cardiovascular comorbidity on mortality in a multi-ethnic 
primary care population. 
This chapter investigated the determinants of mortality in an ethnically diverse 
primary care population, using enhanced electronic data collected from 31,254 people 
in 62 primary care practices within central Birmingham. The analyses identified 
ethnicity as a risk factor for mortality; the risk of death in South Asian and black 
individuals were lower when compared to white individuals. The difference was, in 
part, independent of age, gender, socioeconomic status (SES), renal function and 
comorbidities.  
 
The analyses identified renal function, both estimated glomerular filtration rate 
(eGFR) and albumin creatinine ratio (ACR), and comorbidity as significant risk 
factors for mortality. Additionally, the data showed measurement of ACR in high-risk 
populations was by no means universal; only 11,205 of the 31,254 (35.9%) 
individuals had an ACR recorded. 
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7.2 Chapter 4 Summary: The impact of ethnicity on progression to end-
stage renal disease in pre-dialysis chronic kidney disease. 
Whilst Chapter 3 focused on a multi-ethnic primary care population, Chapter 4 
investigated the impact of ethnicity in a secondary care nephrology population, the 
Renal Impairment in Secondary Care (RIISC) study, where over 30% of individuals 
were of black and minority ethnic backgrounds.  
 
I demonstrated that individuals of South Asian and black ethnicity were at higher risk 
of end stage renal disease (ESRD) than their white counterparts, and that this persisted 
in competing risk analyses (where death was the competing risk). The difference 
between risk of ESRD was explained by known risk factors (age, gender, eGFR and 
ACR); median ACR was highest in South Asians and I identified albuminuria as the 
principal modifiable risk factor. 
 
7.3 Chapter 5 Summary: Serum tryptase concentration and progression 
to end-stage renal disease. 
The work in Chapter 5 analysed participants in the RIISC study to investigate the 
association of serum tryptase to progression of ESRD, and whether this relationship 
was influenced by use of angiotensin converting enzyme inhibitors (ACEi) and 
angiotensin II receptor blockers (ARB).  
 
Analyses identified serum tryptase concentration as an independent prognostic factor 
(after adjustment of the a priori variables of age, gender, eGFR and ACR) for 
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progression to ESRD in those receiving treatments with ACEi/ARB. These data 
suggest the potential of using tryptase to assess pathways that bypass the protective 
effects of ACEi/ARB which could be utilised in the era of stratified medicine. 
 
7.4 Chapter 6 Summary: The Impact of Health Related Quality of Life 
on mortality and progression to end-stage renal disease in pre-
dialysis chronic kidney disease. 
Whilst the earlier chapters concentrated on the endpoints of death and progression to 
ESRD, I was keen to recognise and investigate the impact of CKD on health related 
quality of life (HRQL) and any association between HRQL and clinical endpoints. I 
therefore analysed data on HRQL, assessed with the EuroQol EQ-5D questionnaire, 
within the RIISC study cohort. 
 
I demonstrated that impaired HRQL was common in pre-dialysis CKD and that 
reduced HRQL was associated with a higher risk for death but not ESRD. The 
components associated with an increased risk of death were difficulties with self care 
and a lower EQ-5Dindex score (a global assessment of HRQL where the five individual 
health states from the EQ-5D questionnaire are converted into a score using a set of 
weighted preferences specific to the UK population (194)). I then investigated these 
two aspects (problems with self care and the EQ-5Dindex score) and found that 
although renal function did not influence these components, multiple other factors 
did.  
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7.5 Common themes and future directions 
Within this thesis, there are several common themes which are discussed below. I also 
highlight possible directions for future research. 
 
7.5.1 Increasing comorbidity is associated with death 
I assessed the impact of comorbidity in primary and secondary care cohorts by 
investigating the impact of individual and combined comorbidity. The technique used 
to assess combined comorbidity varied by the population studied, principally due to 
the availability of data; I used cumulative cardiovascular comorbidity in primary care 
(Chapter 3) and the Charlson comorbidity index (CCI) (216) in the RIISC cohort 
(Chapters 4-6). Both were associated with death in multivariable analyses. 
 
This finding is important given the prevalence of comorbidity, especially in older 
individuals (307). An understanding of the impact of comorbidity, and its potential to 
influence the balance between risk of death versus progression to ESRD, is important 
in routine primary care and nephrology practice and the data I present highlights this. 
A discussion regarding silo working by different secondary care specialties is beyond 
the scope of this thesis but increasing comorbidity is likely to require a more 
collaborative approach to healthcare. 
 
Whilst the Charlson comorbidity score is used routinely by health researchers, it was 
developed in 1984 and focused on conditions which influenced mortality within one 
year from hospital discharge. Management of many of the conditions in the Charlson 
scoring system (Table 2.2) has changed dramatically and, whilst attempts to update 
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the scoring system have been proposed (308), their use is not routine. As discussed 
earlier in this thesis, a limitation of the use of the CCI in nephrology research is that 
renal impairment is one factor in the Charlson score, and therefore has the potential to 
minimise the significance of eGFR in multivariable analyses; indeed this was one of 
the findings I report in Chapter 6. 
 
7.5.2 The significance of albuminuria 
Albuminuria, assessed in this work as a urine ACR, has been demonstrated to add 
prognostic information in addition to measurements of eGFR, both in terms of risk of 
ESRD and death. This is in agreement with multiple previous studies, perhaps most 
notably the work of the Chronic Kidney Disease Prognosis Consortium (43, 44, 46, 
309) which analysed the available data in response to the KDIGO controversies 
conference (42) and resulted in the 2012 update of the international CKD staging 
system (54). 
 
The results in this thesis highlight two pertinent issues 
 
7.5.2.1 Primary care underutilises testing for albuminuria 
Chapter 3 demonstrated the significance of elevated ACR and its association with 
mortality in a primary care setting. However, only 35.9% of individuals within the 
cohort had their ACR tested. People were more likely to have it tested if they were of 
Future work 1: An evaluation of current comorbidity scoring systems and 
their utility in nephrology. 
 204 
South Asian descent, male gender, had diabetes or had greater vascular comorbidity. 
The use of ACR in screening for microalbuminuria in diabetes has been established 
practice for many years (40, 41) and these analyses were based on data collected 
before the 2012 update of the CKD staging system; it would therefore be important to 
evaluate whether the use of ACR in primary care has improved since the publication 
of both international and national (e.g. NICE CKD (33)) guidelines. Strategies to 
increase the ACR measurement in routine clinical practice should be encouraged and 
the utility of ACR for risk stratification and for enhanced treatment (e.g. with 
ACEi/ARB and to more rigorous blood pressure targets) highlighted. 
 
Previously, one of the assessment measures for CKD in the Quality and Outcome 
Framework (QOF) primary care pay for performance model was ‘the percentage of 
patients on the CKD register whose notes have a record of a urine albumin creatinine 
ratio (or protein creatinine ratio) test in the preceding 12 months’ (64). This 
component has now been removed and, in QOF 2015-2016, the only stated outcome 
for CKD is ‘The contractor establishes and maintains a register of patients aged 18 
or over with CKD with classification of categories G3a to G5’ (64). Thus, there is no 
longer a financial incentive to assess urine ACR. 
 
 
 
Future work 2: To develop strategies to ensure that ACR is being routinely 
measured within primary care for those with CKD, diabetes or vascular 
comorbidity. 
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7.5.2.2 Albuminuria is the principal modifiable risk factor for ESRD in 
progression of ESRD in people of South Asian ethnicity 
The research presented in Chapter 4 confirms a higher risk of ESRD in individuals of 
South Asian or black ethnicity and that the difference in ESRD risk between 
ethnicities is explained by conventional risk factors of age, gender, eGFR and ACR. 
Importantly this thesis identifies a significant difference in median ACR between 
ethnic groups at baseline and proposes ACR as the key modifiable risk factor. As 
discussed in Chapter 4, prior work has identified higher levels of proteinuria in 
paediatric and adolescent South Asian populations (265, 266), suggesting potential 
genetic or environmental factors may influence albuminuria. 
 
In addition to other serum, plasma, urine and saliva samples collected as part of the 
RIISC study, we collected DNA samples using the The PAXgene tube system 
(Quiagen, Venlo, Netherlands) (Section 2.4.5). This provides an opportunity to 
investigate any genetic basis explaining the increased ACR in non-white ethnic 
groups. 
 
Blood pressure control, especially ACEi/ARB usage in those with albuminuria, is a 
key component to slowing CKD progression. A review of the current literature 
(discussed in Chapter 4) acknowledged there are limited data on response to 
antihypertensive treatment, including renin angiotensin aldosterone system (RAAS) 
blockade, in South Asian individuals. It is therefore important to explore the response 
Future work 3: To investigate a potential genetic basis of increased 
albuminuria in South Asian individuals. 
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to treatment by ethnicity, as this may provide potential to tailor treatment to those 
most likely to respond. I was unable to incorporate ethnicity into the analyses with 
tryptase (Chapter 5) as I needed to balance the number of a priori variables with the 
number of events to reduce the likelihood of overfitting, but it would be important to 
rerun the analyses in the future when more events have occurred. 
 
7.5.3 Ethnicity should be viewed as a non-traditional risk factor for death and 
ESRD. 
The ethnically diverse population within the West Midlands, provided an excellent 
opportunity to explore the relationships between ethnicity, kidney disease and clinical 
outcomes. Both primary and secondary care cohorts demonstrated white participants 
tended to be older and tended to have more comorbidities than those of South Asian 
or black ethnicity. In the analysis of primary care data (Chapter 3), the risk of death 
was lower for South Asian and black participants than for white participants, 
including in the multivariable analyses which included age, renal function and 
comorbidity. In the analysis of the secondary care RIISC cohort (Chapter 4), I did not 
identify a mortality difference between ethnicities. However, there was a difference in 
progression to ESRD (discussed above in Section 7.2) including in competing risk 
analyses.  
 
Future work 4: To assess response to key interventions, especially RAAS 
blockade, within different ethnicities. 
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7.5.4 Socioeconomic status was not significantly associated with adverse 
outcomes. 
In contrast to previous work (see Section 1.5.2), the analyses presented in this thesis 
showed no association between SES and any of the outcomes studied, including 
death, progression to ESRD or reduced HRQL.  
 
Whilst this may be due to the universal healthcare system operating in the UK, other 
explanations are possible. Both primary and secondary care cohorts had a high 
percentage of people in the most deprived national SES quintile (calculated using 
index of multiple deprivation scores (186, 310)) with over 70% in primary care and 
approximately 50% in secondary care studies. We therefore have not been able to 
comprehensively compare the highest to the least socioeconomically deprived. 
Additionally, significant resources have been spent on health promotion programmes 
targeted at inner-city Birmingham (121); the work presented may suggest the lack of 
association between SES and outcomes is related to the success of such programmes. 
 
7.5.5 Serum tryptase is independently associated with ESRD in people 
receiving treatment with ACEi or ARB 
Chapter 5 presents the first data demonstrating serum tryptase concentration as an 
independent prognostic factor for progression to ESRD in patients receiving treatment 
with ACEi/ARB. The chapter provides information regarding potential putative 
mechanisms for this association; perhaps the most compelling are the role of mast cell 
proteases as the main ACE independent pathway of angiotensin II production, and 
therefore may identify individuals who have incomplete RAAS blockade, and the role 
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of proteases promoting renal disease through transforming growth factor beta (TGF-β) 
(by stimulating TGF-β directly and via promotion of angiotensin II) (139).  
 
Combined with studies which have investigated inhibitors of tryptase and chymase in 
animal studies, including chymase inhibition attenuating renal disease in animal 
models (311), the data presented provides further justification for investigation of the 
concept of RAAS breakthough and the potential for trials of mast cell protease 
inhibitors in humans. 
 
7.5.6 Impaired health related quality of life is common in CKD and associated 
with increased risk of death 
This thesis explored the relationship between HRQL, CKD and outcomes. The data 
presented show that impaired HRQL is common and therefore should be explored 
routinely in clinical consultations to identify its presence. The results I have presented 
indicate that a comprehensive and time-consuming assessment may not be necessary; 
a question regarding self-care could potentially be used as a screening tool. 
 
Studies are needed to investigate whether specific interventions can improve patient 
well being and whether these interventions may alter an individual’s risk of death. 
National studies are starting to investigate HRQL in CKD (for example, ‘Think 
Kidneys’ Transforming Participation in Chronic Kidney Disease; TP-CKD (312)) but 
Future work 5: To investigate mechanisms and the concept of RAAS escape/ 
breakthough through a mast cell protease dependent pathway. 
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it is vital the applicability of findings in the ethnically diverse population can be 
demonstrated. 
 
7.6 Key Strengths and Limitations 
I have discussed strengths and weaknesses as a component of individual result 
chapters. Here I summarise the general strengths and weaknesses of my research 
presented in this thesis. 
 
The key strength of the studies presented has been the ability to perform statistically 
robust analyses on high-risk, ethnically diverse primary and secondary care cohorts, 
and present the findings in clinically relevant ways. The results have direct relevance 
to the population managed by nephrologists and primary care physicians in 
Birmingham, other multicultural cities in the UK and beyond. As previously 
highlighted, this is a population under-represented in other national or international 
cohort studies. 
 
The main limitations of the studies presented is their observational nature and a 
recognition that, for the chapters focusing on the RIISC study, the results may not be 
generalisable to a CKD population comprising less advanced renal impairment. 
Additionally, whilst the aetiology of renal disease (see Section 2.4.7.1 for 
Future work 6: To evaluate interventions which, if applied to those with non-
dialysis dependent CKD with impaired HRQL, may lead to an improvement 
in patient well being. 
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classification) is described in the chapters utilising the RIISC cohort, I recognise the 
majority of these diagnoses are ‘presumed’ rather than based on definite histology. 
Indeed, under 30 percent (201/727 in Chapter 4) of patients underwent a renal biopsy. 
Whilst the large majority of patients with significant renal disease do not have a 
kidney biopsy, as in most cases knowledge of histology will not alter management  
(313), it is important to recognised that the presumed diagnosis is not always correct 
(314). This limitation makes it more challenging to assess any association between 
renal diagnosis with outcomes, especially for aetiologies such as diabetic kidney 
disease. Chapter 4 shows a high prevalence of diabetes (36.5%) within the cohort but 
a more modest prevalence of diabetic kidney disease (11.3%). Work is needed on 
increasing the accuracy of diagnoses in nephrology, either through increased use of 
kidney biopsies or through novel biomarkers with high diagnostic discrimination for 
the underlying renal disease. (315).  
 
The chapters utilising the RIISC study had different numbers of participants due to 
the selection criteria stated in each chapter. Chapter 5 had the fewest participants due 
to the requirement to analyse samples for tryptase, and this was limited by laboratory 
and assay capacity. Additionally, the censor dates used in each chapter reflected the 
timing of the analyses. However I believe that, despite these limitations, the detailed 
phenotyping of both primary and secondary care cohorts, and the univariable and 
multivariable analyses performed, provide a sound footing from which to explore the 
future work I have proposed. 
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7.7 Executive Conclusions 
 
This thesis describes the impact of CKD on individuals and society and has discussed 
the previously identified risk factors associated with adverse events, including ESRD, 
death and impaired HRQL. 
 
Though a series of studies, in both primary and secondary care cohorts, I have focused 
on areas of uncertainty which have implications for patient care. 
 
I found that: (i) comorbidity has a profound impact at a population level on survival in 
CKD; (ii) albuminuria is the principle modifiable risk factor for progression to ESRD 
in people of South Asian ethnicity; (iii) serum tryptase is an independent prognostic 
factor for ESRD in patients with CKD receiving treatment with an ACEi or ARB; and 
(iv) Low HRQL is common in CKD and reduced HRQL is associated with a higher 
risk for death. 
 
The findings from this thesis contribute to the understanding of CKD in ethnically 
diverse, high-risk populations and form the basis for further studies. 
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